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COMPOSITIONS AND METHODS OF 
MODULATING 15-PGDH ACTIVITY 
RELATED APPLICATION 
This application claims priority from U.S. Provisional 
Application No. 61/624,670, filed Apr. 16, 2012, the subject 
matter of which is incorporated herein by reference in its 
entirety. 
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rights to the invention. 
BACKGROUND 
20 
15-hydroxy-prostaglandin dehydrogenase (15-PGD H) 
represents the key enzyme in the inactivation of a number of 
active prostaglandins, leukotrienes and hydroxyeicosatetra- 25 
enoic acids (HETEs) (e.g., by catalyzing oxidation of PGE2 
to 15-keto-prostaglandin E2, 15 k-PGE). The human 
enzyme is encoded by the HPGD gene and consists of a 
homodimer with subunits of a size of 29 kDa. The enzyme 
belongs to the evolutionarily conserved superfamily of 30 
short-chain dehydrogenase/reductase enzymes (SD Rs), and 
according to the recently approved nomenclature for human 
enzymes, it is named SDR36Cl. Thus far, two forms of 
15-PGDH have been identified, NAD+-dependent type I 
15-PGDH and the type II NADP-dependent 15-PGDH, also 35 
known as carbonyl reductase 1 (CBRl, SDR21Cl). How-
ever, the preference of CBRl for NADP and the high Km 
values of CBRl for most prostaglandin suggest that the 
majority of the in vivo activity can be attributed to type I 
15-PGDH. 40 
Recent studies suggest that inhibitors of 15-PGDH and 
activators of 15-PGDH could be therapeutically valuable. It 
has been shown that there is an increase in the incidence of 
colon tumors in 15-PGDH knockout mouse models. Amore 
recent study implicates increased 15-PGDH expression in 45 
the protection of thrombin-mediated cell death. It is well 
known that 15-PGDH is responsible for the inactivation of 
prostaglandin E2 (PGE2), which is a downstream product of 
COX-2 metabolism. PGE2 has been found to be neurotoxic 
both in vitro and in vivo; thus, COX-2 specific inhibitors, 50 
which decrease PGE2 release, exhibit neuroprotective 
effects. PGE2 has also been shown to be beneficial in a 
variety of biological processes, such as hair density, dermal 
wound healing, and bone formation. 
55 
SUMMARY 
Embodiments described herein relate to compounds and 
methods of modulating 15-PGDH activities, modulating 60 
tissue prostaglandin levels, and/or treating diseases, disor-
ders, or conditions in which it is desired to modulate 
15-PGDH activity and/or prostaglandin levels. 
In some embodiments, a 15-PGDH inhibitor can be 
administered to a tissue of a subject at an amount effective 65 
to increase prostaglandin levels in the tissue. The 15-PGDH 
inhibitor can include formula (I): 
(I) 
wherein n is 0-2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted (e.g., R1 can be a 
C2_6 alkyl, C2_4 alkyl, or C4 alkyl, which is linear, 
branched, or cyclic and which is unsubstituted or 
substituted); 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)n 1 OR' (wherein nl=l, 2, or 3), CF3 , CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is H or a lower alkyl group); 
R4 and Rs are the same or different and are each selected 
from the group consisting of hydrogen, C1 -C24 alkyl, 
C2-C24 alkenyl, C2-C24 alkynyl, C3 -C20 aryl, CcC24 
alkaryl, C6 -C24 aralkyl, halo, silyl, hydroxyl, sulfhy-
dryl, C1 -C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alky-
nyloxy, Cs-C20 aryloxy, acyl (including C2-C24 alkyl-
carbonyl (-CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (-O-acyl), C2-C24 alkoxycar-
bonyl (-(CO)---0-alkyl), C6 -C20 aryloxycarbonyl 
(-(CO)---0-aryl), C2-C24 alkylcarbonato (-O-
(CO)---0-alkyl), CcC20 arylcarbonato (---0-(CO)-
O-aryl), carboxy (-COOH), carboxylato (-Coo-), 
carbamoyl (-(CO)-NH2), C1 -C24 alkyl-carbamoyl 
(-(CO)-NH(C1 -C24 alkyl)), arylcarbamoyl 
(-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), 
carbamide (-NH-(CO)-NH2), cyano (----CN), iso-
cyano (-N+c-), cyanato (---0-CN), isocyanato 
(-O-N+=C-), isothiocyanato (-S----CN), azido 
(-N W W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2), C1-C24 alkyl amino, 
Cs-C20 aryl amino, C2-C24 alkylamido (-NH-(CO)-
alkyl), C6 -C20 arylamido (-NH-(CO)-aryl), imino 
(-CR NH where R is hydrogen, C1-C24 alkyl, 
Cs-C20 aryl, C6 -C24 alkaryl, C6-C24 aralkyl, etc.), alky-
limino (----CR=N(alkyl), where R=hydrogen, alkyl, 
aryl, alkaryl, aralkyl, etc.), arylimino (----CR=N(aryl), 
where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro 
(-NO2), nitroso (-NO), sulfa (-SO2-OH), sul-
fonato (-SO2---0-), C1-C24 alkylsulfanyl (-S-alkyl; 
also termed "alkylthio"), arylsulfanyl (-S-aryl; also 
termed "arylthio"), C1 -C24 alkylsulfinyl (-(SO)-
alkyl), Cs-C20 arylsulfinyl (-(SO)-aryl), C1 -C24 alkyl-
sulfonyl (-SO2-alkyl), Cs-C20 arylsulfonyl (-SO2-
aryl), phosphono (-P(O)(OH)2), phosphonato (-P 
(0)(0-)2), phosphinato (-P(O)(O-)), phospho 
(-PO2), phosphino (-PH2), combinations thereof, 
and wherein R4 and Rs may be linked to form a cyclic 
or polycyclic ring, wherein the ring is a substituted or 
unsubstituted aryl, a substituted or unsubstituted het-
eroaryl, a substituted or unsubstituted cycloalkyl, and a 
substituted or unsubstituted heterocyclyl; and pharma-
ceutically acceptable salts thereof. 
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In other embodiments, the 15-PGDH inhibitor can i) at 
2.5 µM concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 70 (using a scale on 
which a value of 100 indicates a doubling of reporter output 5 
over baseline); ii) at 2.5 µM concentration stimulate a V9m 
reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 75; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 10 
luciferase output level of greater than 70; iv) at 7.5 µM 
concentration, does not activate a negative control V9m cell 
line expressing TK-renilla luciferase reporter to a level 
greater than 20; and v) inhibits the enzymatic activity of 15 
recombinant 15-PGDH protein at an IC50 ofless than 1 µM. 
In other embodiments, the 15-PGDH inhibitor can i) at 
2.5 µM concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; ii) at 2.5 µM concentration stimu- 20 
late a V9m reporter cell line expressing a 15-PGDH 
luciferase fusion construct to increase luciferase output; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; iv) at 7.5 µM concentration, does 25 
not activate a negative control V9m cell line expressing 
TK-renilla luciferase reporter to a luciferase level greater 
than 20% above background; and v) inhibits the enzymatic 
activity ofrecombinant 15-PGDH protein at an IC50 ofless 
than 1 µM. 30 
In other embodiments, the 15-PGDH inhibitor can inhibit 
the enzymatic activity ofrecombinant 15-PGDH at an IC50 
of less than 1 µM, or preferably at an IC50 of less than 250 
nM, or more preferably at an IC50 of less than 50 nM, or 
more preferably at an IC50 of less than 5 nM. 35 
In still other embodiments, the 15-PGDH inhibitor can be 
applied to skin of a subject to promote and/or stimulate 
pigmentation of the skin and/or hair growth and/or inhibit 
hair loss. The 15-PGDH inhibitor can also be administered 
to a subject to promote wound healing, regenerate tissue, 40 
and/or treat at least one of oral ulcers, ulcerative colitis, 
gastrointestinal ulcers, inflammatory bowel disease, vascu-
lar insufficiency, colitis, Raynaud's disease, Buerger's dis-
ease, diabetic neuropathy, pulmonary artery hypertension, 
cardiovascular disease, diabetic ulcers, renal disease, and 45 
erectile dysfunction. The 15-PGDH inhibitor can further be 
administered to a subject in combination with a prostanoid 
agonist for the purpose of enhancing the therapeutic effect of 
the agonist in prostaglandin responsive conditions. 
In some embodiments, the 15-PGDH inhibitor can be 50 
administered to tissue of a subject to increase tissue stem 
cells. The 15-PGDH inhibitor can also be administered to a 
bone marrow graft donor or a hematopoietic stem cell donor 
to increase the fitness of a donor bone marrow graft or a 
donor hematopoietic stem cell graft. The 15-PGDH inhibitor 55 
can be administered to bone marrow of a subject to increase 
stem cells in the subject. The 15-PGDH inhibitor can further 
be administered to bone marrow of a subject to increase the 
fitness of the marrow as a donor graft. 
In other embodiments the 15-PGDH inhibitor can be 60 
administered to a preparation ofhematopoietic stem cells of 
a subject to increase the fitness of the stem cell preparation 
as a donor graft. The 15-PGDH inhibitor can also be 
administered to a preparation of peripheral blood 
hematopoietic stem cells of a subject to increase the fitness 65 
of the stem cell preparation as a donor graft. The 15-PGDH 
inhibitor can further be administered to a preparation of 
4 
umbilical cord stem cells to increase the fitness of the stem 
cell preparation as a donor graft. 
In yet other embodiments, the 15-PGDH inhibitor can be 
administered to a subject to mitigate bone marrow graft 
rejection, to enhance bone marrow graft engraftment, and/or 
to enhance engraftment of a hematopoietic stem cell graft, or 
an umbilical cord stem cell graft. 
In still other embodiment, the 15-PGDH inhibitor can be 
administered to a subject or to a tissue graft of a subject to 
mitigate graft rejection or to enhance graft engraftment. 
In other embodiments, the 15-PGDH inhibitor can be 
administered to a subject or to tissue of the subject to confer 
resistance to toxic or lethal effects of exposure to radiation. 
In other embodiments, the 15-PGDH inhibitor can be 
administered to a subject for the treatment of osteoporosis, 
bone fractures, or promoting healing after bone injury or 
joint replacement. 
In an alternative example, the 15-PGDH inhibitor can be 
administered to a subject or to the liver of a subject to 
promote liver regeneration following liver resection or fol-
lowing toxic injury to the liver. In one instance, toxic injury 
to the liver may be caused by overdose of acetaminophen or 
related hepatotoxic compounds. 
In still other embodiments of the application, a 15-PGDH 
activator can be administered to a tissue of a subject at an 
amount effective to increase 15-PGDH levels and decrease 
prostaglandin levels in the tissue. The 15-PGDH activator 
can include formula (IV): 
(IV) 
R11 
I 
0 Y2=0 
II I 
U R10 ..,.-X3YN' 
R12 
wherein X3 and Y 2 are independently C or SO; 
U is OR"(wherein R" is H, a substituted or unsubstituted 
alkyl group, or substituted or unsubstituted aryl group) 
or 
Rs, R9 , R10, Ru, and R12 are each selected from the group 
consisting ofH, F, Cl, Br, I, an alkyl group, (CH2)niOR' 
(whereinnl=l, 2, or 3), CF3 , CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is Hor a lower alkyl group), a substituted 
or unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, a substituted or unsubstituted heterocyclyl, 
and Rs and R9 may be linked to form a cyclic or 
polycyclic ring; and pharmaceutically acceptable salts 
thereof. 
In some embodiments, the activator can i) at 7.5 µM 
concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 50 (using a scale on 
which a value of 100 indicates a doubling ofreporter output 
US 10,301,320 B2 
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over baseline); ii) at 7 .5 µM concentration stimulate a V9m 
reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 50; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 5 
luciferase output level of greater than 50; iv) at 7.5 µM 
concentration, does not activate the negative control V9m 
cell line expressing TK-renilla luciferase reporter to a level 
any greater than 25; and v) against recombinant 15-PGDH 
protein the compound shows an IC50 concentration for 10 
inhibiting 15-PGDH enzyme activity of greater than or equal 
to 2.5 µM. 
In some embodiments, the activator can i) at 7.5 µM 
concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to 15 
increase luciferase output; ii) at 7.5 µM concentration stimu-
late a V9m reporter cell line expressing a 15-PGDH 
luciferase fusion construct to increase luciferase output; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to 20 
increase luciferase output; iv) at 7.5 µM concentration, does 
not activate the negative control V9m cell line expressing 
TK-renilla luciferase reporter to a luciferase level any 
greater than 25% above; and v) against recombinant 
15-PGDH protein the compound shows an IC50 concentra- 25 
tion for inhibiting 15-PGDH enzyme activity of greater than 
or equal to 2.5 µM. 
6 
FIGS. 7(A-C) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with SW033291. 
FIGS. S(A-C) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with SW054384 and 
SW145753. 
FIGS. 9(A-I) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with 5 µM 
SW124531. 
FIGS. lO(A-C) illustrate graphs showing 15-PGDH activ-
ity in cell lines treated with SW033291, SW054384, and 
SW145753. Activity is measured as pmol PGE2/min/million 
cells. 
FIGS. ll(A-D) illustrates a table and plots showing 
activity ofrecombinant 15-PGDH protein (a 15-PGDH-GST 
fusion protein) incubated with varying concentrations of the 
test compounds. 
FIGS. 12(A-D) illustrate plots showing the activity of 
recombinant 15-PGDH protein treated with SW033291 and 
SW054384, with panels 12A and C measuring transfer of 
tritium from a radiolabeled PGE2 substrate and panels 12 B 
and D measuring generation of NADH by fluorescence. 
FIG. 13 illustrates a table and plot showing 15-PGDH 
activity measured by following transfer of tritium from a 
radiolabeled PGE2 substrate in cells treated with SW124531 
(upper panel) and in recombinant 15-PGDH protein treated 
with SW124531 (lower panel). 
FIGS. 14(A-B) illustrate melt curves and a table showing 
different compound's ability to directly bind to recombinant 
15-PGDH protein as measured by shifting the melting 
temperature of the protein. 
In other embodiments, the 15-PGDH activator can be 
administered to a subject to treat a neoplasia, such as a colon 
neoplasia. The 15-PGDH activator can also be administered 30 
to a subject to prevent neoplasia, such as a colon neoplasia. 
The 15-PGDH activator can also be administered to a FIGS. 15(A-B) illustrate melt curves temperature of cata-
lytically inactive mutant 15-PGDH protein treated with the 
35 test compounds. 
subject to reduce inflammation and/or pain. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. l(A-C) illustrate graphs showing luciferase activity 
FIGS. 16(A-B) illustrates graphs showing PGE2 levels 
that are assayed in the medium of A549 cells that have been 
stimulated by ILi-beta for 23 hours, with the test com-
pounds. 
FIG. 17 illustrates a graph showing the dose response 
effect of SW033291 on PGE2 production from ILi-beta 
treated A549 cells. 
of cells that express a 15-PGDH luciferase fusion construct 
created by targeted gene knock-in of renilla luciferase into 
the last coding exon of 15-PGDH treated with the com- 40 
pounds SW033291, SW054384, and SW145753 at various 
concentrations. The activity is demonstrated in three differ-
ent colon cancer cell lines all engineered to contain the 
15-PGDH-luciferase fusion. These cell lines are Vaco-9m 
(V9m), LSI 74T, Vaco503 (V503). 
FIGS. 18(A-B) illustrate graphs showing the in vivo 
modulations by compounds (2.5 µM) of PGDH activity as 
45 reflected in PGE2 levels following addition of PGE2 into the 
medium of Vaco-503 cells. FIG. 2 illustrates western blots demonstrating the levels 
of 15-PGDH protein in cell lines V9M, LS174T, and V503 
treated with 7.5 µM of SW033291, SW054384, and 
SW145753 for 48 hours. Untreated FET cells provide a 
positive control for 15-PGDH expression. 
FIG. 19 illustrates images showing the activity of 
SW033291 in speeding the healing of a model wound 
consisting of a scratch in a monolayer of HaCaT cells 
50 observed over 48 hours of treatment. 
FIG. 3 illustrates western blots demonstrating 15-PGDH 
protein levels in colon cell lines treated with SW124531 
(FET cells treated with TGF-13 (10 ng/ml for 48 hours) are 
used as a positive control for 15-PGDH expression in certain 
panels). 
FIG. 4 illustrates western blots demonstrating the levels 
55 
of 15-PGDH protein (wt-PGDH) expressed from a cDNA 
expression vector in V400-S3-2-32 cells treated with 5 µM 
SW! 24531, and protein levels of a catalytically dead mutant 
15-PGDH (mu-PGDH) also expressed from a cDNAexpres- 60 
sion vector in V 400-M3-2-72 cells treated with SW124531. 
FIGS. S(A-C) illustrate 15-PGDH protein levels in V503 
cells treated with SW124531 as assayed by immuno-fluo-
rescence (upper two rows) and by western blot (lower 
panel). 
FIGS. 6(A-F) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with SW033291. 
65 
FIGS. 20(A-B) illustrate graphs showing the quantitation 
of scratch width at O and 48 hours in the control, SW033291 
(2.5 µM) treated cells, and the TGF-beta (1 ng/ml) treated 
cells. 
FIGS. 21(A-B) illustrate plots showing: (A) percent inhi-
bition of PGDH using titrations of 15-PGDH inhibitor 
SW033291 run at different 15-PGDH concentrations; and 
(B) the IC50 of 15-PGDH inhibitor SW033291 versus 
15-PGDH concentration. 
FIGS. 22(A-B) illustrate graphs showing: (A) 15-PGDH 
enzyme inhibiting activity and (B) percent inhibition of 
activity due to of SW033291 as measured before and after 
dialysis of the 15-PGDH and SW033291 mixture. 
FIGS. 23(A-B) illustrate a plot showing reaction rates and 
relative reaction velocity of 15-PGDH at varying concen-
trations of SW033291. 
US 10,301,320 B2 
7 8 
FIGS. 24(A-B) illustrate plots showing: (A) inhibition of FIG. 47 illustrates a graph showing CFU counts in wild 
15-PGDH by SW033291 in the presence of PGE-2; and (B) type bone marrow treated with SW033291 and PGE-2. 
IC50 ofSW033291 against 15-PGDH versus PGE2 concen- FIGS. 48(A-C) illustrate graphs showing: (A) bone mar-
tration. row cellularity of mice treated with SW033291; (B) SKL % 
FIG. 25 illustrates a schematic diagram showing the 5 in whole bone marrow of mice treated with SW033291; and 
structure activity relationships of analogues of SW033291 (C) CFU counts in mice treated SW033291. 
versus their IC50 against 15-PGDH. FIGS. 49(A-B) illustrate: (A) a schematic diagram fol-
FIG. 26 illustrates a schematic diagram showing addi- lowing CD45.2 antigen marked cells in lethally irradiated 
tional analogues of SW033291. C57BL/6J mice rescued with a bone marrow transplant from 
FIGS. 27(A-C) illustrate graphs showing luciferase activ- 10 donor mice treated with SW033291 or with vehicle; and (B) 
ity of colon cancer cell lines V503, LSI 74T, and V503 graphs showing chimerism, of donor B-Cells, myeloid cells, 
treated with 2.5 µMand 7 .5 µM the compounds of FIG. 26. and T-Cells after such treatment. 
FIG. 28 illustrates a graph showing percent inhibition of FIG. 50 illustrates a schematic diagram showing schema 
15-PGDH activity by the compounds of FIG. 26. 15 of a study in which C57BL/61 mice are irradiated with 11 
FIGS. 29(A-B) illustrate plots showing the IC50 against GY on day 0 and followed by treatment with SW033291. 
15-PGDH of SW033291 and SW0206980. FIG. 51 illustrates a schematic diagram of a partial 
FIGS. 30(A-B) illustrate plots showing melting profiles of hepatectomy. 
SW0206890 and SW033291 binding to 15-PGDH. FIGS. 52(A-D) illustrate photographs showing preopera-
FIGS. 31(A-C) illustrate plots showing percent inhibition 20 tive and post-operative view of mouse liver. 
of 15-PGDH activity by SW033291, SW206980, and FIGS. 53(A-D) illustrate photographs showing post-he-
SW206992. patectomy views of the mouse liver ( at left) and regeneration 
FIGS. 32(A-C) illustrate graphs showing luciferase activ- of mouse liver on post-operative day 7 (at right). 
ity of colon cancer cell lines V503, LSI 74T, and V503 FIGS. 54(A-B) illustrate micrographs of post-hepatec-
treated with various concentrations of SW033291. 25 tomy mouse livers of mouse administered SW033291 and 
FIG. 33(A-C) illustrate graphs showing luciferase activity control vehicle, with arrows designating mitotic figures. 
of colon cancer cell lines V503, LSI 74T, and V503 treated FIG. 55 illustrates a graph showing mitosis in liver of 
with various concentrations of SW0206980. SW033291 treated mouse versus the control mouse. 
FIG. 34(A-C) illustrate graphs showing luciferase activity FIG. 56 illustrates a graph showing the liver to body 
of colon cancer cell lines V503, LSI 74T, and V503 treated 30 weight ratios attained following partial hepatectomy in 
with various concentrations of SW0206992. control versus SW033291 treated C57Bl/6J mice. 
FIGS. 35(A-B) illustrate plots showing melting profiles of FIG. 57 illustrates a graph showing the liver to body SW206992, SW0206890 and SW033291 binding to 
15_PGDH. weight ratios attained following partial hepatectomy in 
FIGS. 36(A-B) illustrate plots showing melting profiles of 35 control versus SW033291 twice daily treated C57Bl/6J 
SW206992, SW0206890 and SW033291 binding to mice. 
15-PGDH. FIG. 58 illustrates a graph reprising the liver to body 
FIGS. 37(A-C) illustrate graphs showing the effect of weight ratios attained following partial hepatectomy in 
SW206992, SW0206890 and SW033291 on the regulation control versus SW033291 treated C57Bl/6J mice. 
of PGE-2 in A549 cells stimulated with ILi-Beta. 40 FIGS. 59(A-B) illustrate a graph and plot showing ALT 
FIGS. 38(A-C) illustrate graphs showing the effect of levels following partial hepatectomy in one mouse control 
SW206992, SW0206890 and SW033291 on cell numbers in versus one mouse treated with SW033291. 
A549 cells after stimulated with ILi-Beta. FIG. 60 illustrates a graph showing serum bilirubin levels 
FIG. 39 illustrates a schematic diagram of additional following partial hepatectomy in a control mouse and a 
analogues of SW033291. 45 mouse treated with SW033291. 
FIGS. 40(A-C) illustrate graphs showing luciferase activ- FIG. 61 illustrates a graph showing the liver to body 
ity of colon cancer cell lines V9M, LSI 74T, and V503 weight ratios attained following partial hepatectomy in 
treated with 2.5 µMand 7.5 µM the compounds of FIG. 39. control versus SW033291 treated FVB mice. 
FIG. 41 illustrates a graph showing percent inhibition of FIG. 62 illustrates a graph showing preoperative body 
15-PGDH activity by the compounds of FIG. 40. 50 weights in control versus SW033291 treated FVB mice. 
FIGS. 42(A-D) illustrate a graph showing percent inhi- FIG. 63 illustrates a graph showing the weight of the 
bition of 15-PGDH activity by the compounds of FIG. 40. resected liver segment from mice treated with either 
FIG. 43 shows the dose response curve for induction of a SW033291 or vehicle control and assayed for liver regen-
15-PGDH-luciferase fusion gene reporter in the V9m cell eration. 
line background of SW033291, SW208064, SW208065, 55 FIG. 64 illustrates a graph showing liver weights attained 
SW208066, and SW208067. post partial heptatectomy in SW033291 and control mice. 
FIG. 44 illustrates titration curves of 15-PGDH inhibitor FIG. 65 illustrates a graph showing the liver to body 
compounds in an assay measuring effects on PGE2 levels in weight ratios obtained post partial hepatectomy in 
the medium of A549 cells that have been stimulated with SW033291 treated and control mice. 
ILi-beta. 60 FIG. 66 illustrates a "box and whisker" plot comparing 
FIG. 45 is a plot showing weight change of FVB mice liver to body weight ratio following partial hepatectomy of 
treated with SW033291. SW033291 treated and control FVB mice at post-operative 
FIGS. 46(A-C) illustrate graphs showing: (A) total bone day 4. 
marrow cellularity; (B) SKL population of wild type versus FIG. 67 illustrates a "box and whisker" plot comparing 
PGDH-/- mice; and (C) average CFU counts in wild type 65 liver to body weight ratio following partial hepatectomy of 
versus PGDH-/- mice (designated as either PGDH-/- or as SW033291 treated and control FVB mice at post-operative 
PGDH). day 7. 
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FIG. 68 illustrates a "box and whisker" plot comparing 
liver to body weight ratio following partial hepatectomy of 
SW033291 treated and control FVB mice at post-operative 
day 4. 
FIG. 69 illustrates photographs ofS-phase cells following 5 
partial hepatectomy on post-operative day 2 in livers of 
SW033291 treated and vehicle treated control mice. 
FIG. 70 illustrates a photograph showing high powered 
( 40x) views of representative fields from the study of FIG. 
69. 10 
10 
FIG. 87 illustrates a schematic diagram of analogues of 
SW054384. 
FIG. 88 illustrates a graph showing luciferase activity of 
colon cancer cell V9m treated with 2.5 µMand 7.5 µM the 
compounds of FIG. 87. 
FIG. 89 illustrates a graph showing luciferase activity of 
colon cancer LS174T cells treated with 2.5 µMand 7.5 µM 
the compounds of FIG. 87. 
FIG. 90 illustrates a graph showing luciferase activity of 
colon cancer cell V503 treated with 2.5 µMand 7.5 µM the 
compounds of FIG. 87. 
FIG. 91 illustrates a graph showing percent inhibition of 
15-PGDH activity by the compounds of FIG. 87. 
FIG. 92 is a schematic illustration showing the structures 
FIG. 71 illustrates a "box and whiskers" plot comparing 
percent of BrdU positive cells in livers of SW033291 treated 
versus vehicle control treated mice on post-operative day 2 
following partial hepatectomy. 
FIG. 72 illustrates a graph showing the average changes 
from baseline weight of the cohort of control versus 
SW033291 treated mice all treated with 2% dextran sulfate 
sodium (DSS) in the drinking water. 
15 of 15-PGDH activators SW054384, SW125991, 
SW207997, SW207998, and SW207999. 
FIG. 73 illustrates a graph of the daily disease activity 
index of the cohort of control versus SW033291 treated 
mice all treated with 2% DSS in the drinking water. 
FIG. 93 illustrates a graph showing the activities of 
SW054384, SW125991, SW207997, SW207998, 
SW207999 in lowering PGE2 levels in medium of A549 
20 cells that have been treated with 2.5 µM of each compound 
along with addition of 2.5 ng/ml ILi-beta. 
FIG. 74 illustrates a graph showing the average changes 
from baseline weight of the cohort of DSS treated mice 
receiving a control vehicle versus SW033291. 
FIG. 94 illustrates titration curves of 15-PGDH activator 
compounds in an assay measuring effects on PGE2 levels in 
the medium of A549 cells that have been stimulated with 
25 ILi-beta. 
FIGS. 75(A-B) illustrates: (A) a graph showing the num-
ber of ulcers in a colon of DSS treated mice receiving a 
control vehicle versus SW033291; and (B) photographs 
showing ulcers of DSS treated mice receiving control (left) 
or SW033291 (right). 
FIG. 76 illustrates a graph showing quantitation of ulcer 
burden on day 15 of DSS treated mice. 
30 
FIGS. 77(A-B) illustrate photographs showing colono-
scopic findings and mouse endoscopic index of colitis 
severity (MEICs) for a DSS treated mouse receiving a 35 
control vehicle or SW033291. 
FIG. 95 illustrates a photograph showing assessment of 
toxicity of SW125991 by testing effect of increasing doses 
on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. 
FIG. 96 illustrates a photograph showing assessment of 
toxicity of SW207997 by testing effect of increasing doses 
on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. 
FIG. 97 illustrates a photograph showing assessment of 
toxicity of SW207998 by testing effect of increasing doses 
on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. FIG. 78 illustrates a graph showing MEICS score ofDSS 
treated mice receiving a control vehicle or SW033291. 
FIG. 79 illustrates photomicrographs of high powered 
fields from the mid-colon on day 8 of the DSS protocol from 
control mice, SW033291 treated mice (treatment) and 
15-PGDH knockout mice (KO) and a graph depicting sum 
FIG. 98 illustrates a photograph showing assessment of 
toxicity of SW207999 by testing effect of increasing doses 
40 on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. 
of the average number of BrdU positive cells per crypt in the 
distal plus middle colons of control (Cn), SW033219 treated 
mice (Tx), and 15-PGDHknockoutmice (KO) on day 1, day 45 
8, and day 15 of the DSS treatment protocol. 
FIG. 80 illustrates a graph showing colon length at day 22 
of DSS treated mice receiving a control vehicle or 
SW033291. 
FIG. 81 illustrates a schematic diagram of analogues of 50 
SW054384. 
FIGS. 82(A-C) illustrate graphs showing luciferase activ-
ity of colon cancer cell lines V9M, LS174T, and V503 
treated with 2.5 µMand 7 .5 µM the compounds of FIG. 81. 
FIG. 83 illustrates a graph showing percent inhibition of 55 
15-PGDH activity by the compounds of FIG. 74. 
FIGS. 84(A-C) illustrate: (A) a graph showing activity in 
lowering PGE2 levels in media of A549 cells that are 
stimulated to produce PEG2 by treatment using ILi-beta 
using compounds of FIG. 81; (B) a graph showing toxicity 60 
of A549 cells administered the compounds of FIG. 81; and 
(C) photographs of A549 cells treated with compounds of 
FIG. 81. 
DETAILED DESCRIPTION 
For convenience, certain terms employed in the specifi-
cation, examples, and appended claims are collected here. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly under-
stood by one of ordinary skill in the art to which this 
application belongs. 
The articles "a" and "an" are used herein to refer to one 
or to more than one (i.e., to at least one) of the grammatical 
object of the article. By way of example, "an element" 
means one element or more than one element. 
The terms "comprise," "comprising," "include," "includ-
ing," "have," and "having" are used in the inclusive, open 
sense, meaning that additional elements may be included. 
The terms "such as", "e.g.", as used herein are non-limiting 
and are for illustrative purposes only. "Including" and 
"including but not limited to" are used interchangeably. 
The term "or" as used herein should be understood to 
mean "and/or", unless the context clearly indicates other-
wise. 
It will be noted that the structure of some of the com-FIG. 85 illustrates a plot showing metabolic stability of 
SW054384 by incubation with murine liver S9 microsomes. 
FIG. 86 illustrates a plot showing metabolic stability of 
SW0125991 by incubation withmurine liver S9 microsomes 
65 pounds of the application include asymmetric (chiral) car-
bon atoms. It is to be understood accordingly that the 
isomers arising from such asymmetry are included herein, 
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unless indicated otherwise. Such isomers can be obtained in 
substantially pure form by classical separation techniques 
and by stereochemically controlled synthesis. The com-
pounds of this application may exist in stereoisomeric form, 
therefore can be produced as individual stereoisomers or as 
mixtures. 
The term "isomerism" means compounds that have iden-
tical molecular formulae but that differ in the nature or the 
sequence of bonding of their atoms or in the arrangement of 
their atoms in space. Isomers that differ in the arrangement 
of their atoms in space are termed "stereoisomers". Stereoi-
somers that are not mirror images of one another are termed 
"diastereoisomers", and stereoisomers that are non-super-
imposable mirror images are termed "enantiomers", or 
sometimes optical isomers. A carbon atom bonded to four 
nonidentical substituents is termed a "chiral center". 
The term "chiral isomer" means a compound with at least 
one chiral center. It has two enantiomeric forms of opposite 
chirality and may exist either as an individual enantiomer or 
as a mixture of enantiomers. A mixture containing equal 
amounts of individual enantiomeric forms of opposite chi-
rality is termed a "racemic mixture". A compound that has 
more than one chiral center has 2n-1 enantiomeric pairs, 
where n is the number of chiral centers. Compounds with 
more than one chiral center may exist as either an individual 
diastereomer or as a mixture of diastereomers, termed a 
"diastereomeric mixture". When one chiral center is present, 
a stereoisomer may be characterized by the absolute con-
figuration (R or S) of that chiral center. Alternatively, when 
one or more chiral centers are present, a stereoisomer may 
be characterized as ( +) or (-). Absolute configuration refers 
to the arrangement in space of the substituents attached to 
the chiral center. The substituents attached to the chiral 
center under consideration are ranked in accordance with the 
Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al, 
Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et 
al., Angew. Chem. 1966, 78,413; Cahn and Ingold, J Chem. 
Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 
81; Cahn, J., Chem. Educ. 1964, 41, 116). 
The term "geometric Isomers" means the diastereomers 
that owe their existence to hindered rotation about double 
bonds. These configurations are differentiated in their names 
by the prefixes cis and trans, or Z and E, which indicate that 
the groups are on the same or opposite side of the double 
bond in the molecule according to the Cahn-Ingold-Prelog 
rules. Further, the structures and other compounds discussed 
in this application include all atropic isomers thereof. 
The term "atropic isomers" are a type of stereoisomer in 
which the atoms of two isomers are arranged differently in 
space. Atropic isomers owe their existence to a restricted 
rotation caused by hindrance of rotation of large groups 
about a central bond. Such atropic isomers typically exist as 
a mixture, however as a result of recent advances in chro-
matography techniques, it has been possible to separate 
mixtures of two atropic isomers in select cases. 
The terms "crystal polymorphs" or "polymorphs" or 
"crystal forms" means crystal structures in which a com-
pound ( or salt or solvate thereof) can crystallize in different 
crystal packing arrangements, all of which have the same 
elemental composition. Different crystal forms usually have 
different X-ray diffraction patterns, infrared spectral, melt-
ing points, density hardness, crystal shape, optical and 
electrical properties, stability and solubility. Recrystalliza-
tion solvent, rate of crystallization, storage temperature, and 
other factors may cause one crystal form to dominate. 
Crystal polymorphs of the compounds can be prepared by 
crystallization under different conditions. 
12 
The term "derivative" refers to compounds that have a 
common core structure, and are substituted with various 
groups as described herein. 
The term "bioisostere" refers to a compound resulting 
5 from the exchange of an atom or of a group of atoms with 
another, broadly similar, atom or group of atoms. The 
objective of a bioisosteric replacement is to create a new 
compound with similar biological properties to the parent 
compound. The bioisosteric replacement may be physico-
10 chemically or topologically based. Examples of carboxylic 
acid bioisosteres include acyl sulfonimides, tetrazoles, sul-
fonates, and phosphonates. See, e.g., Patani and LaVoie, 
Chem. Rev. 96, 3147-3176 (1996). 
The phrases "parenteral administration" and "adminis-
15 tered parenterally" are art-recognized terms, and include 
modes of administration other than enteral and topical 
administration, such as injections, and include, without 
limitation, intravenous, intramuscular, intrapleural, intravas-
cular, intrapericardial, intraarterial, intrathecal, intracapsu-
20 lar, intraorbital, intracardiac, intradermal, intraperitoneal, 
transtracheal, subcutaneous, subcuticular, intra-articular, 
subcapsular, subarachnoid, intraspinal and intrastemal injec-
tion and infusion. 
The term "treating" is art-recognized and includes inhib-
25 iting a disease, disorder or condition in a subject, e.g., 
impeding its progress; and relieving the disease, disorder or 
condition, e.g., causing regression of the disease, disorder 
and/or condition. Treating the disease or condition includes 
ameliorating at least one symptom of the particular disease 
30 or condition, even if the underlying pathophysiology is not 
affected. 
The term "preventing" is art-recognized and includes 
stopping a disease, disorder or condition from occurring in 
a subject, which may be predisposed to the disease, disorder 
35 and/or condition but has not yet been diagnosed as having it. 
Preventing a condition related to a disease includes stopping 
the condition from occurring after the disease has been 
diagnosed but before the condition has been diagnosed. 
The term "pharmaceutical composition" refers to a for-
40 mulation containing the disclosed compounds in a form 
suitable for administration to a subject. In a preferred 
embodiment, the pharmaceutical composition is in bulk or in 
unit dosage form. The unit dosage form is any of a variety 
of forms, including, for example, a capsule, an IV bag, a 
45 tablet, a single pump on an aerosol inhaler, or a vial. The 
quantity of active ingredient ( e.g., a formulation of the 
disclosed compound or salts thereof) in a unit dose of 
composition is an effective amount and is varied according 
to the particular treatment involved. One skilled in the art 
50 will appreciate that it is sometimes necessary to make 
routine variations to the dosage depending on the age and 
condition of the patient. The dosage will also depend on the 
route of administration. A variety of routes are contem-
plated, including oral, pulmonary, rectal, parenteral, trans-
55 dermal, subcutaneous, intravenous, intramuscular, intraperi-
toneal, intranasal, inhalational, and the like. Dosage forms 
for the topical or transdermal administration of a compound 
described herein includes powders, sprays, ointments, 
pastes, creams, lotions, gels, solutions, patches, nebulized 
60 compounds, and inhalants. In a preferred embodiment, the 
active compound is mixed under sterile conditions with a 
pharmaceutically acceptable carrier, and with any preserva-
tives, buffers, or propellants that are required. 
The term "flash dose" refers to compound formulations 
65 that are rapidly dispersing dosage forms. 
The term "immediate release" is defined as a release of 
compound from a dosage form in a relatively brief period of 
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time, generally up to about 60 minutes. The term "modified 
release" is defined to include delayed release, extended 
release, and pulsed release. The term "pulsed release" is 
defined as a series of releases of drug from a dosage form. 
The term "sustained release" or "extended release" is 
defined as continuous release of a compound from a dosage 
form over a prolonged period. 
The phrase "pharmaceutically acceptable" is art-recog-
nized. In certain embodiments, the term includes composi-
tions, polymers and other materials and/or dosage forms 
which are, within the scope of sound medical judgment, 
suitable for use in contact with the tissues of human beings 
and animals without excessive toxicity, irritation, allergic 
response, or other problem or complication, commensurate 
with a reasonable benefit/risk ratio. 
The phrase "pharmaceutically acceptable carrier" is art-
recognized, and includes, for example, pharmaceutically 
acceptable materials, compositions or vehicles, such as a 
liquid or solid filler, diluent, excipient, solvent or encapsu-
lating material, involved in carrying or transporting any 
subject composition from one organ, or portion of the body, 
to another organ, or portion of the body. Each carrier must 
be "acceptable" in the sense of being compatible with the 
other ingredients of a subject composition and not injurious 
to the patient. In certain embodiments, a pharmaceutically 
acceptable carrier is non-pyrogenic. Some examples of 
materials which may serve as pharmaceutically acceptable 
carriers include: (1) sugars, such as lactose, glucose and 
sucrose; (2) starches, such as corn starch and potato starch; 
(3) cellulose, and its derivatives, such as sodium carboxym-
ethyl cellulose, ethyl cellulose and cellulose acetate; (4) 
powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) 
excipients, such as cocoa butter and suppository waxes; (9) 
oils, such as peanut oil, cottonseed oil, sunflower oil, sesame 
oil, olive oil, corn oil and soybean oil; (10) glycols, such as 
propylene glycol; (11) polyols, such as glycerin, sorbitol, 
mannitol and polyethylene glycol; (12) esters, such as ethyl 
oleate and ethyl laurate; (13) agar; (14) buffering agents, 
such as magnesium hydroxide and aluminum hydroxide; 
(15) alginic acid; (16) pyrogen-free water; (17) isotonic 
saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phos-
phate buffer solutions; and (21) other non-toxic compatible 
substances employed in pharmaceutical formulations. 
The compounds of the application are capable of further 
forming salts. All of these forms are also contemplated 
herein. 
"Pharmaceutically acceptable salt" of a compound means 
a salt that is pharmaceutically acceptable and that possesses 
the desired pharmacological activity of the parent com-
pound. For example, the salt can be an acid addition salt. 
One embodiment of an acid addition salt is a hydrochloride 
salt. The pharmaceutically acceptable salts can be synthe-
sized from a parent compound that contains a basic or acidic 
moiety by conventional chemical methods. Generally, such 
salts can be prepared by reacting the free acid or base forms 
of these compounds with a stoichiometric amount of the 
appropriate base or acid in water or in an organic solvent, or 
in a mixture of the two; generally, non-aqueous media like 
ether, ethyl acetate, ethanol, isopropanol, or acetonitrile 
being preferred. Lists of salts are found in Remington's 
Pharmaceutical Sciences, 18th ed. (Mack Publishing Com-
pany, 1990). 
The compounds described herein can also be prepared as 
esters, for example pharmaceutically acceptable esters. For 
example, a carboxylic acid function group in a compound 
can be converted to its corresponding ester, e.g., a methyl, 
14 
ethyl, or other ester. Also, an alcohol group in a compound 
can be converted to its corresponding ester, e.g., an acetate, 
propionate, or other ester. 
The compounds described herein can also be prepared as 
5 prodrugs, for example pharmaceutically acceptable prod-
rugs. The terms "pro-drug" and "prodrug" are used inter-
changeably herein and refer to any compound, which 
releases an active parent drug in vivo. Since prodrugs are 
known to enhance numerous desirable qualities of pharma-
lO ceuticals ( e.g., solubility, bioavailability, manufacturing, 
etc.) the compounds can be delivered in prodrug form. Thus, 
the compounds described herein are intended to cover 
prodrugs of the presently claimed compounds, methods of 
15 delivering the same and compositions containing the same. 
"Prodrugs" are intended to include any covalently bonded 
carriers that release an active parent drug in vivo when such 
prodrug is administered to a subject. Prodrugs are prepared 
by modifying functional groups present in the compound in 
20 such a way that the modifications are cleaved, either in 
routine manipulation or in vivo, to the parent compound. 
Prodrugs include compounds wherein a hydroxy, amino, 
sulfhydryl, carboxy, or carbonyl group is bonded to any 
group that may be cleaved in vivo to form a free hydroxyl, 
25 free amino, free sulfhydryl, free carboxy or free carbonyl 
group, respectively. 
Examples of prodrugs include, but are not limited to, 
esters (e.g., acetate, dialkylaminoacetates, formates, phos-
phates, sulfates, and benzoate derivatives) and carbamates 
30 (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional 
groups, ester groups ( e.g., ethyl esters, morpholinoethanol 
esters) of carboxyl functional groups, N-acyl derivatives 
(e.g., N-acetyl)N-Marmich bases, Schiff bases and enamino-
nes of amino functional groups, oximes, acetals, ketals and 
35 enol esters of ketone and aldehyde functional groups in 
compounds of Formula I, and the like, See Bundegaard, H. 
"Design of Prodrugs" p 1-92, Elesevier, New York-Oxford 
(1985). 
The term "protecting group" refers to a grouping of atoms 
40 that when attached to a reactive group in a molecule masks, 
reduces or prevents that reactivity. Examples of protecting 
groups can be found in Green and Wuts, Protective Groups 
in Organic Chemistry, (Wiley, 2.sup.nd ed. 1991); Harrison 
and Harrison et al., Compendium of Synthetic Organic 
45 Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996); and 
Kocienski, Protecting Groups, (Verlag, 3rd ed. 2003). 
The term "amine protecting group" is intended to mean a 
functional group that converts an amine, amide, or other 
nitrogen-containing moiety into a different chemical group 
50 that is substantially inert to the conditions of a particular 
chemical reaction. Amine protecting groups are preferably 
removed easily and selectively in good yield under condi-
tions that do not affect other functional groups of the 
molecule. Examples of amine protecting groups include, but 
55 are not limited to, formyl, acetyl, benzyl, t-butyldimethyl-
silyl, t-butyldiphenylsilyl, t-butyloxycarbonyl (Boe), 
p-methoxybenzyl, methoxymethyl, tosyl, trifluoroacetyl, 
trimethylsilyl (TMS), fluorenyl-methyloxycarbonyl, 2-trim-
ethylsilyl-ethyoxycarbonyl, l-methyl-1-( 4-biphenylyl) 
60 ethoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl 
(CBZ), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and 
substituted trityl groups, 9-fluorenylmethyloxycarbonyl 
(FMOC), nitro-veratryloxycarbonyl (NVOC), and the like. 
Those of skill in the art can identify other suitable amine 
65 protecting groups. 
Representative hydroxy protecting groups include those 
where the hydroxy group is either acylated or alkylated such 
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as benzyl, and trityl ethers as well as alkyl ethers, tetrahy-
dropyranyl ethers, trialkylsilyl ethers and ally! ethers. 
Additionally, the salts of the compounds described herein, 
can exist in either hydrated or unhydrated (the anhydrous) 
form or as solvates with other solvent molecules. Nonlim-
iting examples of hydrates include monohydrates, dihy-
drates, etc. Nonlimiting examples of solvates include etha-
nol solvates, acetone solvates, etc. 
The term "solvates" means solvent addition forms that 
16 
or more of the subject compositions. If it is administered 
prior to clinical manifestation of the unwanted condition 
(e.g., disease or other unwanted state of the host animal) 
then the treatment is prophylactic, i.e., it protects the host 
5 against developing the unwanted condition, whereas if it is 
administered after manifestation of the unwanted condition, 
the treatment is therapeutic (i.e., it is intended to diminish, 
ameliorate, or stabilize the existing unwanted condition or 
side effects thereof). 
The terms "therapeutic agent", "drug", "medicament" and 
"bioactive substance" are art-recognized and include mol-
ecules and other agents that are biologically, physiologically, 
or pharmacologically active substances that act locally or 
systemically in a patient or subject to treat a disease or 
contain either stoichiometric or non stoichiometric amounts 10 
of solvent. Some compounds have a tendency to trap a fixed 
molar ratio of solvent molecules in the crystalline solid state, 
thus forming a solvate. If the solvent is water the solvate 
formed is a hydrate, when the solvent is alcohol, the solvate 
formed is an alcoholate. Hydrates are formed by the com-
bination of one or more molecules of water with one of the 
substances in which the water retains its molecular state as 
H20, such combination being able to form one or more 
hydrate. 
15 condition. The terms include without limitation pharmaceu-
tically acceptable salts thereof and prodrugs. Such agents 
may be acidic, basic, or salts; they may be neutral molecules, 
polar molecules, or molecular complexes capable of hydro-
gen bonding; they may be prodrugs in the form of ethers, 
The compounds, salts and prodrugs described herein can 
exist in several tautomeric forms, including the enol and 
imine form, and the keto and enamine form and geometric 
isomers and mixtures thereof. Tautomers exist as mixtures of 
a tautomeric set in solution. In solid form, usually one 
tautomer predominates. Even though one tautomer may be 
described, the present application includes all tautomers of 
the present compounds. A tautomer is one of two or more 
structural isomers that exist in equilibrium and are readily 
converted from one isomeric form to another. This reaction 
results in the formal migration of a hydrogen atom accom-
panied by a switch of adjacent conjugated double bonds. In 
solutions where tautomerization is possible, a chemical 
equilibrium of the tautomers will be reached. The exact ratio 
of the tautomers depends on several factors, including 
temperature, solvent, and pH. The concept oftautomers that 
are interconvertable by tautomerizations is called tautomer-
1sm. 
Of the various types oftautomerism that are possible, two 
are commonly observed. In keto-enol tautomerism a simul-
taneous shift of electrons and a hydrogen atom occurs. 
Tautomerizations can be catalyzed by: Base: 1. deproto-
nation; 2. formation of a delocalized anion ( e.g., an enolate ); 
3. protonation at a different position of the anion; Acid: 1. 
protonation; 2. formation of a delocalized cation; 3. depro-
tonation at a different position adjacent to the cation. 
The term "analogue" refers to a chemical compound that 
is structurally similar to another but differs slightly in 
composition (as in the replacement of one atom by an atom 
of a different element or in the presence of a particular 
functional group, or the replacement of one functional group 
by another functional group). Thus, an analogue is a com-
pound that is similar or comparable in function and appear-
ance, but not in structure or origin to the reference com-
pound. 
20 esters, amides and the like that are biologically activated 
when administered into a patient or subject. 
The phrase "therapeutically effective amount" or "phar-
maceutically effective amount" is an art-recognized term. In 
certain embodiments, the term refers to an amount of a 
25 therapeutic agent that produces some desired effect at a 
reasonable benefit/risk ratio applicable to any medical treat-
ment. In certain embodiments, the term refers to that amount 
necessary or sufficient to eliminate, reduce or maintain a 
target of a particular therapeutic regimen. The effective 
30 amount may vary depending on such factors as the disease 
or condition being treated, the particular targeted constructs 
being administered, the size of the subject or the severity of 
the disease or condition. One of ordinary skill in the art may 
empirically determine the effective amount of a particular 
35 compound without necessitating undue experimentation. In 
certain embodiments, a therapeutically effective amount of 
a therapeutic agent for in vivo use will likely depend on a 
number of factors, including: the rate of release of an agent 
from a polymer matrix, which will depend in part on the 
40 chemical and physical characteristics of the polymer; the 
identity of the agent; the mode and method of administra-
tion; and any other materials incorporated in the polymer 
matrix in addition to the agent. 
The term "ED50" is art-recognized. In certain embodi-
45 ments, ED50 means the dose of a drug, which produces 50% 
of its maximum response or effect, or alternatively, the dose, 
which produces a pre-determined response in 50% of test 
subjects or preparations. The term "LD50" is art-recognized. 
In certain embodiments, LD50 means the dose of a drug, 
50 which is lethal in 50% of test subjects. The term "therapeutic 
index" is an art-recognized term, which refers to the thera-
peutic index of a drug, defined as LD50/ED50. 
The terms "IC50," or "half maximal inhibitory concentra-
tion" is intended to refer to the concentration of a substance 
55 ( e.g., a compound or a drug) that is required for 50% 
inhibition of a biological process, or component of a pro-
cess, including a protein, subunit, organelle, ribonucleopro-
tein, etc. 
A "patient," "subject," or "host" to be treated by the 
subject method may mean either a human or non-human 
animal, such as a mammal, a fish, a bird, a reptile, or an 
amphibian. Thus, the subject of the herein disclosed meth-
ods can be a human, non-human primate, horse, pig, rabbit, 
dog, sheep, goat, cow, cat, guinea pig or rodent. The term 60 
does not denote a particular age or sex. Thus, adult and 
newborn subjects, as well as fetuses, whether male or 
female, are intended to be covered. In one aspect, the subject 
With respect to any chemical compounds, the present 
application is intended to include all isotopes of atoms 
occurring in the present compounds. Isotopes include those 
atoms having the same atomic number but different mass 
numbers. By way of general example and without limitation, 
isotopes of hydrogen include tritium and deuterium, and is a mammal. A patient refers to a subject afflicted with a 
disease or disorder. 
The terms "prophylactic" or "therapeutic" treatment is 
art-recognized and includes administration to the host of one 
65 isotopes of carbon include C-13 and C-14. 
When a bond to a substituent is shown to cross a bond 
connecting two atoms in a ring, then such substituent can be 
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bonded to any atom in the ring. When a substituent is listed 
without indicating the atom via which such substituent is 
bonded to the rest of the compound of a given formula, then 
such substituent can be bonded via any atom in such 
substituent. Combinations of substituents and/or variables 
are permissible, but only if such combinations result in 
stable compounds. 
18 
having 5 to 8 carbon atoms. The term "substituted alkenyl" 
refers to alkenyl substituted with one or more substituent 
groups, and the terms "heteroatom-containing alkenyl" and 
"heteroalkenyl" refer to alkenyl or heterocycloalkenyl ( e.g., 
5 heterocylcohexenyl) in which at least one carbon atom is 
replaced with a heteroatom. If not otherwise indicated, the 
terms "alkenyl" and "lower alkenyl" include linear, 
branched, cyclic, unsubstituted, substituted, and/or heteroa-When an atom or a chemical moiety is followed by a 
subscripted numeric range ( e.g., C1_6), it is meant to encom-
pass each number within the range as well as all intermediate 10 
ranges. For example, "C1 _6 alkyl" is meant to include alkyl 
groups with 1, 2, 3, 4, 5, 6, 1-6, 1-5, 1-4, 1-3, 1-2, 2-6, 2-5, 
2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, and 5-6 carbons. 
tom-containing alkenyl and lower alkenyl, respectively. 
The term "alkynyl" refers to a linear or branched hydro-
carbon group of 2 to 24 carbon atoms containing at least one 
triple bond, such as ethynyl, n-propynyl, and the like. 
Generally, although again not necessarily, alkynyl groups 
can contain 2 to about 18 carbon atoms, and more particu-The term "alkyl" is intended to include both branched 
15 larly can contain 2 to 12 carbon atoms. The term "lower 
alkynyl" intends an alkynyl group of 2 to 6 carbon atoms. 
The term "substituted alkynyl" refers to alkynyl substituted 
with one or more substituent groups, and the terms "het-
eroatom-containing alkynyl" and "heteroalkynyl" refer to 
( e.g., isopropyl, tert-butyl, isobutyl), straight-chain e.g., 
methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, 
nonyl, decyl), and cycloalkyl (e.g., alicyclic) groups (e.g., 
cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooc-
tyl), alkyl substituted cycloalkyl groups, and cycloalkyl 
substituted alkyl groups. Such aliphatic hydrocarbon groups 
have a specified number of carbon atoms. For example, C1_6 
alkyl is intended to include Ci, C2 , C3 , C4 , C5 , and C6 alkyl 
groups. As used herein, "lower alkyl" refers to alkyl groups 
having from 1 to 6 carbon atoms in the backbone of the 
carbon chain. "Alkyl" further includes alkyl groups that 25 
have oxygen, nitrogen, sulfur or phosphorous atoms replac-
ing one or more hydrocarbon backbone carbon atoms. In 
certain embodiments, a straight chain or branched chain 
alkyl has six or fewer carbon atoms in its backbone (e.g., 
20 alkynyl in which at least one carbon atom is replaced with 
a heteroatom. If not otherwise indicated, the terms "alkynyl" 
and "lower alkynyl" include linear, branched, unsubstituted, 
substituted, and/or heteroatom-containing alkynyl and lower 
alkynyl, respectively. 
The terms "alkyl", "alkenyl", and "alkynyl" are intended 
to include moieties which are diradicals, i.e., having two 
points of attachment. Anonlimiting example of such an alkyl 
moiety that is a diradical is ----CH2 CH2-, i.e., a C2 alkyl 
group that is covalently bonded via each terminal carbon 
C1 -C6 for straight chain, C3 -C6 for branched chain), for 
example four or fewer. Likewise, certain cycloalkyls have 
from three to eight carbon atoms in their ring structure, such 
as five or six carbons in the ring structure. 
The term "substituted alkyls" refers to alkyl moieties 
having substituents replacing a hydrogen on one or more 
carbons of the hydrocarbon backbone. Such substituents can 
include, for example, alkyl, alkenyl, alkynyl, halogen, 
hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbo-
nyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, 
arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylamin-
ocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, 
alkoxyl, phosphate, phosphonato, phosphinato, cyano, 
amino (including alkylamino, dialkylamino, arylamino, dia-
rylamino, and alkylarylamino ), acylamino (including alky-
lcarbonylamino, arylcarbonylamino, carbamoyl and ureido ), 
amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxy-
late, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfona-
mido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, 
alkylaryl, or an aromatic or heteroaromatic moiety. 
Cycloalkyls can be further substituted, e.g., with the sub-
stituents described above. An "alkylaryl" or an "aralkyl" 
moiety is an alkyl substituted with an aryl (e.g., phenylm-
ethyl (benzyl)). If not otherwise indicated, the terms "alkyl" 
and "lower alkyl" include linear, branched, cyclic, unsub-
stituted, substituted, and/or heteroatom-containing alkyl or 
lower alkyl, respectively. 
The term "alkenyl" refers to a linear, branched or cyclic 
hydrocarbon group of 2 to about 24 carbon atoms containing 
at least one double bond, such as ethenyl, n-propenyl, 
isopropenyl, n-butenyl, isobutenyl, octenyl, decenyl, tetra-
decenyl, hexadecenyl, eicosenyl, tetracosenyl, cyclopente-
nyl, cyclohexenyl, cyclooctenyl, and the like. Generally, 
although again not necessarily, alkenyl groups can contain 2 
to about 18 carbon atoms, and more particularly 2 to 12 
carbon atoms. The term "lower alkenyl" refers to an alkenyl 
group of 2 to 6 carbon atoms, and the specific term 
"cycloalkenyl" intends a cyclic alkenyl group, preferably 
30 atom to the remainder of the molecule. 
The term "alkoxy" refers to an alkyl group bound through 
a single, terminal ether linkage; that is, an "alkoxy" group 
may be represented as -O-alkyl where alkyl is as defined 
above. A "lower alkoxy" group intends an alkoxy group 
35 containing 1 to 6 carbon atoms, and includes, for example, 
methoxy, ethoxy, n-propoxy, isopropoxy, t-butyloxy, etc. 
Preferred substituents identified as "C1 -C6 alkoxy" or 
"lower alkoxy" herein contain 1 to 3 carbon atoms, and 
particularly preferred such substituents contain 1 or 2 carbon 
40 atoms (i.e., methoxy and ethoxy). 
The term "aryl" refers to an aromatic substituent contain-
ing a single aromatic ring or multiple aromatic rings that are 
fused together, directly linked, or indirectly linked (such that 
the different aromatic rings are bound to a common group 
45 such as a methylene or ethylene moiety). Ary! groups can 
contain 5 to 20 carbon atoms, and particularly preferred aryl 
groups can contain 5 to 14 carbon atoms. Examples of aryl 
groups include benzene, phenyl, pyrrole, furan, thiophene, 
thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, 
50 oxazole, isooxazole, pyridine, pyrazine, pyridazine, and 
pyrimidine, and the like. Furthermore, the term "aryl" 
includes multicyclic aryl groups, e.g., tricyclic, bicyclic, 
e.g., naphthalene, benzoxazole, benzodioxazole, benzothi-
azole, benzoimidazole, benzothiophene, methylenedioxy-
55 phenyl, quinoline, isoquinoline, naphthridine, indole, ben-
zofuran, purine, benzofuran, deazapurine, or indolizine. 
Those aryl groups having heteroatoms in the ring structure 
may also be referred to as "aryl heterocycles", "hetero-
cycles," "heteroaryls" or "heteroaromatics". The aromatic 
60 ring can be substituted at one or more ring positions with 
such substituents as described above, as for example, halo-
gen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, 
alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alky-
lcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alk-
65 enylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcar-
bonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, 
alkylthiocarbonyl, phosphate, phosphonato, phosphinato, 
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cyano, amino (including alkylamino, dialkylamino, ary-
lamino, diary! amino, and alkylaryl amino), acylamino (in-
cluding alkylcarbonylamino, arylcarbonylamino, carbamoyl 
and ureido ), amidino, imino, sulfhydryl, alkylthio, arylthio, 
thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfa- 5 
moyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, 
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic 
moiety. Ary! groups can also be fused or bridged with 
alicyclic or heterocyclic rings, which are not aromatic so as 
to form a multicyclic system ( e.g., tetralin, methylenedioxy- 10 
phenyl). If not otherwise indicated, the term "aryl" includes 
unsubstituted, substituted, and/or heteroatom-containing 
aromatic substituents. 
The term "alkaryl" refers to an aryl group with an alkyl 
substituent, and the term "aralkyl" refers to an alkyl group 15 
with an aryl substituent, wherein "aryl" and "alkyl" are as 
defined above. Exemplary aralkyl groups contain 6 to 24 
carbon atoms, and particularly preferred aralkyl groups 
contain 6 to 16 carbon atoms. Examples of aralkyl groups 
include, without limitation, benzyl, 2-phenyl-ethyl, 3-phe- 20 
nyl-propyl, 4-phenyl-butyl, 5-phenyl-pentyl, 4-phenylcyclo-
hexy I, 4-benzylcyclohexy I, 4-phenylcyclohexy lmethy I, 
4-benzylcyclohexylmethyl, and the like. Alkaryl groups 
include, for example, p-methylphenyl, 2,4-dimethylphenyl, 
p-cyclohexylphenyl, 2, 7-dimethylnaphthyl, 7-cyclooctyl- 25 
naphthyl, 3-ethyl-cyclopenta-1,4-diene, and the like. 
The terms "heterocyclyl" or "heterocyclic group" include 
closed ring structures, e.g., 3- to 10-, or 4- to 7-membered 
rings, which include one or more heteroatoms. "Heteroa-
tom" includes atoms of any element other than carbon or 30 
hydrogen. Examples of heteroatoms include nitrogen, oxy-
gen, sulfur and phosphorus. 
Heterocyclyl groups can be saturated or unsaturated and 
include pyrrolidine, oxolane, thiolane, piperidine, pipera-
zine, morpholine, lactones, lactams, such as azetidinones 35 
and pyrrolidinones, sultams, and sultones. Heterocyclic 
groups such as pyrrole and furan can have aromatic char-
acter. They include fused ring structures, such as quinoline 
and isoquinoline. Other examples of heterocyclic groups 
include pyridine and purine. The heterocyclic ring can be 40 
substituted at one or more positions with such substituents as 
described above, as for example, halogen, hydroxyl, alkyl-
carbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy-
carbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, 
aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, 45 
phosphonato, phosphinato, cyano, amino (including alkyl 
amino, dialkylamino, arylamino, diarylamino, and alkylary-
lamino ), acylamino (including alkylcarbonylamino, arylcar-
bonylamino, carbamoyl and ureido ), amidino, imino, sulf-
hydryl, alkylthio, arylthio, thiocarboxylate, sulfates, 50 
sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, 
cyano, azido, heterocyclyl, or an aromatic or heteroaromatic 
moiety. Heterocyclic groups can also be substituted at one or 
more constituent atoms with, for example, a lower alkyl, a 
lower alkenyl, a lower alkoxy, a lower alkylthio, a lower 55 
alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, 
-CF3 , or -CN, or the like. 
The term "halo" or "halogen" refers to fluoro, chloro, 
bromo, and iodo. "Counterion" is used to represent a small, 
negatively charged species such as fluoride, chloride, bro- 60 
mide, iodide, hydroxide, acetate, and sulfate. 
The terms "substituted" as in "substituted alkyl," "sub-
stituted aryl," and the like, as alluded to in some of the 
aforementioned definitions, is meant that in the alkyl, aryl, 
or other moiety, at least one hydrogen atom bound to a 65 
carbon (or other) atom is replaced with one or more non-
hydrogen substituents. Examples of such substituents 
20 
include, without limitation: functional groups such as halo, 
hydroxyl, silyl, sulfhydryl, C1 -C24 alkoxy, C2-C24 alkeny-
loxy, C2-C24 alkynyloxy, C5 -C20 aryloxy, acyl (including 
C2-C24 alkylcarbonyl (-CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (---0-acyl), C2-C24 alkoxycarbonyl 
(-(CO)---0-alkyl), CcC20 aryloxycarbonyl (-(CO)-O-
aryl), C2-C24 alkylcarbonato (---0-(CO)---O-alkyl), 
C6-C20 arylcarbonato (---0-(CO)-O-aryl), carboxy 
(-COOH), carboxylato (-COO-), carbamoyl (-(CO)-
NH2), mono-(C1 -C24 alkyl)-substituted carbamoyl 
(-(CO)-NH(C1-C24 alkyl)), di-(C1-C4 alkyl)-substituted 
carbamoyl (-(CO)-N(C1 -C24 alkyl)2), mono-substituted 
arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl 
(-(CS)-NH2), carbamido (-NH-(CO)-NH2), cyano 
(-CN), isocyano (-N+C-), cyanato (---0-CN), isocya-
nato (-ON+C-), isothiocyanato (-S-CN), azido 
(-N W=W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2), mono- and di-(C1-C24 alkyl)-
substituted amino, mono- and di-(C5 -C20 aryl)-substituted 
amino, C2-C24 alkylamido (-NH-(CO)-alkyl), C6 -C20 
arylamido (-NH-(CO)-aryl), imino (-CR NH where 
R=hydrogen, C1 -C24 alkyl, C5 -C20 aryl, C6 -C24 alkaryl, 
CcC24 aralkyl, etc.), alkylimino (-CR N(alkyl), where 
R=hydrogen, alkyl, aryl, alkaryl, etc.), arylimino (-CR N 
(aryl), where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro 
(-NO2), nitroso (-NO), sulfa (-SO2---0H), sulfonato 
(-SO2-o-), C1 -C24 alkylsulfanyl (-S-alkyl; also termed 
"alkylthio"), arylsulfanyl (-S-aryl; also termed "arylthio"), 
C1-C24 alkylsulfinyl (-(SO)-alkyl), C5 -C20 arylsulfinyl 
(-(SO)-aryl), C1 -C24 alkylsulfonyl (-SO2-alkyl), C5 -C20 
arylsulfonyl (-SO2-aryl), phosphono (-P(O)(OH)2), 
phosphonato (-P(O)(O-)2), phosphinato (-P(O)(O-)), 
phospho (-PO2), and phosphino (-PH2); and the hydro-
carbyl moieties C1 -C24 alkyl, C2-C24 alkenyl, C2-C24 alky-
nyl, C5 -C20 aryl, CcC24 alkaryl, and CcC24 aralkyl. 
In addition, the aforementioned functional groups may, if 
a particular group permits, be further substituted with one or 
more additional functional groups or with one or more 
hydrocarbyl moieties such as those specifically enumerated 
above. Analogously, the above-mentioned hydrocarbyl moi-
eties may be further substituted with one or more functional 
groups or additional hydrocarbyl moieties such as those 
specifically enumerated. 
When the term "substituted" appears prior to a list of 
possible substituted groups, it is intended that the term apply 
to every member of that group. For example, the phrase 
"substituted alkyl, alkenyl, and aryl" is to be interpreted as 
"substituted alkyl, substituted alkenyl, and substituted aryl." 
Analogously, when the term "heteroatom-containing" 
appears prior to a list of possible heteroatom-containing 
groups, it is intended that the term apply to every member 
of that group. For example, the phrase "heteroatom-contain-
ing alkyl, alkenyl, and aryl" is to be interpreted as "heteroa-
tom-containing alkyl, substituted alkenyl, and substituted 
aryl. 
"Optional" or "optionally" means that the subsequently 
described circumstance may or may not occur, so that the 
description includes instances where the circumstance 
occurs and instances where it does not. For example, the 
phrase "optionally substituted" means that a non-hydrogen 
substituent may or may not be present on a given atom, and, 
thus, the description includes structures wherein a non-
hydrogen substituent is present and structures wherein a 
non-hydrogen substituent is not present. 
The terms "stable compound" and "stable structure" are 
meant to indicate a compound that is sufficiently robust to 
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survive isolation, and as appropriate, purification from a 
reaction mixture, and formulation into an efficacious thera-
peutic agent. 
22 
double-stranded polynucleotides. In some embodiments, 
"nucleic acid" refers to inhibitory nucleic acids. Some 
categories of inhibitory nucleic acid compounds include 
antisense nucleic acids, RNAi constructs, and catalytic The terms "free compound" is used herein to describe a 
compound in the unbound state. 5 nucleic acid constructs. Such categories of nucleic acids are 
well-known in the art. Throughout the description, where compositions are 
described as having, including, or comprising, specific com-
ponents, it is contemplated that compositions also consist 
essentially of, or consist of, the recited components. Simi-
larly, where methods or processes are described as having, 10 
including, or comprising specific process steps, the pro-
cesses also consist essentially of, or consist of, the recited 
processing steps. Further, it should be understood that the 
order of steps or order for performing certain actions is 
immaterial so long as the compositions and methods 15 
described herein remains operable. Moreover, two or more 
steps or actions can be conducted simultaneously. 
The term "small molecule" is an art-recognized term. In 
certain embodiments, this term refers to a molecule, which 
has a molecular weight of less than about 2000 amu, or less 20 
than about 1000 amu, and even less than about 500 amu. 
All percentages and ratios used herein, unless otherwise 
indicated, are by weight. 
The term "neoplasm" refers to any abnormal mass of cells 
or tissue as a result of neoplasia. The neoplasm may be 25 
benign, potentially malignant (precancerous), or malignant 
(cancerous). An adenoma is an example of a neoplasm. 
Embodiments described herein relate to compounds and 
methods of modulating 15-PGDH activity, modulating tis-
sue prostaglandin levels, and/or treating diseases, disorders, 
or conditions in which it is desired to modulate 15-PGDH 
activity and/or prostaglandin levels. "Inhibitors," "activa-
tors," and "modulators" of 15-PGDH expression or of 
15-PGDH activity are used to refer to inhibitory, activating, 
or modulating molecules, respectively, identified using in 
vitro and in vivo assays for 15-PGDH expression or 
15-PGDH activity, e.g., ligands, agonists, antagonists, and 
their homologs and mimetics. The term "modulator" 
includes inhibitors and activators. Inhibitors are agents that, 
e.g., inhibit expression of 15-PGDH or bind to, partially or 
totally block stimulation, decrease, prevent, delay activa-
tion, inactivate, desensitize, or down regulate the activity of 
15-PGDH, e.g., antagonists. Activators are agents that, e.g., 
induce or activate the expression of a 15-PGDH or bind to, 
stimulate, stabilize, increase, open, activate, facilitate, or 
enhance activation, sensitize or up regulate the activity of 
15-PGDH, e.g., agonists. Modulators include naturally 
occurring and synthetic ligands, small chemical molecules, 
and the like. 
15-PGDH inhibitors described herein can provide a phar-
The terms "adenoma", "colon adenoma" and "polyp" are 
used herein to describe any precancerous neoplasm of the 
colon. 
The term "colon" as used herein is intended to encompass 
the right colon (including the cecum), the transverse colon, 
the left colon and the rectum. 
The terms "colorectal cancer" and "colon cancer" are 
used interchangeably herein to refer to any cancerous neo-
plasia of the colon (including the rectum, as defined above). 
30 macologic method for elevating prostaglandin levels in 
tissue. Known activities of prostaglandins include promot-
ing hair growth, promoting skin pigmentation, and promot-
ing skin darkening or the appearance of skin tanning. Known 
activities of prostaglandins also include ameliorating pul-
The terms "gene expression" or "protein expression" 
includes any information pertaining to the amount of gene 
transcript or protein present in a sample, as well as infor-
mation about the rate at which genes or proteins are pro-
duced or are accumulating or being degraded ( e.g., reporter 
gene data, data from nuclear runoff experiments, pulse-chase 
data etc.). Certain kinds of data might be viewed as relating 
35 monary artery hypertension. 15-PGDH inhibitors described 
herein may also be utilized to increase tissue stem cell 
numbers for purposes that would include increasing resis-
tance to tissue damage by radiation, increasing resistance to 
environmental exposures to radiation, increasing stem cell 
40 numbers to increase fitness of bone marrow or other types of 
transplantation (through either in vivo exposure to 
15-PGDH inhibitors described herein to increase stem cell 
numbers prior to harvest of a transplanted tissue, or through 
to both gene and protein expression. For example, protein 
levels in a cell are reflective of the level of protein as well 45 
as the level of transcription, and such data is intended to be 
included by the phrase "gene or protein expression infor-
mation". Such information may be given in the form of 
amounts per cell, amounts relative to a control gene or 
protein, in unitless measures, etc.; the term "information" is 50 
not to be limited to any particular means of representation 
and is intended to mean any representation that provides 
relevant information. The term "expression levels" refers to 
a quantity reflected in or derivable from the gene or protein 
expression data, whether the data is directed to gene tran- 55 
script accumulation or protein accumulation or protein syn-
thesis rates, etc. 
The terms "healthy" and "normal" are used interchange-
ably herein to refer to a subject or particular cell or tissue 
that is devoid (at least to the limit of detection) of a disease 60 
condition. 
The term "nucleic acid" refers to polynucleotides such as 
deoxyribonucleic acid (DNA), and, where appropriate, ribo-
nucleic acid (RNA). The term should also be understood to 
include analogues of either RNA or DNA made from nucleo- 65 
tide analogues, and, as applicable to the embodiment being 
described, single-stranded ( such as sense or anti sense) and 
ex vivo exposure of a harvested tissue prior to transplant into 
a recipient host). 15-PGDH inhibitors described herein may 
also be utilized for purposes that would include promoting 
liver regeneration, including liver regeneration after liver 
resection, and liver regeneration after toxic insults, which 
for example may be the toxic insult of acetaminophen 
overdose. Prostaglandin signaling is also known to promote 
wound healing, protect the stomach from ulceration, and 
promote healing of ulcers of stomach and intestines. Addi-
tionally, 15-PGDH inhibitors described herein can promote 
activity of human keratinocytes in "healing" scratches 
across cultures of keratinocyte cells. Hence, 15-PGDH 
inhibitors described herein may be utilized to also heal 
ulcers of other tissues, including, but not limited to skin, and 
including but not limited to diabetic ulcers. Further, 
15-PGDH inhibitors described herein may be utilized for the 
treatment of erectile dysfunction. 
15-PGDH activators described herein can increase levels 
of 15-PGDH protein in cells and in increase levels of 
15-PGDH enzymatic activity in cells. Increasing tissue 
levels of 15-PGDH can decrease tissue levels of prostaglan-
dins. Activities associated with compounds that decrease 
tissue prostaglandins include decreasing development of 
human tumors, particularly decreasing development of 
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human colon tumors. Accordingly, compounds that increase 
tissue 15-PGDH activity can lower risk of development of 
colon and other tumors. Compounds that increase 15-PDGH 
activity can also be used to treat colon and other tumors. 
Compounds that increase 15-PDGH may be used to treat or 5 
to prevent tumors when given singly, or when given in 
combination with inhibitors of cyclooxygenase-1 and/or 
cyclooxygenase-2 enzymes, or when given in combination 
with other therapeutic agents. 
15-PGDH inhibitors and activators described herein can 10 
be identified using assays in which putative modulator 
compounds are applied to cells expressing 15-PGDH and 
then the functional effects on 15-PGDH activity are deter-
mined. Samples or assays comprising 15-PGDH that are 
treated with a potential activator, inhibitor, or modulator are 15 
compared to control samples without the inhibitor, activator, 
or modulator to examine the extent of effect. Control 
samples (untreated with modulators) are assigned a relative 
15-PGDH activity value of 100%. Inhibition of 15-PGDH is 
achieved when the 15-PGDH activity value relative to the 20 
control is about 80%, optionally 50% or 25%, 10%, 5% or 
1 %. Activation ofl 5-PGDH is achieved when the 15-PGDH 
activity or expression value relative to the control is 105%, 
optionally 110%, optionally 125%, optionally 150%, option-
ally 200%, 300%, 400%, 500%, or 1000-3000% or more 25 
higher. 
Agents tested as modulators of 15-PGDH can be any 
small chemical molecule or compound. Typically, test com-
pounds will be small chemical molecules, natural products, 
or peptides. The assays are designed to screen large chemical 30 
libraries by automating the assay steps and providing com-
pounds from any convenient source to assays, which are 
typically run in parallel (e.g., in microtiter formats on 
microtiter plates in robotic assays). Modulators also include 
agents designed to increase the level of 15-PGDH mRNA or 35 
the level of translation from an mRNA. 
In some embodiments, the modulator of 15-PGDH can be 
a 15-PGDH inhibitor that includes a compound having the 
following formula (I): 
40 
(I) 
45 
50 
wherein n is 0-2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted ( e.g., R1 can be 
C2_6 alkyl, C2_4 alkyl, or C4 alkyl, which is linear, 55 
branched, or cyclic and which is unsubstituted or 
substituted); 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)n 1 OR' (wherein nl=l, 2, or 3), CF3 , CH2- 60 
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is Hor a lower alkyl group); 
R4 and Rs are the same or different and are each selected 65 
from the group consisting of hydrogen, C1 -C24 alkyl, 
C2-C24 alkenyl, C2-C24 alkynyl, C3 -C20 aryl, CcC24 
24 
alkaryl, CcC24 aralkyl, halo, silyl, hydroxyl, sulfhy-
dryl, C1 -C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alky-
nyloxy, Cs-C20 aryloxy, acyl (including C2-C24 alkyl-
carbonyl (--CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (-O-acyl), C2-C24 alkoxycar-
bonyl (-(CO)---0-alkyl), CcC20 aryloxycarbonyl 
(-(CO)---0-aryl), C2-C24 alkylcarbonato (-O-
(CO)---0-alkyl), C6 -C20 arylcarbonato (---0-(CO)-
O-aryl), carboxy (-COOH), carboxylato (--Coo-), 
carbamoyl (-(CO)-NH2), C1 -C24 alkyl-carbamoyl 
(-(CO)-NH(C1 -C24 alkyl)), arylcarbamoyl 
(-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), 
carbamide (-NH-(CO)-NH2), cyano (----CN), iso-
cyano (-N+c-), cyanato (---0-CN), isocyanato 
(-O-N+=C-), isothiocyanato (-S----CN), azido 
(-N W W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2), C1-C24 alkyl amino, 
Cs-C20 aryl amino, C2-C24 alkylamido (-NH-(CO)-
alkyl), CcC20 arylamido (-NH-(CO)-aryl), imino 
(-CR NH where R is hydrogen, C1-C24 alkyl, 
Cs-C20 aryl, CcC24 alkaryl, CcC24 aralkyl, etc.), alky-
limino (----CR=N(alkyl), where R=hydrogen, alkyl, 
aryl, alkaryl, aralkyl, etc.), arylimino (----CR=N(aryl), 
where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro 
(-NO2), nitroso (-NO), sulfa (-SO2-OH), sul-
fonato (-SO2---0-), C1-C24 alkylsulfanyl (-S-alkyl; 
also termed "alkylthio"), arylsulfanyl (-S-aryl; also 
termed "arylthio"), C1 -C24 alkylsulfinyl (-(SO)-
alkyl), Cs-C20 arylsulfinyl (-(SO)-aryl), C1 -C24 alkyl-
sulfonyl (-SO2-alkyl), Cs-C20 arylsulfonyl (-SO2-
aryl), phosphono (-P(O)(OH)2), phosphonato (-P 
(0)(0-)2), phosphinato (-P(O)(O-)), phospho 
(-PO2), phosphino (-PH2), combinations thereof, 
and wherein R4 and Rs may be linked to form a cyclic 
or polycyclic ring, wherein the ring is a substituted or 
unsubstituted aryl, a substituted or unsubstituted het-
eroaryl, a substituted or unsubstituted cycloalkyl, and a 
substituted or unsubstituted heterocyclyl; and pharma-
ceutically acceptable salts thereof. 
In other embodiments, the 15-PGDH inhibitor can include 
a compound having the following formula (II): 
(II) 
wherein n is 0-2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic, and 
which is unsubstituted or substituted; 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)n 1 OR' (wherein nl=l, 2, or 3), CF3 , CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is H or a lower alkyl group); 
Z1 is NR', 0 or S (wherein R' is Hor a lower alkyl group); 
X1 and Y1 are the same or different and are each selected 
from the group consisting of hydrogen, C1 -C24 alkyl, 
C2-C24 alkenyl, C2-C24 alkynyl, C3 -C20 aryl, CcC24 
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alkaryl, CcC24 aralkyl, halo, silyl, hydroxyl, sulfhy-
dryl, C1 -C24 alkoxy, C2 -C24 alkenyloxy, C2 -C24 alky-
nyloxy, C5 -C20 aryloxy, acyl (including C2 -C24 alkyl-
carbonyl (-CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (-O-acyl), C2 -C24 alkoxycar- 5 
bony! (-(CO)---0-alkyl), CcC20 aryloxycarbonyl 
(-(CO)---0-aryl), C2 -C24 alkylcarbonato (-O-
(CO)---0-alkyl), C6 -C20 arylcarbonato (-O-(CO)-
O-aryl), carboxy (-COOR), carboxylato (-Coo-), 
carbamoyl (-(CO)-NH2 ), C1-C24 alkyl-carbamoyl 10 
(-(CO)-NH(C1-C24 alkyl)), arylcarbamoyl 
(-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2 ), 
carbamido (-NH-(CO)-NH2 ), cyano (-CN), iso-
cyano (-N+c-), cyanato (-O----CN), isocyanato 15 (-O-N+=C-), isothiocyanato (-S----CN), azido 
(-N W=W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2 ), C1-C24 alkyl amino, 
C5-C20 aryl amino, C2 -C24 alkylamido (-NH-(CO)-
alkyl), CcC20 arylamido (-NH-(CO)-aryl), imino 20 
(-CR NH where R is hydrogen, C1 -C24 alkyl, 
C5-C20 aryl, CcC24 alkaryl, CcC24 aralkyl, etc.), alky-
limino (-CR=N(alkyl), where R=hydrogen, alkyl, 
aryl, alkaryl, aralkyl, etc.), arylimino (-CR N(aryl), 
where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro 25 
(-NO2), nitroso (-NO), sulfa (-SO2-OH), sul-
fonato (-SO2---0-), C1-C24 alkylsulfanyl (-S-alkyl; 
also termed "alkylthio"), arylsulfanyl (-S-aryl; also 
termed "arylthio"), C1 -C24 alkylsulfinyl (-(SO)-
alkyl), C5 -C20 arylsulfinyl (-(SO)-aryl), C1 -C24 alkyl- 30 
sulfonyl (-SO2 -alkyl), C5 -C20 arylsulfonyl (-SO2 -
aryl), phosphono (-P(O)(OH)2 ), phosphonato (-P 
(0)(0-)2), phosphinato (-P(O)(O-)), phospho 
(-PO2), phosphino (-PH2), combinations thereof, 35 
and wherein X1 and Y1 may be linked to form a cyclic 
or polycyclic ring, wherein the ring is a substituted or 
unsubstituted aryl, a substituted or unsubstituted het-
eroaryl, a substituted or unsubstituted cycloalkyl, and a 
substituted or unsubstituted heterocyclyl; and pharma- 40 
ceutically acceptable salts thereof. 
Examples of 15-PGDH inhibitors having formulas (I) or 
(II) include the following compounds: 
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and pharmaceutically acceptable salts thereof. 
In certain embodiments, the 15-PGDH inhibitor having 
formula (I) or (II) can be selected that can ia) at 2.5 µM 
concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 70 (using a scale on 
which a value of 100 indicates a doubling of.reporter output 
over baseline); iia) at 2.5 µM concentration stimulate a V9m 
reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 75; iiia) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 70; and iva) at 7 .5 µM 
concentration, does not activate a negative control V9m cell 
line expressing TK-renilla luciferase reporter to a level 
greater than 20; and va) inhibits the enzymatic activity of 
recombinant 15-PGDH protein at an IC50 ofless than 1 µM 
In other embodiments, the 15-PGDH inhibitor can ib) at 
2.5 µM concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; iib) at 2.5 µM concentration 
stimulate a V9m reporter cell line expressing a 15-PGDH 
luciferase fusion construct to increase luciferase output; iiib) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; ivb) at 7.5 µM concentration, 
does not activate a negative control V9m cell line expressing 
TK-renilla luciferase reporter to a luciferase level greater 
than 20% above background; and vb) inhibits the enzymatic 
activity of.recombinant 15-PGDH protein at an IC50 ofless 
than 1 µM. 
In other embodiments, the 15-PGDH inhibitor can inhibit 
the enzymatic activity of recombinant 15-PGDH at: ic) an 
IC50 of less than 1 uM, or preferably iic) at an IC50 of less 
than 250 nM, or more preferably iiic) at an IC50 ofless than 
50 nM, or more preferably iv) at an IC50 ofless than 5 nM. 
An example of a 15-PGDH inhibitor having formula (I) 
that meets the above noted criteria (ia-va) includes a com-
pound having the formula (III): An example of a 15-PGDH 
inhibitor having formula (I) that meets the above noted 
criteria (ib-vb) includes a compound having the formula 
50 (III): An example of a 15-PGDH inhibitor having formula (I) 
that meets the above noted criteria ic, and/or iic, and or iiic, 
and or ivc, includes a compound having the formula (III): In 
still other embodiments, the 15-PGDH inhibitor can include 
a compound having the following formula (III): 
55 
60 
65 
(III) 
(O)n 
z t 
"R1 
R,;; R2 
~ N/ 
x-'' I 2 \ R3 
R1 
wherein n is 0-2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted; 
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R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)n 1 OR' (wherein nl=l, 2, or 3), CF3 , CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is Hor a lower alkyl group); 
Z1 is NR', 0 or S (wherein R' is Hor a lower alkyl group); 
X2 is Nor C; 
30 
solvent, such as N,N-dimethylformamide, N,N-dimethylac-
etamide, acetonitrile, dimethylsulfoxide and hexamethyl 
phosphoric acid triamide. Among non-reactive organic sol-
vents that are ordinarily used in the organic synthesis, 
5 preferable solvents are those from which water generated in 
the reaction can be removed by a Dean-Stark trap. The 
examples of such solvents include, but are not limited to 
benzene, toluene, xylene and the like. The reaction product 
thus obtained may be isolated and purified by condensation, 
10 
extraction and the like, which is ordinarily conducted in the 
field of the organic synthesis, if desired, by silica gel column 
chromatography. The individual enantiomers of PGDH 
inhibitors having the formula III can be separated by a 
R6 and R7 are optional and if present are the same or 
different and are each selected from the group consist-
ing of a H, F, Cl, Br, I, a lower alkyl group, (CH2)n 1 OR' 
(whereinnl=l, 2, or3), CF3 , CH2----CH2X, O----CH2-
CH2X, CH2-CH2-CH2X, O-CH2-CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is H or a lower alkyl group); substituted or 
unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, and a substituted or unsubstituted hetero- 20 
cyclyl; and pharmaceutically acceptable salts thereof. 
15 preparative HPLC using chromatography columns contain-
ing chiral stationary phases. 
Further, embodiments of this application include any 
modifications for the preparation method of the 15-PGDH 
inhibitors described above. In this connection, any interme-
diate product obtainable from any step of the preparation 
method can be used as a starting material in the other steps. 
Such starting material can be formed in situ under certain 
reaction conditions. Reaction reagents can also be used in 
the form of their salts or optical isomers. 
15-PGDH inhibitors having formula (III) can be synthe-
sized as shown: 
Any reaction solvent can be used in the above preparation 
process as long as it is not involved in the reaction. For 
example, the reaction solvent includes ethers such as diethyl 
ether, tetrahydrofuran and dioxane; halogenized hydrocar-
bons, such as dichloromethane and chloroform; amines such 
25 
Depending on the kinds of the substituents to be used in 
the preparation of the 15-PGDH inhibitors, and the inter-
mediate product and the preparation method selected, novel 
15-PGDH inhibitors can be in the form of any possible 
30 isomers such as substantially pure geometrical ( cis or trans) 
isomers, optical isomers (enantiomers) and racemates. 
35 
40 
45 
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In some embodiments, a 15-PGDH inhibitor having for-
mula (III) can include a compound with the following 
formula: 
f s 
,--::::; 0 
// 
s 
~ 
and pharmaceutically acceptable salts thereof. 
Advantageously, the 15-PDGH inhibitor having formula 
(III) was found to: i) inhibit recombinant 15-PGDH at 1 nM 
concentration; ii) inhibit 15-PGDH in cell lines at 100 nM 
concentration, iii) increase PGE2 production by cell lines; 
55 iv) is chemically stable in aqueous solutions over broad pH 
range; v) is chemically stable when incubated with hepato-
cyte extracts, vi) is chemically stable when incubated with 
hepatocyte cell lines; vii) shows 253 minutes plasma half-
life when injected IP into mice; and viii) shows no imme-
60 diate toxicity over 24 hours when injected IP into mice at 0.6 
µmole/per mouse and at 1.2 µmole/per mouse and also no 
toxicity when injected IP into mice at 0.3 µmole/per mouse 
twice daily for 21 days. 
as pyridine, piperidine and triethylamine; alkylketones, such 65 
as acetone, methylethylketone and methylisobutyl; alcohols, 
such as methanol, ethanol and propanol; non-protonic polar 
In other embodiments, a 15-PGDH inhibitor having for-
mula (III) can include a compound with the following 
formula: 
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and pharmaceutically acceptable salts thereof. 
In still other embodiments, a 15-PGDH inhibitor having 
formula (III) can include a compound with the following 
formula: 
f s 
·; o-
\. f 
\_\_ 
and pharmaceutically acceptable salts thereof. 
In other embodiments, the 15-PDHG inhibitor can com-
prise a ( +) or (-) optical isomer of a 15-PGDH inhibitor 
having formula (III). In still other embodiments, the 
15-PDHG inhibitor can comprise a mixture at least one of a 
( +) or (-) optical isomer of a 15-PGDH inhibitor having 
formula (III). For example, the 15-PGDH inhibitor can 
comprise a mixture of: less than about 50% by weight of the 
(-) optical isomer of a 15-PGDH inhibitor having formula 
(III) and greater than about 50% by weight of the ( +) optical 
isomer of a 15-PGDH inhibitor having formula (III), less 
than about 25% by weight of the (-) optical isomer of a 
15-PGDH inhibitor having formula (III) and greater than 
about 75% by weight of the ( +) optical isomer of a 
15-PGDH inhibitor having formula (III), less than about 
10% by weight of the(-) optical isomer of a 15-PGDH 
inhibitor having formula (III) and greater than about 90% by 
weight of the(+) optical isomer of a 15-PGDH inhibitor 
having formula (III), less than about 1 % by weight of the (-) 
optical isomer of a 15-PGDH inhibitor having formula (III) 
and greater than about 99% by weight of the ( +) optical 
isomer of a 15-PGDH inhibitor having formula (III), greater 
than about 50% by weight of the (-) optical isomer of a 
15-PGDH inhibitor having formula (III) and less than about 
50% by weight of the ( +) optical isomer of a 15-PGDH 
inhibitor having formula (III), greater than about 75% by 
weight of the(-) optical isomer of a 15-PGDH inhibitor 
having formula (III) and less than about 25% by weight of 
the (+) optical isomer of a 15-PGDH inhibitor having 
formula (III), greater than about 90% by weight of the (-) 
optical isomer of a 15-PGDH inhibitor having formula (III) 
and less than about 10% by weight of the ( +) optical isomer 
of a 15-PGDH inhibitor having formula (III), or greater than 
about 99% by weight of the (-) optical isomer of a 
15-PGDH inhibitor having formula (III) and less than about 
32 
1 % by weight of the ( +) optical isomer of a 15-PGDH 
inhibitor having formula (III). 
In a still further embodiment, the 15-PDGH inhibitor can 
consist essentially of or consist of the ( +) optical isomer of 
5 a 15-PGDH inhibitor having formula (III). In yet another 
embodiment, the PDGH inhibitor can consist essentially of 
or consist of the(-) optical isomer of a 15-PGDH inhibitor 
having formula (III). 
The 15-PGDH inhibitors described herein can be used for 
10 the prevention or the treatment of diseases that are associ-
ated with 15-PGDH and/or decreased prostaglandin levels 
and/or where it desirable to increase prostaglandin levels in 
the subject. For example, as discussed above, it is known 
that prostaglandins play an important role in hair growth. 
15 Specifically, internal storage of various types (A2 , F2 a, E2 ) 
of prostaglandins in the various compartments of hair fol-
licles or their adjacent skin environments has been shown to 
be essential in maintaining and increasing hair density 
(Colombe Let. al, 2007, Exp. Dermatol, 16(9), 762-9). It has 
20 been reported that 15-PGDH, which is involved in the 
degradation of prostaglandins is present in the hair follicle 
dermal papillae, inactivates prostaglandins, especially, 
PGF 2 a and PGE2 , to cause scalp damage and alopecia 
(Michelet J F et. al., 2008, Exp. Dermatol, 17(10), 821-8). 
25 Thus, the compounds described herein, which have a sup-
pressive or inhibitory activity against 15-PGDH that 
degrades prostaglandins, can improve scalp damage, prevent 
alopecia and promote hair growth and be used in a pharma-
ceutical composition for the prevention of alopecia and the 
30 promotion of hair growth. 
In other embodiments, the 15-PGDH inhibitors described 
herein can be used in a pharmaceutical composition for 
promoting and/or inducing and/or stimulating pigmentation 
of the skin and/or skin appendages, and/or as an agent for 
35 preventing and/or limiting depigmentation and/or whitening 
of the skin and/or skin appendages, in particular as an agent 
for preventing and/or limiting canities. 
In still other embodiments, the 15-PGDH inhibitors 
described herein can be used in a pharmaceutical composi-
40 tion for the prevention or the treatment of cardiovascular 
disease and/or diseases of vascular insufficiency, such as 
Raynaud's disease, Buerger's disease, diabetic neuropathy, 
and pulmonary artery hypertension. Prostaglandins includ-
ing prostaglandin homologues produced in the body have 
45 been known to maintain the proper action of the blood vessel 
wall, especially to contribute to vasodilation for blood flow, 
preventing platelet aggregation and modulating the prolif-
eration of smooth muscle that surrounds blood vessel walls 
(Yan. Cheng et. al., 2006, J. Clin., Invest). In addition, the 
50 inhibition of prostaglandins production or the loss of their 
activity causes the degeneration of the endothelium in the 
blood vessel walls, platelet aggregation and the dysfunction 
of cellular mechanism in the smooth muscle. Among others, 
the production of prostaglandins in blood vessels was shown 
55 to be decreased in hypertension patients, including pulmo-
nary artery hypertension. 
In other embodiments, the 15-PGDH inhibitors described 
herein can be used in a pharmaceutical composition for the 
prevention or the treatment of oral and/or gastrointestinal 
60 diseases, such as oral ulcers, gum disease, gastritis, colitis, 
ulcerative colitis, and gastric ulcers. Gastritis and gastric 
ulcer, representatives of the gastrointestinal diseases, are 
defined as the conditions where gastrointestinal mucus 
membrane is digested by gastric acid to form ulcer. In the 
65 stomach walls generally consisting of mucosa, submucosa, 
muscle layer and serosa, gastric ulcer even damages sub-
mucosa and muscle layer, while gastritis damages mucosa 
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only. Although the morbidity rates of gastritis and gastric 
ulcer are relatively high, the causes thereof have not been 
clarified yet. Until now, they are known to be caused by an 
imbalance between aggressive factors and defensive factors, 
that is, the increase in aggressive factors such as the increase 5 
in gastric acid or pepsin secretion, or the decrease in 
defensive factors such as structural or morphological deficit 
of the gastric mucus membrane, the decrease in mucus and 
bicarbonate ion secretion, the decrease in prostaglandin 
production, or the like. 10 
Currently available therapeutic agents for gastritis and 
gastric ulcer comprise various drugs for strengthening the 
defensive factors such as an antacid, which does not affect, 
gastric acid secretion but neutralizes gastric acid that has 
been already produced, an inhibitor of gastric acid secretion, 15 
a promoter of prostaglandin secretion, and a coating agent 
for stomach walls. Especially, prostaglandins are known to 
be essential in maintaining the mechanism for protecting and 
defending gastric mucus membrane (Wallace J L., 2008, 
Physiol Rev., 88(4), 1547-65, S. J. Konturek et al., 2005, 20 
Journal of Physiology and Pharmacology, 56(5)). In view of 
the above, since the 15-PGDH inhibitors described herein 
show a suppressive or inhibitory activity against 15-PGDH, 
which degrades prostaglandins that protect gastric mucus 
membrane, they can be effective for the prevention or the 25 
treatment of gastrointestinal diseases, inter alia, gastritis and 
gastric ulcer. 
In the kidney, prostaglandins modulate renal blood flow 
and may serve to regulate urine formation by both renovas-
cular and tubular effects. In clinical studies, PGE1 has been 30 
used to improve creatinine clearance in patients with chronic 
renal disease, to prevent graft rejection and cyclosporine 
toxicity in renal transplant patients, to reduce the urinary 
albumin excretion rate and N-acetyl-beta-D-glucosamini-
dase levels in patients with diabetic nephropathy ( see Porter, 35 
Am., 1989, J. Cardiol., 64: 22E-26E). In addition, U.S. Pat. 
No. 5,807,895 discloses a method of preventing renal dys-
function by intravenous administration of prostaglandins 
such as PGE1 , PGE2 and PGI2 . Furthermore, it has been 
reported that prostaglandins serve as vasodilators in the 40 
kidney, and, thus, the inhibition of prostaglandin production 
in the kidney results in renal dysfunction (Hao. C M, 2008, 
Annu Rev Physiol, 70, 357.about.77). 
Thus, the 15-PGDH inhibitors described herein, which 
have a suppressive or inhibitory activity against 15-PGDH 45 
that degrades prostaglandins, may be effective in the pre-
vention or the treatment of renal diseases that are associated 
with renal dysfunction. 
The term "renal dysfunction" as used herein includes such 
manifestations as follows: lower than normal creatinine 50 
34 
bone formation by inhibiting 15-PGDH activity. 15-PGDH 
inhibitors can also be used to increase bone density, treat 
osteoporosis, promote healing of fractures, or promote heal-
ing after bone surgery or joint replacement. 
In yet other embodiments, the 15-PGDH inhibitors 
described herein can effective for treating 15-PGDH 
expressing cancers. Inhibition of 15-PGDH can inhibit the 
growth, proliferation, and metastasis of 15-PGDH express-
ing cancers. 
In still other embodiments, the 15-PGDH inhibitors 
described herein can be effective for wound healing. Among 
various prostaglandins, PGE2 is known to serve as a media-
tor for wound healing. Therefore, when skin is injured by 
wounds or burns, the inhibition of 15-PGDH activity can 
produce the treatment effect of the wounds or the burns by 
PGE2 . 
Additionally, as discussed above, increased prostaglandin 
levels have been shown to stimulate signaling through the 
Wnt signaling pathway via increased beta-catenin mediated 
transcriptional activity. Wnt signaling is known to be a key 
pathway employed by tissue stem cells, and increasing 
PGE2 signaling has in model organisms been shown to 
increase numbers of hematopoietic stem cells. Hence, 
15-PGDH inhibitors described herein may be utilized to 
increase tissue stem cell numbers for purposes that would 
include increasing resistance to tissue damage by radiation, 
increasing resistance to environmental exposures to radia-
tion, increasing stem cell numbers to increase fitness of bone 
marrow or other types of transplantation (through either in 
vivo exposure to 15-PGDH inhibitors described herein to 
increase stem cell numbers prior to harvest of a transplanted 
tissue, or through ex vivo exposure of a harvested tissue 
prior to transplant into a recipient host, or through treatment 
of the recipient host either before, during, or after receipt of 
the transplant). 
In some embodiments, the 15-PGDH inhibitor can be 
administered to a bone marrow graft donor or a hematopoi-
etic stem cell donor to increase the fitness of a donor bone 
marrow graft or a donor hematopoietic stem cell graft. 
In other embodiments, the 15-PGDH inhibitor can also be 
administered to bone marrow of a subject to increase stem 
cells in the subject or to increase the fitness of the marrow 
as a donor graft. 
In still other embodiments, the 15-PGDH inhibitor can be 
administered to a preparation of hematopoietic stem cells, 
peripheral blood hematopoietic stem cells, or umbilical cord 
stem cells of the subject to increase the fitness of the stem 
cell preparation as a donor graft or to decrease the number 
of units of umbilical cord blood required for transplantation. 
In yet other embodiments, the 15-PGDH inhibitor can be 
administered to a subject to mitigate bone marrow graft 
rejection, to enhance bone marrow graft engraftment, to 
enhance engraftment of a hematopoietic stem cell graft, or 
an umbilical cord stem cell graft, to enhance engraftment of 
clearance, lower than normal free water clearance, higher 
than normal blood urea, nitrogen, potassium and/or creati-
nine levels, altered activity of kidney enzymes such as 
gamma glutamyl synthetase, alanine phosphatidase, 
N-acetyl-beta-D-glucosaminidase, or beta-w-microglobulin; 
and increase over normal levels of macroalbuminuria. 
Prostaglandins including PGE1 , PGE2 and PGF2 a have 
also been shown to stimulate bone resorption and bone 
formation to increase the volume and the strength of the 
bone (H. Kawaguchi et. al., Clinical Orthop. Rel. Res., 313, 
1995; J. Keller et al., Eur. Jr. Exp. Musculoskeletal Res., 1, 
1992, 8692). Considering that 15-PGDH inhibits the activi-
ties of prostaglandins as mentioned in the above, the inhi-
bition of 15-PGDH activity may lead to the promotion of 
bone resorption and bone formation that are inhibited by 
15-PGDH. Thus, the 15-PGDH inhibitors described herein 
can be effective for the promotion of bone resorption and 
55 a hematopoietic stem cell graft, or an umbilical cord stem 
cell graft, and/or to decrease the number of units of umbili-
cal cord blood required for transplantation into the subject. 
The administration can be, for example, following treatment 
of the subject or the marrow of the subject with radiation 
60 therapy, chemotherapy, or immunosuppressive therapy. 
In other embodiments, the 15-PGDH inhibitor can be 
administered to a recipient of a bone marrow transplant, of 
a hematopoietic stem cell transplant, or of an umbilical cord 
stem cell transplant, in order to decrease the administration 
65 of other treatments or growth factors. 
In further embodiments, the 15-PGDH inhibitor can be 
administered to a subject or to a tissue graft of a subject to 
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m1t1gate graft rejection, to enhance graft engraftment, to 
enhance graft engraftment following treatment of the subject 
or the marrow of the subject with radiation therapy, chemo-
therapy, or immunosuppressive therapy, to confer resistance 
to toxic or lethal effects of exposure to radiation, confer 5 
resistance to the toxic effect of Cytoxan, the toxic effect of 
fludarabine, the toxic effect of chemotherapy, or the toxic 
effect of immunosuppressive therapy, to decrease infection, 
and/or to decrease pulmonary toxicity from radiation. 
Additionally, in model organism PGE2 signaling stimu- 10 
!ates liver regeneration and increase survival after exposure 
to hepatoxic agents, such as acetaminophen. Hence, 
15-PGDH inhibitors described herein may be utilized to 
increase liver regeneration after liver resection, or to 
increase liver regeneration and increase survival after expo- 15 
sures to hepatoxic agents, including but not limited to 
acetaminophen and similar compounds. 
PGEl analogues have also been used in the treatment of 
erectile dysfunction. Accordingly, in some embodiments, 
15-PGDH inhibitors described herein can used either alone 20 
or combination with a prostaglandin for the treatment of 
erectile dysfunction. 
36 
the like and incorporated into oral liquid dosage forms such 
as solutions, syrups or elixirs in accordance with conven-
tional methods. One example of the buffers may be sodium 
citrate. Examples of the stabilizing agents include traga-
canth, acacia and gelatin. 
In some embodiments, the 15-PGDH inhibitors described 
herein may be incorporated into an injection dosage form, 
for example, for a subcutaneous, intramuscular or intrave-
nous route by adding thereto pH adjusters, buffers, stabiliz-
ing agents, relaxants, topical anesthetics. Examples of the 
pH adjusters and the buffers include sodium citrate, sodium 
acetate and sodium phosphate. Examples of the stabilizing 
agents include sodium pyrosulfite, EDTA, thioglycolic acid 
and thiolactic acid. The topical anesthetics may be procaine 
HCl, lidocaine HCl and the like. The relaxants may be 
sodium chloride, glucose and the like. 
In other embodiments, the 15-PGDH inhibitors described 
herein may be incorporated into suppositories in accordance 
with conventional methods by adding thereto pharmaceuti-
cally acceptable carriers that are known in the art, for 
example, polyethylene glycol, lanolin, cacao butter or fatty 
acid triglycerides, if necessary, together with surfactants 
such as Tween. 
The pharmaceutical composition may be formulated into 
The 15-PGDH inhibitors described herein can be pro-
vided in a pharmaceutical composition or cosmetic compo-
sition depending on the pathological or cosmetic condition 
or disorder being treated. A pharmaceutical composition 
containing the 15-PGDH inhibitors described herein as an 
active ingredient may be manufactured by mixing the 
derivative with a pharmaceutically acceptable carrier(s) or 
an excipient(s) or diluting the 15-PGDH inhibitors with a 
diluent(s) in accordance with conventional methods. The 
pharmaceutical composition may further contain fillers, anti-
cohesives, lubricants, wetting agents, flavoring agents, 
emulsifying agents, preservatives and the like. The pharma-
ceutical composition may be formulated into a suitable 
formulation in accordance with the methods known to those 
skilled in the art so that it can provide an immediate, 
controlled or sustained release of the 15-PGDH inhibitors 
after being administered into a mammal. 
25 various dosage forms as discussed above and then admin-
istered through various routes including an oral, inhala-
tional, transdermal, subcutaneous, intravenous or intramus-
cular route. The dosage can be a pharmaceutically effective 
amount. The pharmaceutically effective amount can be an 
30 amount of the 15-PGDH inhibitor to treat or improve 
alopecia, cardiovascular disease, gastrointestinal disease, 
wounds, and renal disease. The pharmaceutically effective 
amount of the compound will be appropriately determined 
depending on the kind and the severity of the disease to be 
35 treated, age, sex, body weight and the physical condition of 
the patients to be treated, administration route, duration of 
therapy and the like. Generally, the effective amount of the 
compound may be in the range of about 1 to 1,000 mg in the 
oral administration, about 0.1 to 500 mg in the intravenous 
40 administration, about 5 to 1,000 mg in the rectal adminis-
tration. Generally, the daily dosage for adults is in the range 
of about 0.1 to 5,000 mg, preferably about to 1,000 mg but 
camiot be determined uniformly because it depends on age, 
sex, body weight and the physical condition of the patients 
In some embodiments, the pharmaceutical composition 
may be formulated into a parenteral or oral dosage form. The 
solid dosage form for oral administration may be manufac-
tured by adding excipient, if necessary, together with binder, 
disintegrants, lubricants, coloring agents, and/or flavoring 
agents, to the 15-PGDH inhibitors and shaping the resulting 
mixture into the form of tablets, sugar-coated pills, granules, 
powder or capsules. The additives that can be added in the 
composition may be ordinary ones in the art. For example, 
examples of the excipient include lactose, sucrose, sodium 
chloride, glucose, starch, calcium carbonate, kaolin, micro-
crystalline cellulose, silicate and the like. Exemplary binders 
include water, ethanol, propanol, sweet syrup, sucrose solu-
tion, starch solution, gelatin solution, carboxymethylcellu-
lose, hydroxypropyl cellulose, hydroxypropyl starch, meth-
ylcellulose, ethylcellulose, shellac, calcium phosphonate 
and polypyrrolidone. Examples of the disintegrant include 
dry starch, sodium arginate, agar powder, sodium bicarbon-
ate, calcium carbonate, sodium lauryl sulfate, stearic mono-
glyceride and lactose. Further, purified talc, stearates, 
sodium borate, and polyethylene glycol may be used as a 60 
lubricant; and sucrose, bitter orange peel, citric acid, tartaric 
acid, may be used as a flavoring agent. In some embodi-
ments, the pharmaceutical composition can be made into 
aerosol formulations ( e.g., they can be nebulized) to be 
administered via inhalation. 
45 to be treated. The formulation may be administered once a 
day or several times a day with a divided dose. 
Cosmetic compositions containing the 15-PGDH inhibi-
tor can include any substance or preparation intended to be 
brought into contact with the various superficial parts of the 
50 human body ( epidermis, body hair and hair system, nails, 
lips and external genital organs) or with the teeth or the 
buccal mucous membranes for the purpose, exclusively or 
mainly, of cleansing them, of giving them a fragrance, of 
modifying their appearance and/or of correcting body odors 
55 and/or protecting them or of maintaining them in good 
condition. 
The cosmetic composition can comprise a cosmetically 
acceptable medium that may be water or a mixture of water 
and at least one solvent selected from among hydrophilic 
organic solvents, lipophilic organic solvents, amphiphilic 
organic solvents, and mixtures thereof. 
For topical application, the cosmetic composition can be 
administered in the form of aqueous, alcoholic, aqueous-
alcoholic or oily solutions or suspensions, or of a dispersion 
65 of the lotion or serum type, of emulsions that have a liquid 
or semi-liquid consistency or are pasty, obtained by disper-
sion of a fatty phase in an aqueous phase (0/W) or vice versa 
The 15-PGDH inhibitors described herein may be com-
bined with flavoring agents, buffers, stabilizing agents, and 
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(W /0) or multiple emulsions, of a free or compacted powder 
to be used as it is or to be incorporated into a physiologically 
acceptable medium, or else of microcapsules or micropar-
ticles, or of vesicular dispersions of ionic and/or nonionic 
type. It may thus be in the form of a salve, a tincture, milks, 5 
a cream, an ointment, a powder, a patch, an impregnated 
pad, a solution, an emulsion or a vesicular dispersion, a 
lotion, aqueous or anhydrous gels, a spray, a suspension, a 
shampoo, an aerosol or a foam. It may be anhydrous or 
aqueous. It may also comprise solid preparations constitut- 10 
ing soaps or cleansing cakes. 
The cosmetic compositions may in particular comprise a 
hair care composition, and in particular a shampoo, a setting 
lotion, a treating lotion, a styling cream or gel, restructuring 
lotions for the hair, a mask, etc. The cosmetic compositions 15 
can be a cream, a hair lotion, a shampoo or a conditioner. 
These can be used in particular in treatments using an 
application that may or may not be followed by rinsing, or 
else in the form of a shampoo. A composition in the form of 
a foam, or else in the form of spray or an aerosol, then 20 
comprising propellant under pressure, is also intended. It can 
thus be in the form of a lotion, serum, milk, cream, gel, 
salve, ointment, powder, balm, patch, impregnated pad, cake 
or foam. 
In particular, the compositions for application to the scalp 25 
or the hair can be in the form of a hair care lotion, for 
example for daily or twice-weekly application, of a shampoo 
or of a hair conditioner, in particular for twice-weekly or 
weekly application, of a liquid or solid soap for cleansing the 
scalp, for daily application, of a hairstyle shaping product 30 
(lacquer, hair setting product or styling gel), of a treatment 
mask, or of a foaming gel or cream for cleansing the hair. 
These may also be in the form of a hair dye or mascara to 
be applied with a brush or a comb. 
38 
weeks depending upon the combination selected). "Combi-
natorial therapy" or "combination therapy" is intended to 
embrace administration of these therapeutic agents in a 
sequential manner, that is, wherein each therapeutic agent is 
administered at a different time, as well as administration of 
these therapeutic agents, or at least two of the therapeutic 
agents, in a substantially simultaneous marmer. Substantially 
simultaneous administration can be accomplished, for 
example by administering to the subject an individual dose 
having a fixed ratio of each therapeutic agent or in multiple, 
individual doses for each of the therapeutic agents. Sequen-
tial or substantially simultaneous administration of each 
therapeutic agent can be effected by any appropriate route 
including, but not limited to, oral routes, intravenous routes, 
intramuscular routes, and direct absorption through mucous 
membrane tissue. The therapeutic agents can be adminis-
tered by the same route or by different routes. The sequence 
in which the therapeutic agents are administered is not 
narrowly critical. 
In some embodiments, the additional active agent can be 
chosen in particular from lipoxygenase inhibitors as 
described in EP 648488, the bradykinin inhibitors described 
in particular in EP 845700, prostaglandins and their deriva-
tives, in particular those described in WO 98/33497, WO 
95/11003, JP 97-100091, JP 96-134242, the agonists or 
antagonists of the receptors for prostaglandins, and the 
nonprostanoic analogues of prostaglandins as described in 
EP1175891 andEP1175890, WO0l/74307, WO0l/74313, 
WO 01/74314, WO 01/74315 or WO 01/72268. 
In other embodiments, the 15-PGDH inhibitors can be 
administered in combination with active agents, such as 
vasodilators, prostanoid agonists, antiandrogens, 
cyclosporins and their analogues, antimicrobials, triter-
penes, alone or as a mixture. The vasodilators can include 
potassium charmel agonists including minoxidil and its 
derivatives, aminexil and the compounds described in U.S. 
Pat. Nos. 3,382,247, 5,756,092, 5,772,990, 5,760,043, 
5,466,694, 5,438,058, 4,973,474, chromakalin and diazox-
ide. The antiandrogens can include 5.alpha.-reductase 
inhibitors such as finasteride and the compounds described 
in U.S. Pat. No. 5,516,779, cyprosterone acetate, azelaic 
acid, its salts and its derivatives, and the compounds 
described in U.S. Pat. No. 5,480,913, flutamide and the 
compounds described in U.S. Pat. Nos. 5,411,981, 5,565,467 
Moreover, for topical application to the eyelashes or body 35 
hair, the compositions may be in the form of a pigmented or 
unpigmented mascara, to be applied with a brush to the 
eyelashes or alternatively to beard or moustache hair. For a 
composition administration by injection, the composition 
may be in the form of an aqueous lotion or an oily suspen- 40 
sion. For oral use, the composition may be in the form of 
capsules, granules, oral syrups or tablets. According to a 
particular embodiment, the composition is in the form of a 
hair cream or hair lotion, a shampoo, a hair conditioner or a 
mascara for the hair or for the eyelashes. 45 and 4,910,226. The antimicrobial compounds can include 
selenium derivatives, ketoconazole, triclocarban, triclosan, 
zinc pyrithione, itraconazole, asiatic acid, hinokitiol, mipi-
rocine, and the compounds described in EP 680745, cliny-
In a known manner, the cosmetic compositions may also 
contain adjuvants that are normal in the cosmetics field, such 
as hydrophilic or lipophilic gelling agents, hydrophilic or 
lipophilic additives, preservatives, antioxidants, solvents, 
fragrances, fillers, UV-screening agents, odor absorbers and 50 
dyestuffs. The amounts of these various adjuvants are those 
conventionally used in the cosmetics field, and are for 
example from 0.1 % to 20%, in particular less than or equal 
to 10%, of the total weight of the composition. According to 
their nature, these adjuvants can be introduced into the fatty 55 
phase, into the aqueous phase and/or into the lipid spherules. 
In some embodiments, the 15-PGDH inhibitor can be 
administered in a combinatorial therapy or combination 
therapy that includes administration of a 15-PGDH inhibitor 
with one or more additional active agents. The phrase 60 
"combinatorial therapy" or "combination therapy" embraces 
the administration of the 15-PGDH inhibitor, and one or 
more therapeutic agents as part of a specific treatment 
regimen intended to provide beneficial effect from the 
co-action of these therapeutic agents. Administration of 65 
these therapeutic agents in combination typically is carried 
out over a defined period (usually minutes, hours, days or 
cine hydrochloride, benzoyl or benzyl peroxide and mino-
cycline. The anti-inflanimatory agents can include inhibitors 
specific for Cox-2 such as for example NS-398 and DuP-697 
(B. Batistini et al., DN&P 1994; 7(8):501-511) and/or inhibi-
tors of lipoxygenases, in particular 5-lipoxygenase, such as 
for example zileuton (F. J. Alvarez & R. T. Slade, Pharma-
ceutical Res. 1992; 9(11):1465-1473). 
Other active compounds, which can be present in phar-
maceutical and/or cosmetic compositions can include 
aminexil and its derivatives, 60-[(9Z,12Z)octadec-9,12-di-
enoyl]hexapyranose, benzalkonium chloride, benzethonium 
chloride, phenol, oestradiol, chlorpheniramine maleate, 
chlorophyllin derivatives, cholesterol, cysteine, methionine, 
benzyl nicotinate, menthol, peppermint oil, calcium pantho-
tenate, panthenol, resorcinol, protein kinase C inhibitors, 
prostaglandin H synthase 1 or COX-1 activators, or COX-2 
activators, glycosidase inhibitors, glycosaminoglycanase 
inhibitors, pyroglutamic acid esters, hexosaccharidic or 
acylhexosaccharidic acids, substituted ethylenearyls, N-acy-
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lated amino acids, flavonoids, derivatives and analogues of 
ascomycin, histamine antagonists, triterpenes, such as urso-
lic acid and the compounds described in U.S. Pat. Nos. 
5,529,769, 5,468,888, 5,631,282, saponins, proteoglycanase 
inhibitors, agonists and antagonists of oestrogens, pseudop- 5 
terins, cytokines and growth factor promoters, IL-1 or IL-6 
inhibitors, IL-10 promoters, TNF inhibitors, vitamins, such 
as vitamin D, analogues of vitamin B12 and panthotenol, 
hydroxy acids, benzophenones, esterified fatty acids, and 
hydantoin. 10 
40 
U is OR"(wherein R" is H, a substituted or unsubstituted 
alkyl group, or substituted or unsubstituted aryl group) 
or 
Rs, R9 , R10, Ru, and R12 are each selected from the group 
consisting ofH, F, Cl, Br, I, an alkyl group, (CH2)niOR' 
(whereinnl=l, 2, or 3), CF3 , CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is Hor a lower alkyl group), a substituted 
or unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, a substituted or unsubstituted heterocyclyl, 
and Rs and R9 may be linked to form a cyclic or 
polycyclic ring; and pharmaceutically acceptable salts 
thereof. 
Pharmaceutical and/or cosmetic compositions including 
the 15-PGDH inhibitor described herein can additionally 
contain, for example, at least one compound chosen from 
prostaglandins, in particular prostaglandin PGEi, PGE2, 
their salts, their esters, their analogues and their derivatives, 15 
in particular those described in WO 98/33497, WO 
95/11003, JP 97-100091, JP 96-134242, in particular ago-
nists of the prostaglandin receptors. It may in particular 
contain at least one compound such as the agonists (in acid 
form or in the form of a precursor, in particular in ester form) 20 
of the prostaglandin F 2a receptor, such as for example 
latanoprost, fluprostenol, cloprostenol, bimatoprost, unopro-
stone, the agonists (and their precursors, in particular the 
esters such as travoprost) of the prostaglandin E2 receptors In other embodiments, the 15-PDGH activator can 
such as 17-phenyl PGE2, viprostol, butaprost, misoprostol, 25 include a compound having the formula (V): 
sulprostone, 16,16-dimethyl PGE2, 11-deoxy PGEi, 1-de-
oxy PGEi, the agonists and their precursors, in particular 
esters, of the prostacycline (IP) receptor such as cicaprost, 
iloprost, isocarbacycline, beraprost, eprostenol, treprostinil, 
the agonists and their precursors, in particular the esters, of 30 
the prostaglandin D2 receptor such as BW245C ((4S)-(3-
[(3R,S)-3-cyclohexyl-3-isopropyl]-2,5-dioxo)-4-imidazoli-
dineheptanoic acid), BW246C (( 4R)-(3-[(3R,S)-3-cyclo-
hexy 1-3-isopropy l]-2,5-dioxo )-4-imidazolidineheptanoic 
acid), the agonists and their precursors, in particular the 35 
esters, of the receptor for the thromboxanes A2 (TP) such as 
I-BOP ([1 S-[la,2a(Z), 3b(1E,3S),4a]]-7-[3-[3-hydroxy-4-
[ 4-(iodophenoxy )-1-buteny l]-7 -oxabicyclo-[2 .2 .1 ]hept-2-
y l]-5-heptenoic acid). 
Advantageously, the composition can include at least one 40 
15-PGDH inhibitor as defined above and at least one pros-
taglandin or one prostaglandin derivative such as for 
example the prostaglandins of series 2 including in particu-
lar PGF 2 a and PGE2 in saline form or in the form of 
precursors, in particular of the esters (example isopropyl 45 
esters), their derivatives such as 16,16-dimethyl PGE2, 
17-phenyl PGE2 and 16,16-dimethyl 17-phenyl PGF2w 
prostaglandins of series 1 such as 11-deoxyprostaglandin 
El, 1-deoxyprostaglandin El in saline or ester form, is their 
analogues, in particular latanoprost, travoprost, fluprostenol, 50 
unoprostone, bimatoprost, cloprostenol, viprostol, butaprost, 
misoprostol, their salts or their esters. 
In accordance with another aspect of the application, the 
modulator of 15-PGDH can be a 15-PGDH activator that 
can promote or stimulate the activity of 15-PGDH. In certain 55 
embodiments, the 15-PDGH activator can include a com-
pound having the formula (IV): 
(V) 
R11 
I 
0 O=S=O 
I 
N......_ 
U R10 
R12 
wherein U is OR" (wherein R" is H, a substituted or 
unsubstituted alkyl group, or substituted or unsubsti-
tuted aryl group) or 
Rs, R9 , R10, Ru, and R12 are each selected from the group 
consisting ofH, F, Cl, Br, I, an alkyl group, (CH2)niOR' 
(whereinnl=l, 2, or 3), CF3 , CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is Hor a lower alkyl group), a substituted 
or unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, a substituted or unsubstituted heterocyclyl, 
and Rs and R9 may be linked to form a cyclic or 
polycyclic ring; and pharmaceutically acceptable salts 
thereof. 
(IV) In certain embodiments, a 15-PGDH activator having 
wherein X3 and Y 2 are independently C or SO; 
60 formula (IV) or (V) can be selected that can: ia) at 7.5 µM 
concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 50 (using a scale on 
which a value of 100 indicates a doubling ofreporter output 
65 over baseline); iia) at 7 .5 µM concentration stimulate a V9m 
reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 50; iiia) 
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at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 50; iva) at 7.5 µM 
concentration, does not activate the negative control V9m 
cell line expressing TK-renilla luciferase reporter to a level 5 
any greater than 25; and va) against recombinant 15-PGDH 
protein the compound shows an IC50 concentration for 
inhibiting 15-PGDH enzyme activity of greater than 2.5 µM. 
In certain embodiments, a 15-PGDH activator having 
formula (IV) or (V) can be selected that can: ib) at 7.5 µM 10 
concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; iib) at 7 .5 µM concentration 
stimulate a V9m reporter cell line expressing a 15-PGDH 15 
luciferase fusion construct to increase luciferase output; iiib) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; ivb) at 7 .5 µM concentration, 
does not activate the negative control V9m cell line express- 20 
ing TK-renilla luciferase reporter to a luciferase level any 
greater than 25% above; and vb) against recombinant 
15-PGDH protein the compound shows an IC50 concentra-
tion for inhibiting 15-PGDH enzyme activity of greater than 
or equal to 2.5 µM. 25 
In other embodiments, a 15-PGDH activator having for-
mula (IV) or (V) that meets the above noted criteria (ia-va) 
and/or that meet the above noted criteria (ib-vb) includes a 
compound having the formula (VI): 
(VI) 
and pharmaceutically acceptable salts thereof. 
In other embodiments, the 15-PGDH activator can be an 
analogue of a compound having the formula (VI). Such 
analogues can have the following formula (VII): 
(VII) 
0 
H3C~~-Ph 0 
4LH,-L 
OCH3 
wherein U is OR" (wherein R" is H, a substituted or 
unsubstituted alkyl group, or substituted or unsubsti-
tuted aryl group) or 
Rs and R9 are each selected from the group consisting of 
H, F, Cl, Br, I, an alkyl group, (CH2 )niOR' (wherein 
30 
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nl=l, 2, or 3), CF3 , CH2----CH2X, O----CH2----CH2X, 
CH2-CH2-CH2X, O----CH2----CH2X (wherein X=F, 
Cl, Br, or I), CN, (C=O)-R', N(R')2 , NO2 , (C=O)N 
(R')2 , O(CO)R', OR', SR', COOR' (wherein R' is Hor 
a lower alkyl group), a substituted or unsubstituted aryl, 
a substituted or unsubstituted cycloalkyl, a substituted 
or unsubstituted heterocyclyl, and Rs and R9 may be 
linked to form a cyclic or polycyclic ring; and phar-
maceutically acceptable salts thereof. 
Examples of 15-PGDH activators having the formula 
(VII) include: 
0 
O=S-Ph O I ~ II -voMe; 
MeO I II 
Y"1r-N-CH2-C-NH ✓,p 
~OMe 
OMe 
0 
II 
=S-Ph O ~ I 
t-CH2-M-NH (n 
~Ac; 
OMe 
0 
O=~-Ph O -v~ Me; Meov:I II N-CH2-C-NH ✓,p 
OMe 
0 
O=~-Ph O F
3
C-D~ Meov:I II N-CH2-C-NH ✓,p ; 
OMe 
0 
II -VF; O=S-Ph O I ~ MeOV:I II N-CH2-C-NH # 
OMe 
Cl 
0 -& II Cl; O=S-Ph O I ~ 
MeO I II 
Y"1r-N-CH2-C-NH ✓,p 
~OMe 
0 
O=S-Ph O I ~ II -vc1; 
MeO I II 
Y"1r-N-CH2-C-NH # 
~OMe 
OMe 0 
II H2N-C 
=S-Ph I ~ ¢=a 11 Lm,-rNH-D• 
OMe 
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-continued 
OMe 0 A O=TI Meo-M~ y--=c:,-rNH--0. 
OMe 
OMe 
¢=1=::J-NH-0 • 
OMe 
0 
O=~-Ph O Cl))~ Meov:I II N-CH2-C-NH # ; 
OMe 
0 
O=~-Ph O Cl))~ Meov:I II N-CH2-C-NH # ; 
OMe 
and pharmaceutically acceptable salts thereof. 
Other examples of compounds having formula (VII) 
include: 
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-continued 
o-L1{ llh 
Me~-{J--_' OMe; 
Q 
NH 
0-~-N;\O llh 
Me~-{J--_' OMe; 
Q 
NH 
0-~-N;\O llh 
Me~-{J--_' OMe; 
45 
-continued Q-
NH 
0-~-N;\O II h 
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unsubstituted cycloalkyl, and a substituted or unsub-
stituted heterocyclyl; and pharmaceutically acceptable 
salts thereof. 
Examples of 15-PGDH activators having the formula 
5 (VIII) include: 
0 
0- II 0 Ph-S=O N NH-M-CH2-h--CX1 °) 
~ 0 ; 
0 
II 
O=S-Ph 0 111-J-CH2-M-NH-o 
MeO~ 
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~OMe 
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Still other examples of compounds having the formula 
(VIII) include: 
and pharmaceutically acceptable salts thereof. 
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In still other embodiments, the 15-PGDH activator can be 
an analogue of compound (VI) having the formula (IX): 
(IX) 5 
10 
wherein R11 is H, F, Cl, Br, I, a lower alkyl group, 
(CH2 )niOR' (wherein nl=l, 2, or 3), CF3 , CH2 - 15 
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', N(R')2 , NO2 , (C=O)N(R')2 , O(CO)R', 
OR', SR', COOR' (wherein R' is H or a lower alkyl 
group), a substituted or unsubstituted aryl, a substituted 20 
or unsubstituted cycloalkyl, and a substituted or unsub-
stituted heterocyclyl; and pharmaceutically acceptable 
salts thereof. 
Examples of 15-PGDH activators having the formula (IX) 
include: 
and pharmaceutically acceptable salts thereof. 
Still other examples of compounds having formula (IX) 
include: ('YCl 
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HN ~ A MeO # 
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with other components (e.g., an NSAID), can be made into 
aerosol formulations (i.e., they can be "nebulized") to be 
administered via inhalation. The 15-PGDH activator can 
also be provided alone or in combination with other com-
ponents in aqueous and non-aqueous solutions, isotonic 
sterile solutions, which can contain antioxidants, buffers, 
bacteriostats, and solutes that render the formulation iso-
tonic, and aqueous and non-aqueous sterile suspensions that 
'-o""Y yo / . 
O'-..._ HNX) 
I# 
s 
I 
10 can include suspending agents, solubilizers, thickening 
agents, stabilizers, and preservatives. Compositions includ-
ing the 15-PGDH activator can be administered, for 
example, orally, nasally, topically, intravenously, intraperi-
15 toneally, or intrathecally. The formulations can be presented 
in unit-dose or multi-dose sealed containers, such as 
ampoules and vials. Solutions and suspensions can be pre-
pared from sterile powders, granules, and tablets of the kind 
previously described. The modulators can also be adminis-
20 
tered as part of a prepared food or drug. 
The dose administered to a patient should be sufficient to 
induce a beneficial response in the subject over time. The 
optimal dose level for any patient will depend on a variety 
25 of factors including the efficacy of the specific modulator 
employed, the age, body weight, physical activity, and diet 
of the patient, on a possible combination with other drugs, 
and on the severity of the case of diabetes. It is recom-
and pharmaceutically acceptable salts thereof. 
The 15-PGDH activators described herein can be used for 30 
mended that the daily dosage of the 15-PGDH activator can 
be determined for each individual patient by those skilled in 
the art. The size of the dose also will be determined by the 
existence, nature, and extent of any adverse side-effects that 
accompany the administration of a particular compound in a 
the prevention or the treatment of diseases that are associ-
ated with decreased 15-PGDH levels and/or increased pros-
taglandin levels. Increasing tissue levels of 15-PGDH 
should decrease tissue levels of prostaglandins. Activities 
associated with compounds that decrease tissue prostaglan-
dins include decreasing development of human tumors. For 
example, administration of 15-PGDH activators can be used 
35 particular subject. 
40 
to treat patients with colon neoplasia, e.g., colon cancer or 
colon adenoma, or to treat and prevent new disease in 
patients with a history of colon neoplasia, or to reverse 
resistance to NSAID therapy for neoplasia therapy or neo-
plasia preventive therapy. Further, administration of 
15-PGDH activators described herein can be used to treat 
subjects having an NSAID-responsive condition. In certain 45 
embodiments, 15-PGDH activators enhance NSAID-re-
sponsiveness in subjects who are relatively unresponsive to 
NSAID treatment. 
The 15-PGDH activators described herein can be also be 
used in a method of treating any NSAID-responsive condi- 50 
tion. The NSAID-responsive condition applies to a subject 
who is NSAID-resistant or a subject who was determined to 
be resistant to NSAID therapy. In the method, a therapeu-
tically effective amount of 15-PGDH activators can be 
administered alone or in combination with an effective an 55 
effective amount of 15-PGDH protein, cDNA, or an active 
fragment thereof. The patient may be a subject at risk of 
developing colon neoplasia (e.g., based on family history), 
or a subject at risk of colon adenoma relapse, but is 
suspected of being resistant to NSAID therapy. Further, the 60 
patient may be any subject who is undergoing or about to 
undergo NSAID therapy for any NSAID-responsive condi-
tion, but who experiences NSAID resistance. 
The 15-PGDH activators described herein can be pro-
vided in a pharmaceutical composition that includes phar- 65 
maceutically acceptable carrier. In some embodiments, the 
15-PGDH activator can be provided alone or in combination 
In some embodiments, the 15-PGDH activator can be 
administered in a combination therapy includes administra-
tion of a single pharmaceutical dosage formulation that 
contains a 15-PGDH activator and one or more additional 
active agents, as well as administration of a 15-PGDH 
activator and each active agent in its own separate pharma-
ceutical dosage formulation. For example, a 15-PGDH acti-
vator and celecoxib can be administered to the human 
subject together in a single oral dosage composition, such as 
a tablet or capsule, or each agent can be administered in 
separate oral dosage formulations. In other embodiments, an 
NSAID, e.g., celecoxib or aspirin, may be administered with 
an effective amount of the 15-PGDH activator. Where 
separate dosage formulations are used, a 15-PGDH activator 
and one or more additional active agents can be adminis-
tered at essentially the same time (i.e., concurrently), or at 
separately staggered times (i.e., sequentially). Combination 
therapy is understood to include all these regimens. 
The invention is further illustrated by the following 
example, which is not intended to limit the scope of the 
claims. 
Example 1 
This Example describes the activities of four compounds 
with respect to the enzyme 15-Prostaglandin Dehydrogenase 
(15-PGDH) (encoded by the gene HPGD). The compounds 
are SW033291, SW054384, SW124531, SW145753 and 
have the following formulas: 
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SW033291 
0 
0 
// 
s~ 
H3CO II q=c~J_ij-0 
0 
I 
OCH3 
SW054384 
(YN O~N= 
0 
SW145753 
SW124531 
FIG. 1 shows that SW033291, SW054384, and 
SW145753 all increase luciferase activity of cells the 
express a 15-PGDH luciferase fusion construct created by 
targeted gene knock-in of renilla luciferase into the last 
coding exon of 15-PGDH. The activity is demonstrated in 
three different colon cancer cell lines all engineered to 
contain the 15-PGDH-luciferase fusion. These cell lines are 
Vaco-9m (V9m), LSI 74T, Vaco503 (V503). SW054384 is in 
general the best inducer, and shows maximum activity at 
6.25 µM. Value of 1.0 on the Y-axis is the basal level of 
reporter activity in cells treated with drug free DMSO 
vehicle. 
FIG. 2 shows western blots demonstrating that 
SW033291, SW054384, and SW145753 all increase levels 
of 15-PGDH protein in cell lines V503, LSI 74T, and V503 
treated with 7.5 µM compound for 48 hours. Untreated FET 
cells provide a positive control for 15-PGDH expression. 
FIG. 3 shows western blot demonstrating SW124531 also 
increases 15-PGDH protein levels in colon cell lines (FET 
cells treated with TGF-!3 (10 ng/ml) for 48 hours are used as 
a positive control for 15-PGDH expression in certain pan-
els). 
72 
FIG. 4 shows western blot demonstrating 5 µM 
SW124531 increases levels of 15-PGDH protein (wt-
PGDH) expressed from a cDNA expression vector in V 400-
S3-2-32 cells, and also increases protein levels of a cata-
5 lytically dead mutant 15-PGDH (mu-PGDH) also expressed 
from a cDNA expression vector in V400-M3-2-72 cells. As 
these proteins are expressed from a heterologous CMV 
promoter, the findings suggest that the compounds work 
directly on stabilizing the 15-PGDH protein. The com-
10 pounds show no effects on levels of a related enzyme, 
17-beta-estradiol-dehydrogenase. 
FIG. 5 shows increase in 15-PGDH protein levels in V503 
cells treated with SW124531 as assayed by immuno-fluo-
rescence (upper two rows) and by western blot (lower 
15 panel). 
FIGS. 6-9 show that SW033291, SW054384, SW145753, 
and SW124531 do not in general alter 15-PGDH mRNA 
levels in treated colon cancer cell lines as assessed by 
real-time PCR. The only exception is the slight increase in 
20 15-PGDH mRNAin SW033291 treated V503 cells, which is 
less than the induction of 15-PGDH protein as well as 
15-PGDH-luciferase reporter levels seen in SW033291 
treated V503 cells. In these studies parental cell lines (not 
containing the 15-PGDH-luciferase reporter) are employed. 
25 FIG. 10 shows the effects of three compounds on total 
15-PGDH activity in cell lines treated with the compounds. 
Cell lines were treated with compounds at 7 .5 µM for 48 
hours, and then pelleted. Pellets were lysed and total 
15-PGDH activity measured and normalized to 1,000,000 
30 input cells per pellet. 15-PGDH activity was assayed by 
measuring the transfer of tritium from 15(S)-[15-3H] PGE2 
to glutamate by coupling 15-PGDH with glutamate dehy-
drogenase as described in (Chi X, Freeman B M, Tong M, 
Zhao Y, Tai H H. 15-Hydroxyprostaglandin dehydrogenase 
35 (15-PGDH) is up-regulated by flurbiprofen and other non-
steroidal anti-inflammatory drugs in human colon cancer 
HT29 cells. Arch Biochem Biophys. 2009; 487(2):139-45.). 
Activity is measured as pmol PGEimin/million cells. As 
shown, SW033291 markedly inhibits 15-PGDH activity in 
40 all three of the cell lines tested. We conclude that although 
SW033291 increases total 15-PGDH protein levels in cells, 
it also inactivates 15-PGDH enzyme activity. 
In contrast, 15-PGDH enzyme activity is increased in 
cells treated with SW054384 and in cells treated with 
45 SW145753. 
FIG. 11 shows the effect on activity of recombinant 
15-PGDH protein (a 15-PGDH-GST fusion protein) incu-
bated with varying concentrations of the test compounds, 
with 15-PGDH activity across a range of compound con-
50 centrations recorded on the table and displayed on the 
corresponding graphs. As shown, SW033291 is a potent 
inhibitor of 15-PGDH activity, with an IC50 of <1.25 nM. 
This contrasts with the IC50 of between 25 nM-62.5 nM 
measured for the commercial 15-PGDH inhibitor available 
55 from Cayman Chemical (Cayman catalogue item 10638, 
Cayman Chemical number 13695). 
FIG. 11 also shows that at very high concentration 
SW054384 can inhibit recombinant 15-PGDH activity, with 
an IC50 of between 5 µM-50 µM. We conclude that 
60 SW054384 increases total 15-PGDH level and activity in 
cells treated with 7 .5 µM compound, but can inhibit in vitro 
recombinant 15-PGDH protein in vitro assays using 5 
µM-50 µM compound. 
FIG. 11 also shows that SW145753 can inhibit activity of 
65 recombinant 15-PGDH enzyme in an in vitro assay at an 
IC50 between 12-6.25 nM. This suggests the activity of 
SW145753 in increasing versus in inhibiting 15-PGDH 
US 10,301,320 B2 
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activity may be discordant in cells versus in the in vitro 
assay (perhaps due to washout of drugs when washing the 
cells), or may be concentration dependent. 
FIG. 12 shows repeat testing of the effects of SW033291 
and SW054384 on activity of recombinant 15-PGDH pro- 5 
tein tested in vitro. Assays were done by measuring the 
transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 
1 µM PGE2 substrate) shown at left (panels A, C), or by 
direct fluorescence monitoring of NADH generation by 
15-PGDH (done at 20 µM PGE2 substrate) shown at right 10 
(panels B, D). SW033291 is again confirmed as a highly 
potent 15-PGDH inhibitor with an IC50 of 0.7 nM as 
measured in the tritium assay and an IC50 of 1.6 nM as 
measured in the fluorescence assay. The relative insensitivity 
of the IC50 to substrate concentration suggests that 15 
SW033291 is a non-competitive inhibitor of 15-PGDH. 
SW054384 shows very weak inhibitory activity, with 
IC50s that are 10,000 fold higher than that of SW033291 
(8.4 µM and 11 µM in the tritium and fluorescent based 
assays respectively). This is consistent with the activity of 20 
SW054384 being on balance to increase 15-PGDH protein 
level and enzyme activity in cells. 
FIG. 13 shows results of assays of 15-PGDH activity 
using the tritium method in cells treated with SW124531 
(upper panel) and in recombinant 15-PGDH protein treated 25 
with SW124531 (lower panel). SW124531 shows activity in 
increasing 15-PGDH activity in most cell lines, though this 
activity is best in cell lines in which basal 15-PGDH activity 
74 
FIG. 16 shows the in vivo modulation by compounds of 
15-PGDH activity as reflected in PGE2 levels that are 
assayed in the medium of A549 cells that have been stimu-
lated by ILl-beta for 23 hours, with compound added for the 
last 5 hours (blue bars). The increment in PGE2 level shows 
the clear inhibition of 15-PGDH activity in the cells by 
addition of SW033291 (as well as SW145753, SW124531, 
and a commercial 15-PGDH inhibitor from Cayman Chemi-
cal. In an additional iteration (red bars) (2), SW054384 was 
added commencing 24 hours before addition of ILl-beta, 
and then maintained for the next 26 hours in the presence of 
ILl-beta. The lower level of PGE2 produced supports that in 
these cells SW054384 increased the 15-PGDH activity. 
Panel at left shows raw data; whereas, panel at right shows 
data normalized for cell numbers present at end of the 
experiment. PGE2 levels are assayed by ELISA. 
FIG. 17 shows the dose response of effect on SW033291 
on PGE2 production from ILl-beta treated A549 cells, as 
reflected in PGE2 levels that are assayed in the medium of 
A549 cells that have been stimulated by ILl-beta for 24 
hours, with SW033291 added for the last 8 hours. 
FIG. 18 shows the in vivo modulations by 2.5 µM 
compounds of 15-PGDH activity as reflected in PGE2 levels 
following addition of PGE2 into the medium of Vaco-503 
cells. In this study cells are treated with compound for 24 
hours after which PGE2 is added into the medium. After an 
added 24 hours PGE2 levels remaining in the medium are is >10 units. SW124531 also inhibits activity of 15-PGDH 
recombinant protein at an IC50 of 50 nM. 
FIG. 14 shows assay of different compounds for ability to 
directly bind to recombinant 15-PGDH protein as measured 
30 assayed by Elisa. Data labeled "medium" is a control lane 
with PGE2 added to medium alone, in the absence of cells. 
Data labeled DMSO is a control in which cells are treated 
with DMSO only (the diluent for the compounds). The by shifting the melting temperature of the protein. The 
melting of the protein is followed by measurement of the 
fluorescence of SYPRO Orange dye (Sigma #S5692) that 35 
increases as the dye binds to hydrophobic residues exposed 
as the protein melt. The graph at upper left shows the melt 
curves of 15-PGDH with all of the assays done in the 
presence of the different compounds superimposed on each 
other. The graph at upper right plots the negative derivative 40 
of fluorescence versus temperature for each of the curves 
shown at left, with the melting point measured as the 
temperature of the negative peak (i.e., the point of most 
rapid change in the fluorescence versus temperature plot). 
The results are shown in tabular form on the table below. 45 
Lapatinib is used as a negative control. There is no binding 
of any drug in the absence of enzyme co-factor ( either NAD 
difference between the "medium" and the "DMSO" lanes 
represents the cell dependent degradation of PGE2 by 
15-PGDH. Again demonstrated, is the near complete block-
ade of 15-PGDH activity by addition of2.5 uM SW033291, 
as reflected by the blockade in PGE2 degradation. Addition-
ally demonstrated is the stimulation of 15-PGDH activity by 
SW054384, as reflected by the increased degradation of 
PGE2 . 
FIG. 19 shows the activity of 2.5 µM SW033291 in 
speeding the healing of a model wound consisting of a 
scratch in a monolayer of HaCaT cells observed over 48 
hours of treatment. TGF-beta serves as the positive control 
in the assay. 
or NADH). In the presence of either NAD or NADH, 
SW033291 creates two peaks in the melting curve, with one 
of these peaks displaced by 15 degrees Celsius, consistent 
with SW033291 binding directly to 15-PGDH. SW124531 
and SW145753 also show evidence of direct binding to 
15-PGDH. In this assay, SW054384 cannot be demonstrated 
FIG. 20 shows the quantitation of the width of the scratch 
at O and 48 hours in the control, 2.5 µM SW033291 treated 
50 cells, and the TGF-beta (1 ng/ml) treated cells. 
Example 2 
to bind 15-PGDH. It is possible that SW054384 does bind 
to 15-PGDH, but that the binding is weak and is melted off 
at a temperature below the melting temperature of the 
15-PGDH protein. Assays were done at both 10 µMand 100 
µM cofactor (testing both NAD and NADH), which com-
pares well with the published Km of NAD of 15.8 µM. 
55 Analysis of Analogues of Lead Compounds SW033291, a 
15-PGDH Inhibitor 
FIG. 15 shows that none of the four compounds tested 60 
induce a shift in the melting temperature of catalytically 
inactive mutant 15-PGDH protein. We interpret the induc-
tion of 15-PGDH mutant protein by SW124531 as suggest-
ing that SW124531 likely has weak binding to mutant 
15-PGDH that is able to stabilize protein at 37° C., but with 65 
the drug melted off at a temperature below 50° C., that is the 
melting temperature of the protein. 
This Example provides data on a group of structural 
analogues of SW033291. Data provided includes level of 
induction of a 15-PGDH-luciferase fusion gene reporter, 
recorded as % increased luciferase activity over basal level, 
in three colon cancer cell lines, V9m, V503, and LS174T, 
engineered to contain the reporter, and treated with either 2.5 
uM or 7.5 uM compound (i.e., Values are recorded on a scale 
where 100 indicates of doubling of luciferase activity over 
baseline level). Also recorded is the IC50 of each compound 
for inhibiting enzymatic activity ofrecombinant 15-PGDH 
in an in vitro assay. 
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TABLE 2 
Enzyme 
inhibition 
(!Cso, 
ID nM) 
SW033291 1.23 nM 
SW033291 
isomer B 
0.76 nM 
SW033291 56.56 nM 
isomer A 
SW033292 
413423 
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V503 V503 
V9M V9M LS174T LS174T reporter reporter 
reporter reporter reporter reporter activity activity 
activity activity activity activity (2.5 (7.5 
(2.5 uM) (7.5 uM) (2.5 uM) (7.5 uM) uM) uM) 
98.24 93.16 123.46 106.73 126.32 99.34 
Note: Structures shown are for illustrative purposes. 
We don'd know which structure corresponds to Isomer 
A or B. Residual activity of isomer A may be due to 
small amounts of Isomer B present in the preparation. 
Note: Structures shown are for illustrative purposes. We 
don't know which structure corresponds to Isomer A or B. 
Residual activity of isomer A may be due to small 
amounts of Isomer B present in the preparation. 
1.51 
-5.65 -8.76 3.41 3.91 7.89 3.13 
US 10,301,320 B2 
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TABLE 2-continued 
V503 V503 
Enzyme V9M V9M LS174T LS174T reporter reporter 
inhibition reporter reporter reporter reporter activity activity 
(!Cso, activity activity activity activity (2.5 (7.5 
Structures ID nM) (2.5 uM) (7.5 uM) (2.5 uM) (7.5 uM) uM) uM) 
980653 8.83 11.96 5.76 10.99 -10.47 -15.21 
F 
405320 8.77 -15.45 9.95 -2.57 -7.73 -33.68 
SW208078 25 nM 36.16 34.90 72.71 40.01 87.73 83.77 
~r 
II 
0 
SW208079 125 nM 36.01 32.75 53.42 43.83 85.29 61.82 
0 
// 
s 
\ 
Me 
SW033290 525 nM -34.33 -25.45 -0.24 -6.58 30.93 17.71 
0 
II 
S-
Ii 
0 
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TABLE 2-continued 
Enzyme V9M 
inhibition reporter 
(!Cso, activity 
ID nM) (2.5 uM) 
SW208080 2.64 nM 102.08 
SW208081 18 nM 37.79 
SW206976 >7.5 uM 11.80 
SW206977 >7.5 uM 3.5028 
SW206978 >7.5 uM 7.5141 
80 
V503 V503 
V9M LS174T LS174T reporter reporter 
reporter reporter reporter activity activity 
activity activity activity (2.5 (7.5 
(7.5 uM) (2.5 uM) (7.5 uM) uM) uM) 
98.65 117.81 116.64 103.70 127.19 
63.56 64.53 95.14 90.46 105.37 
17.51 42.38 20.56 16.79 49.53 
0.45 34.88 29.35 33.00 37.62 
8.02 31.44 26.19 38.84 35.75 
us 10,301,320 B2 
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TABLE 2-continued 
V503 V503 
Enzyme V9M V9M LS174T LS174T reporter reporter 
inhibition reporter reporter reporter reporter activity activity 
(!Cso, activity activity activity activity (2.5 (7.5 
Structures ID nM) (2.5 uM) (7.5 uM) (2.5 uM) (7.5 uM) uM) uM) 
s SW206979 >7.5 uM -12.59 -20.62 34.26 32.79 21.66 42.92 
f s SW206980 0.97 nM 99.37 92.71 117.24 92.15 129.57 108.51 
_--,:::; 0 
// 
s 
NH2 ~ 
cs 
SW206992 1.411 nM 86.44 121.75 85.81 72.03 161.20 145.39 
0 N // 
s 
NH2 ~ 
ext/ SW208064 151.4 nM 82.58 50.11 126.18 96.23 126.18 96.23 
NH2 ~ 
OyN SW208065 4.865 nM 120.19 118.92 73.50 87.74 73.50 87.74 0 
I // s N::::,,._ ~ 
SW208066 1.368 nM 122.72 111.63 123.89 93.74 123.89 93.74 
0 
// 
s~ 
us 10,301,320 B2 
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TABLE 2-continued 
V503 V503 
Enzyme V9M V9M LS! 74T LS! 74T reporter reporter 
inhibition reporter reporter reporter reporter activity activity 
(ICso, activity activity activity activity (2.5 (7.5 
Structures ID nM) (2.5 uM) (7.5 uM) (2.5 uM) (7.5 uM) uM) uM) 
SW208067 2.395 nM 121.69 108.47 94.30 79.63 94.30 79.63 
0 
s~ 
SW208068 >7.5 uM 12.90 12.35 14.90 15.00 14.90 15.00 
SW208069 >7.5 uM -14.48 0.23 19.47 15.13 19.47 15.13 
0 SW208070 >7.5 uM 22.56 12.11 19.69 15.43 19.69 15.43 
II 
(XN S~ '<:::::: 
NH2 
We first note that the 15-PGDH inhibitory activity of 
SW033291 is at least 98% due to the activity of one of the 
two optical isomers of this compound, designated isomer A 
and B. The structural assignment of isomer A versus isomer 55 
B is not yet established. 
There is an important effect on the length of the carbon 
side chain of SW033291 on the IC50 for inhibiting recom-
binant 15-PGDH in vitro. Compared to SW033291 (4 car- 60 
bans): SW208080 (5 carbons) has IC50 1.5 times higher, 
SW208081 (6 carbons) has IC50 10 times higher, and 
SW208079 (1 carbon) has IC50 over 60-fold higher, with 
marked loss of activity in inducing the cell line reporters. 65 
The sulfoxide group appears to be a critical substituent, as 
inactive substitutions of the sulfoxide include the corre-
sponding: ketone (SW206976), amide (SW206977), ester 
(SW206978), and carboxylic acid (SW206979). However, 
inhibitory activity is observed for the sulfone analogs. 
Deletion of the phenyl group on SW033291 (SW206980) 
lowers the IC50 by half. SW206980 continues to be a highly 
active compound in reporter induction when applied to 
reporter cell lines at 2.5 uM concentration. 
Example 3 
The following Example describes the synthesis of 
SW033291 and analogues thereof as well as provides mass 
spectrometry NMR confirmation of the structures. 
US 10,301,320 B2 
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Scheme 1 
0 
R'(~,s 
"("cN 
c1.........,,.s~Me 1.0 equiv. 
Et3N 1.5 equiv. 
CH3CN reflux, 45 min 
I -.. l"Jn R\XN S'-../S" __...Me 
.# CN 
R' 
I 
1 
'<> L--:Jn RVN s..........,s...._J,Me 
.# CN 
R' R' R ~ thiophene, R' ~ Ph, n ~ 3, 92% 
R ~ thiophene, R' ~ Ph, n ~ 0 
R ~ thiophene, R' ~ Ph, n ~ 4 
R ~ thiophene, R' ~ Ph, n ~ 5 
R ~ thiazole, R' ~ Ph, n ~ 3, 90% 
R ~ thiophene, R' ~ H, n ~ 3, 58% 
R ~ thiazole, R' ~ H, n ~ 3, 70% 
R~HR'~Hn~3,57% 
0 RYNYSY~ Me 
~~f'" 
R' NH2 
SW208078: R ~ thiophene, R' ~ Ph, n ~ 3, 
SW033290: R ~ thiophene, R' ~ Ph, n ~ 0 
0 
I 
s 
\ 
Bu 
35 
40 
45 
SW033291 2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl) 
thieno[2,3-b ]pyridin-3-amine was prepared using procedure 50 
describe by Kalugin. To the solution of 4-(((butylthio) 
methyl)sulfinyl)-2,6-diphenylpyrimidine-5-carbonitrile 
(0.53 mmol, 220 mg) in DMF (0.25 M)/EtOH (0.5 M) was 
added KOH (0.32 mmol, 18 mg, 0.6 equiv., 0.1 Min water). 
The reaction mixture was stirred at 35° C. for 40 min. Once 55 
complete, the reaction was diluted with EtOAc and washed 
with 10% aq. solution of acidic acid, the organic phase was 
separated and aqueous layer was extracted twice with 
EtOAc, dried over magnesium sulfate, filtered and concen-
trated under reduced pressure to give 211 mg of SW033291 60 
2-(butylsulfiny 1)-4-phenyl-6-( thiophen-2-yl )thieno [2,3-b] 
pyridin-3-amine (96%). 1H NMR (400 MHz, CDC13 ) Ii 
7.67-7.60 (m, lH), 7.57-7.35 (m, 7H), 7.10 (dd, J=5.0, 3.7 
Hz, lH), 4.54 (s, 2H), 3.26 (ddd, J=12.8, 9.1, 6.0 Hz, lH), 
3.09 (ddd, J=12.8, 9.1, 6.6 Hz, lH), 1.83-1.61 (m, 2H), 65 
1.53-1.38 (m, 2H), 0.93 (t, J=7.3 Hz, 3H). ESI-MS (m/z): 
413 [M+Ht. 
R ~ thiophene, R' ~ Ph, n ~ 3, 98% 
R ~ thiophene, R' ~ Ph, n ~ 0 
R ~ thiophene, R' ~ Ph, n ~ 4 
R ~ thiophene, R' ~ Ph, n ~ 5 
R ~ thiazole, R' ~ Ph, n ~ 3, 98% 
R ~ thiophene, R' ~ H, n ~ 3, 92% 
R ~ thiazole, R' ~ H, n ~ 3, 97% 
R~ H, R' ~ H, n ~3, 56% 
KOH,DMF, 
37° C. 
0.6 equiv. 
SW033291: R ~ thiophene, R' ~ Ph, n ~ 3, 96% 
SW208079: R ~ thiophene, R' ~ Ph, n ~ 0 
SW208080: R ~ thiophene, R' ~ Ph, n ~ 4 
SW208081: R ~ thiophene, R' ~ Ph, n ~ 5 
SW208066: R ~ thiazole, R' ~ Ph, n ~ 3, 95% 
SW206980: R ~ thiophene, R' ~ H, n ~ 3, 92% 
SW206992: R ~ thiazole, R' ~ H, n ~ 3, 87% 
SW208064: R~ H, R' ~ H, n ~3, 11% 
0 
I 
s'-.../s'---
Bu 
CN 
2-(((butylthio )methyl)sulfinyl)-4-phenyl-6-(thiophen-2-
yl)nicotinonitrile. Acetic Acid (900 µL) and hydrogen per-
oxide (0.57 mmol, 1.5 equiv., 30% solution in water) were 
added to the solution of 2-(((butylthio )methyl)sulfinyl)-4-
phenyl-6-(thiophen-2-yl)nicotinonitrile (0.38 mmol, 150 
mg) in chloroform (900 µL). The reaction mixture was 
stirring at 32° C. for 45 min. The reaction was then diluted 
with EtOAc and washed with saturated NaHCO3 solution, 
dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to give 153 mg of designed product 
(98%). 1H NMR (400 MHz, CDC13 ) Ii 7.75 (dd, J=3.8, 1.1 
Hz, lH), 7.66-7.57 (m, 2H), 7.58-7.51 (m, 4H), 7.47 (s, lH), 
7.16 (dd, J=5.0, 3.8 Hz, lH), 4.74 (d, J=13.0 Hz, lH), 4.41 
(d, J=13.0 Hz, lH), 2.97 (dt, J=13.0, 8.2 Hz, lH), 2.81 (dt, 
J=12.9, 7.3 Hz, lH), 1.94-1.76 (m, 2H), 1.53-1.38 (m, 2H), 
0.94 (t, J=7.4 Hz, 3H). ESI-MS (m/z): 413 [M+Ht 
US 10,301,320 B2 
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CN 
10 
2-(( (butylthio )methyl)thio )-4-phenyl-6-(thiophen-2-yl) 
nicotinonitrile. A mixture of 4-phenyl-6-(thiophen-2-yl)-2- 15 
thioxo-1,2-dihydropyridine-3-carbonitrile (0.34 mmol, 101 
mg), butyl(chloromethyl)sulfane (0.34 mmol, 48 mg, 1.0 
equiv.) and Et3N (0.51 mmol, 72 µL, 1.5 equiv.) was 
88 
4.53 (s, 2H), 2.74 (t, J=8.0 Hz, 2H), 1.72-1.57 (m, 2H), 
1.49-1.34 (m, 2H), 0.90 (t, J=7.4 Hz, 3H). ESI-MS (m/z): 
397 [M+Ht. 
s 
CN 
4-pheny 1-6-( thiophen-2-y 1)-2-thioxo-l ,2-dihydropyri-
refluxed in dry CH3 CN (350 µL) for 20 min. The reaction 20 dine-3-carbonitrile. To a solution of 3-phenyl-1-(thiophen-
mixture was then diluted with EtOAc and water. The organic 2-yl)prop-2-en-1-one (2.34 mmol, 500 mg) and cyanothio-
phase was separated and aqueous layer was extracted twice acetamide (7.0 mmol, 717 mg, 3.0 equiv.) in ethanol (7 mL), 
with EtOAc. The combined extractions were washed with a few drops of piperidine were added. The reaction was 
saturated NaCl solution, dried over magnesium sulfate, 25 refluxed for 3 h. The solid that formed was collected and 
filtered and concentrated under reduced pressure. The resi-
due was purified by flash chromatography to give 124 mg of 
designed product (92% ). 1 H NMR ( 400 MHz, CDCl3 ) Ii 7. 70 
(dd, J=3.8, 1.1 Hz, lH), 7.64-7.56 (m, lH), 7.55-7.47 (m, 
5H), 7.40 (d, J=l.1 Hz, lH), 7.14 (dd, J=5.0, 3.8 Hz, lH), 
recrystallized from acetic acid to give designed product in 
46% isolated yield. 1H NMR (400 MHz, DMSO-d6) Ii 8.17 
(d,J=3.8Hz, lH), 7.96(d,J=5.0Hz, lH), 7.74-7.62(m,2H), 
7.54 (dd, J=5.1, 2.0Hz, 3H), 7.31-7.19 (m, lH), 7.01 (s, lH). 
ESI-MS (m/z): 295 [M+Ht. 
Scheme 2 
o'\_______J\ 
H~ 1.0equiv. 
0 s 
~CN X 
Cs H2N X = C, conditions A X = N, conditions B 
)---0 KOHffimH 
A: X = C, cyanothioacetamide 3 equiv.; piperidine 0.5 equiv.; 
EtOH reflux, 3 h, 46% 
B: X = N, cyanothioacetamide 1.1 euiv.; DABCO 0.5 equiv.; 
EtOH, reflux, 12 h, 40% 
~1 s 
PPh3 
-NaOH 
0 
II Br 
EtO~ 
s 0 
Dondoni, A.; Marra, A,; Merino, P. J. Am. Chem. Soc., 1994, 116, 3324 
s 
CN 
Parveen, H.; Iqbal, P.F.; Azam, A. Synth. Comm, 2008, 38, 3973 
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5 
3-pheny 1-1-( thiophen-2-y l)prop-2-en-1-one was prepared 
from benzaldehyde and l-(thiophen-2-yl)ethanone via aldol 
condensation using procedure described by Azam showed in 10 
Scheme 2. 1 H NMR ( 400 MHz, CDCl3 ) ll 7 .88-7 .80 (m, 2H), 
7.67 (dd, J=4.9, 1.1 Hz, lH), 7.66-7.59 (m, 2H), 7.47-7.34 
(m, 4H), 7.18 (dd, J=5.0, 3.8 Hz, lH). ESI-MS (m/z): 215 
[M+Ht. 15 
0 
20 
90 
S W208080- l -A 2-(penty lsulfinyl )-4-phenyl-6-( thiophen-
2-y l)thieno[2,3-b ]pyridin-3-amine was prepared by using 
synthetic procedures described for the preparation of analog 
SW033291 and showed in Scheme 1 and 2. 1H NMR (500 
MHz, CD2Cl2 ) Ii 7.98-7.36 (m, SH), 7.33-6.85 (m, lH), 4.47 
(s, 2H), 3.28-3.15 (m, lH), 3.09-2.99 (m, lH), 1.81-1.59 (m, 
2H), 1.50-1.25 (m, 4H), 0.88 (t, J=7.2 Hz, 3H). ESI-MS 
(m/z): 427 [M+Ht. 
0 
I 
s 
\ 
Hex 
S W20808 l -1-A 2-(hexy lsulfinyl )-4-phenyl-6-( thiophen-
3-pheny l-1-( thiazol-2-y l)prop-2-en-1-one was prepared 25 2-yl)thieno[2,3-b ]pyridin-3-amine was prepared by using 
from via Wittig reaction using procedure described by 
Merino showed in Scheme 2. 1 H NMR ( 400 MHz, Chloro-
form-d) Ii 8.06 (d, J=3.0 Hz, lH), 7.99 (s, lH), 7.96 (s, lH), 
7.75-7.67 (m, 3H), 7.44-7.38 (m, 3H). ESI-MS (m/z): 216 
[M+Ht. 
0 
I 
s 
\ 
Me 
SW208079-l-A 2-(methy lsulfinyl )-4-pheny 1-6-( thio-
phen-2-yl)thieno[2,3-b ]pyridin-3-amine was prepared by 
synthetic procedures described for the preparation of analog 
SW033291 and showed in Scheme 1 and 2. 1H NMR (500 
MHz, CD2Cl2 ) Ii 7.78-7.66 (m, lH), 7.63-7.46 (m, 7H), 
30 7.27-7.02 (m, lH), 4.11 (s, 2H), 3.43-3.20 (m, lH), 3.11 
(ddd, J=13.8, 9.4, 6.4 Hz, lH), 1.89-1.63 (m, 2H), 1.58-1.39 
(m, 4H), 1.40-1.21 (m, 2H), 0.91 (d, J=6.8 Hz, 3H). ESI-MS 
(m/z): 441 [M+Ht. 
35 
er 
s 0 I 
s 
40 \ 
Bu 
45 
using synthetic procedures described for the preparation of 
analog SW033291 and showed in Scheme 1 and 2. 1H NMR 50 
(500 MHz, CDCl3 ) ll 7.67-7.50 (m, 5H), 7.50-7.36 (m, 3H), 
7.16-7.09 (m, lH), 4.58 (s, 2H), 2.99 (s, 3H). ESI-MS (m/z): 
371 [M+Ht. 
SW208066, 2-(butylsulfinyl)-4-phenyl-6-(thiazol-2-yl) 
thieno[2,3-b ]pyridin-3-amine was prepared by using syn-
thetic procedures described for the preparation of analog 
SW033291 and showed in Scheme 1 and 2. 1H NMR (400 
MHz, CDCl3 ) Ii 8.06 (s, lH), 7.92 (d, J=3.2 Hz, lH), 
7.65-7.39 (m, 6H), 4.63 (s, 2H), 3.28 (ddd, J=12.8, 9.0, 6.2 
0 
I 
s 
\ 
Pent 
55 Hz, lH), 3.11 (ddd, J=12.8, 9.0, 6.8 Hz, lH), 1.85-1.63 (m, 
2H), 1.56-1.42 (m, 2H), 0.94 (t, J=7.3 Hz, 3H). ESI-MS 
(m/z): 414 [M+Ht. 
60 
0 
I 
s 
\ 
Bu 
65 
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hydrogen peroxide (0.036 mmol, 1.5 equiv., 30% solution in 
water) were added to the solution of SW033291 2-(butyl-
sulfiny 1)-4-pheny 1-6-( thiophen-2-y l)thieno [2,3-b ]pyridin-3-
amine (0.024 mmol, 10 mg) in chloroform (50 µL). The 
reaction mixture was stirring at 32° C. for 4 h. The reaction 
was diluted with EtOAc and washed with saturated NaHCO3 
SW206980, 2-(butylsulfinyl)-6-(thiophen-2-yl)thieno[2, 
3-b ]pyridin-3-amine was prepared by using synthetic pro-
cedures described for the preparation of analog SW033291 
and showed in Scheme 1 and 2. 1 H NMR ( 400 MHz, CDCl3 ) 5 
Ii 7.79 (d, J=8.5, lH), 7.65-7.49 (m, 2H), 7.39 (dt, J=5.1, 0.7 
Hz, lH), 7.06 (dd, J=5.0, 3.7, Hz, lH), 5.20 (s, 2H), 3.26 
(ddd, J=12.8, 9.0, 6.2 Hz, lH), 3.10 (ddd, J=12.8, 9.1, 6.6 
Hz, lH), 1.78-1.60 (m, 2H), 1.55-1.39 (m, 2H), 0.92 (t, 
J=7.3 Hz, 3H). ESI-MS (m/z): 337 [M+Ht 
solution, dried over magnesium sulfate, filtered and concen-
10 trated under reduced pressure to give crude 2-(butylsulfo-
nyl )-4-phenyl-6-( thiophen-2-y l)thieno[2,3-b ]pyridin-3-
er 15 0 s I 
s 
\ 
Bu 
NH2 20 
SW206992, 2-(butylsulfinyl)-6-(thiazol-2-yl)thieno[2,3-
b ]pyridin-3-amine was prepared by using synthetic proce-
dures described for the preparation of analog SW033291 and 25 
showed in Scheme 1 and 2. 1 H NMR ( 400 MHz, CDCl3 ) Ii 
8.15 (d, J=8.5 Hz, lH), 7.95 (d, J=8.5 Hz, lH), 7.90 (d, J=3.2 
Hz, lH), 7.44 (d, J=3.2 Hz, lH), 3.29 (ddd, J=12.7, 9.0, 6.2 
Hz, lH), 3.13 (ddd, J=12.8, 9.0, 6.7 Hz, lH), 1.83-1.61 (m, 30 
2H), 1.59-1.38 (m, 2H), 0.92 (t, J=7.3 Hz, 3H). ESI-MS 
(m/z): 338 [M+Ht. 
35 
amine, which was purified by flash chromatography in 8% 
isolated yield. 1H NMR (400 MHz, CDCl3 ) ll 7.71 (d, J=3.8 
Hz, lH), 7.64-7.54 (m, 3H), 7.53-7.42 (m, 4H), 7.15 (dd, 
1=5.0, 3.7 Hz, lH), 5.09 (s, 2H), 3.38-3.02 (m, 2H), 1.92-
1.67 (m, 2H), 1.52-1.28 (m, 2H), 0.92 (t, J=7.4 Hz, 3H). 
ESI-MS (m/z): 429 [M+Ht. 
0 
II 
S-Me 
II 
0 
SW033290-2-A 2-(methylsulfonyl)-4-phenyl-6-(thio-
phen-2-yl)thieno[2,3-b ]pyridin-3-amine was prepared by 
using synthetic procedures described for the preparation of 
analog SW208078-l-A and showed in Scheme 1 and 2. 1H 
SW208064, 2-(butylsulfinyl)thieno[2,3-b ]pyridin-3-
40 NMR (500 MHz, CDCl3 ) ll 7.78-7.68 (m, lH), 7.64-7.54 (m, 
3H), 7.53-7.45 (m, 4H), 7.18-7.10 (m, lH), 5.08 (s, 2H), 
3.14 (s, 3H). ESI-MS (m/z): 387 [M+Ht. 
amine was prepared by using synthetic procedures described 
for the preparation of analog SW033291 and showed in 45 
Scheme 1. 1H NMR (400 MHz, CDCl3 ) Ii 8.61 (dd, J=4.7, 
1.6 Hz, lH), 7.89 (dd, J=8.1, 1.6 Hz, lH), 7.33 (dd, J=8.1, 
4.6 Hz, lH), 3.39-3.18 (m, lH), 3.20-3.03 (m, lH), 1.74 (p, 
J=7.6 Hz, 2H), 1.63-1.38 (m, 2H), 0.94 (t, J=7.3 Hz, 3H). 50 
ESI-MS (m/z): 255 [M+Ht. 
55 
0 
II 
S-Bu 
II 
0 
~N 
~I N:::::,.._ 
0 
I 
s 
\ 
Bu 
SW208065, 6-(butylsulfinyl)-2,4-diphenylthieno[2,3-d] 
60 
pyrimidin-5-amine. To the solution of 4-(((butylthio )methyl) 
sulfinyl)-2,6-diphenylpyrimidine-5-carbonitrile (0.07 mmol, 
30 mg) in DMF (0.25 M) was added KOH (0.035 mmol, 2 
mg, 0.5 equiv., 0.1 Min water). The reaction mixture was 
SW208078- l-A 2-(butylsulfonyl)-4-phenyl-6-(thiophen-
2-yl)thieno[2,3-b ]pyridin-3-amine. Acetic Acid (50 µL) and 
65 
stirred at room temperature for 20 min. Once complete, the 
reaction was diluted with EtOAc and washed with 5% aq. 
solution of acidic acid. The organic phase was separated and 
US 10,301,320 B2 
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were washed with saturated NaCl solution, dried over mag-
nesium sulfate, filtered and concentrated under reduced 
pressure. The residue obtained was then purified by flash 
chromatography to give 59 mg of designed product (75%). 
1H NMR (400 MHz, CDC13 ) ll 8.75-8.36 (m, 2H), 8.35-7.91 
(m, 2H), 7.71-7.41 (m, 6H), 4.59 (s, 2H), 2.74 (t, J=7.5 Hz, 
2H), 1.75-1.58 (m, 2H), 1.49-1.34 (m, 2H), 0.91 (t, J=7.3 
aqueous layer was extracted twice with EtOAc, dried over 
magnesium sulfate, filtered and concentrated under reduced 
pressure to give crude product, which was purified by flash 
chromatography in 70% isolated yield. 1 H NMR ( 400 MHz, 5 
CDC13 ) Ii 8.73-8.37 (m, 2H), 7.78-7.68 (m, 2H), 7.66-7.55 
(m, 3H), 7.53-7.40 (m, 3H), 4.83 (s, 2H), 3.30 (ddd, J=12.7, 
8.9, 6.3 Hz, lH), 3.21-3.01 (m, lH), 1.87-1.66 (m, 2H), 
1.57-1.41 (m, 2H), 0.95 (t, J=7.3 Hz, 3H). ESI-MS (m/z): 
408 [M+Ht 
10 Hz, 3H). ESI-MS (m/z): 392 [M+Ht. 
0 
I OyN s~s......_ ~ Bu 
N # 
CN 
4-( ( (buty lthio )methyl )sulfiny 1)-2,6-dipheny lpyrimidine-
5-carbonitrile. Acetic Acid (600 µL) and hydrogen peroxide 
(0.37 mmol, 1.5 equiv., 30% solution in water) were added 
15 Oyij s 
N # 
CN 
20 
25 
to the solution of 4-(((butylthio )methyl)thio )-2,6-diphe- 30 
nylpyrimidine-5-carbonitrile (0.25 mmol, 98 mg) in chloro-
4,6-dipheny 1-2-thioxo-l ,2-dihydropyridine-3-carbonitrile 
was prepared according procedure described by Soto. A 
mixture of NaOiPr (1.5 mmol, 1.0 equiv., prepared in situ 
from sodium and dry iPrOH), benzothioamide (1.5 mmol, 
205 mg, 1.0 equiv.) and 2-(ethoxy(phenyl)methylene)ma-
lononitrile (1.5 mmol, 297 mg, 1.5 equiv.) in iPrOH (75 mL) 
form (900 µL). The reaction mixture was stirring at 32° C. 
was stirred for 5 h at room temperature. The reaction was 
for 45 min. Once complete, the reaction was diluted with 
then acidified with con. HCl and stirred overnight, evapo-EtOAc and washed with saturated NaHCO3 solution, dried 35 
rated and obtained solid was recrystallized from acetic acid 
to give 265 mg of 4,6-diphenyl-2-thioxo-1,2-dihydropyri-
dine-3-carbonitrile (61 %). 1H NMR (400 MHz, DMSO-d6 ) 
Ii 8.23-8.12 (m, 2H), 8.07-7.91 (m, 2H), 7.74-7.49 (m, 6H). 
over magnesium sulfate, filtered and concentrated under 
reduced pressure to give 88 mg of designed product (98%). 
1H NMR (400 MHz, CDC13 ) Ii 8.57 (dt, J=7.7, 1.2 Hz, 2H), 
8.28-8.05 (m, 2H), 7.80-7.40 (m, 6H), 4.82 (d, J=13.2 Hz, 
lH), 4.49 (d, J=13.3, lH), 2.95 (dt, J=13.0, 8.1 Hz, lH), 2.84 
(dt, J=13.0, 7.3 Hz, lH), 1.91-1.74 (m, 2H), 1.56-1.40 (m, 
2H), 0.95 (t, J=7.4 Hz, 3H). ESI-MS (m/z): 408 [M+Ht 
S~SBu 
CN 
4-(( (butylthio )methyl)thio )-2,6-diphenylpyrimidine-5-
carbonitrile. A mixture of 4,6-diphenyl-2-thioxo-1,2-dihy-
dropyridine-3-carbonitrile (0.35 mmol, 101 mg), butyl(chlo-
romethyl)sulfane (0.35 mmol, 48 mg, 1.0 equiv.) and Et3N 
(0.87 mmol, 2.5 equiv.) was refluxed in dry CH3 CN (200 
40 ESI-MS (m/z): 290 [M+Ht 
45 
50 
55 
0 
I 
s 
\ 
Bu 
SW208067, 6-(butylsulfinyl)-4-phenyl-2-(thiophen-2-yl) 
thieno[2,3-d]pyrimidin-5-amine was prepared by using syn-
thetic procedures described for the preparation of analog 
60 SW208065 and showed in Scheme 3. 
1H NMR (400 MHz, 
CDC13 ) Ii 8.10 (dd, J=3.7, 1.3 Hz, lH), 7.74-7.65 (m, 2H), 
7.62-7.53 (m, 3H), 7.50 (dd, J=5.0, 1.2 Hz, lH), 7.14 (dd, 
1=5.0, 3.7 Hz, lH), 4.79 (s, 2H), 3.28 (ddd, J=12.8, 9.0, 6.2 
µL) for 20 min. The reaction was diluted with EtOAc and 65 Hz, lH), 3.11 (ddd, J=12.8, 9.0, 6.7 Hz, lH), 1.84-1.63 (m, 
2H), 1.54-1.41 (m, 2H), 0.94 (t, J=7.3 Hz, 3H). ESI-MS water. The organic phase was separated and aqueous layer 
was extracted twice with EtOAc. The combined extractions (m/z): 414 [M+Ht. 
Ph 
WS206977-1 
0 
Cl II 
~NHPr 
EtONa/EtOH 
1.6 equiv. 
61% 
0 
95 
D.___Bu 
0 
BrJ_OEt 
EtONa/EtOH 
1.6 equiv. 
79% 
s 
CN 
Ph 
WS206978-1 
1.6 equiv. 
Et3N 1.6 equiv. 
0 
BrJ_OEt 
1.6 equiv. 
Et3N 1.6 equiv. 
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7 4% after 2 steps 
NaOH,DMF 
63% after 2 steps 
96 
Ph 
WS206976-1 
1
KOH/MeOH 
1.0 equiv. 
98% 
Ph 
WS206979-1 
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SW206976-l, 1-(3-amino-4-pheny 1-6-( thiophen-2-yl) 
thieno[2,3-b ]pyridin-2-yl)pentan-1-one. To the solution of 15 
2-( (2-oxohexyl )thio )-4-pheny 1-6-( thiophen-2-y l)nicotinoni-
trile (0.13 mmol, 50 mg) in ethanol (500 µL) was added 
KOH (0.13 mmol, 2 mg, 1.0 equiv.). The reaction mixture 
98 
(m, 4H), 4.52 (s, 2H), 2.75 (t, J=7.8 Hz, 2H), 1.73-1.54 (m, 
2H), 1.51-1.26 (m, 2H), 0.91 (t, J=7.3 Hz, 3H). ESI-MS 
(m/z): 393 [M+Ht. 
SW206977, 3-amino-4-phenyl-N-propyl-6-(thiophen-2-
was stirred at 500 C. for 30 min. Once complete, the reaction 20 yl)thieno[2,3-b ]pyridine-2-carboxamide. A mixture of 
was diluted with EtOAc and washed with 10% aq. HCI. The 4-phenyl-6-(thiophen-2-yl)-2-thioxo-1,2-dihydropyridine-
3-carbonitrile (0.12 mmol, 35 mg), 2-chloro-N-propylacet-
amide (0.12 mmol, 16 mg, 1.0 equiv.) and EtONa (0.19 
organic phase was separated and aqueous layer was 
extracted twice with EtOAc, dried over magnesium sulfate, 
filtered and concentrated under reduced pressure to afford 
designed product in 98% yield. 
25 mmol, 1.6 equiv.) in ethanol (1 mL) was stirred at 50° C. 
When the reaction was complete as judged by TLC, the 
reaction was diluted with EtOAc and washed with 10% aq. 
HCI. The organic phase was separated and aqueous layer 
1H NMR (400 MHz, CDCl3 ) Ii 7.65 (dd, J=3.8, 1.1 Hz, 
lH), 7.62-7.56 (m, 2H), 7.55-7.48 (m, 4H), 7.40 (s, lH), 
7.13 (dd, J=5.0, 3.8 Hz, lH), 4.13 (s, 2H), 2.72 (t, J=7.4 Hz, 
2H), 1.72-1.56 (m, 2H), 1.42-1.25 (m, 2H), 0.88 (t, J=7.3 
Hz, 3H). ESI-MS (m/z): 393 [M+Ht. 
30 was extracted twice with EtOAc, dried over magnesium 
sulfate, filtered and concentrated under reduced pressure to 
afford designed product in 61% yield. 1H NMR (400 MHz, 
CDCl3 ) ll 7.65 (d, J=3.7, lH), 7.58-7.49 (m, 3H), 7.49-7.38 
35 (m, 4H), 7.10 (dd J=4.9, 3.7 Hz, lH), 5.75 (s, 2H), 5.59-5.38 
(m, lH), 3.35 (td J=7.0, 5.9 Hz, lH), 1.64-1.58 (m, 2H), 0.96 
(t, J=7.4 Hz, 3H). ESI-MS (m/z): 394 [M+Ht. 
40 
CN 
45 
SW206978, Ethyl 3-amino-4-phenyl-6-(thiophen-2-yl) 
thieno[2,3-b ]pyridine-2-carboxylate. A mixture of 4-phenyl-
2-( (2-oxohexy l)thio )-4-phenyl-6-( thiophen-2-y l)nicoti-
nonitrile. A mixture of 4-phenyl-6-(thiophen-2-yl)-2-thioxo-
1,2-dihydropyridine-3-carbonitrile (0.068 mmol, 20 mg), 50 
Et3N (0.11 mmol, 15 µL, 1.6 equiv.) and 2-butyloxirane 
(0.11 mmol, 11 mg, 1.6 equiv.) in MeOH (500 µL) was 
stirred at room temperature. When the reaction was com-
plete as judged by TLC, the reaction mixture was evapo-
rated; the crud product dissolved in DCM and DMP (0.10 
mmol, 1.5 equiv.) was added at 0° C. The reaction mixture 
55 6-(thiophen-2-yl)-2-thioxo-1,2-dihydropyridine-3-carboni-
trile (0.34 mmol, 100 mg), ethyl 2-chloroacetate (0.54 
mmol, 1.6 equiv.) and EtONa (0.54 mmol, 1.6 equiv.) in 
was stirred at room temperature for 2 h and then was ethanol (1 mL) was stirred at reflux. When the reaction was 
quenched by addition of 1: 1 mixture of 20% Na2 S2O3 / 60 complete as judged by TLC, the reaction was diluted with 
NaHCO3 solution. The organic layer was separated, dried 
over magnesium sulfate and the solvent was removed under 
reduced pressure. The crude product was purified by flash 
chromatography to afford designed product in 72% yield. 1 H 65 
NMR (400 MHz, CDCl3 ) Ii 8.02 (s, lH), 7.97 (d, J=3.1 Hz, 
lH), 7.71-7.59 (m, 2H), 7.55 (d, J=3.2 Hz, lH), 7.55-7.46 
EtOAc and washed with 10% aq. HCI. The organic phase 
was separated and aqueous layer was extracted twice with 
EtOAc, dried over magnesium sulfate, filtered and concen-
trated under reduced pressure to afford designed product in 
79% yield. 1H NMR (400 MHz, DMSO-d6) ll 8.01 (d, J=3.7 
Hz, lH), 7.87-7.67 (m, 2H), 7.56 (d, J=6.5 Hz, 5H), 7.36-
US 10,301,320 B2 
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6.90 (m, lH), 5.73 (s, 2H), 4.23 (q, J=7.1 Hz, 2H), 1.25 (t, 
1=7.0 Hz, 3H). ESI-MS (m/z): 381 [M+Ht. 
SW206979, 3-Amino-4-phenyl-6-(thiophen-2-yl)thieno 
[2,3-b]pyridine-2-carboxylic acid. To a solution of -phenyl-
6-(thiophen-2-yl)-2-thioxo-1,2-dihydropyridine-3-carboni-
trile (0.34 mmol, 100 mg) and ethyl 2-chloroacetate (0.54 
mmol, 1.6 equiv.) in ethanol (1 mL), Et3N (0.54 mmol, 1.6 
SW208068, 2-(butylthio )pyridin-3-amine. To the solution 
ofbutane-1-thiol (7.0 mmol, 628 mg, 1.1 equiv.) in THF (30 
10 mL) was added NaH (6.6 mmol, 158 mg, 1.05 equiv.) at 0° 
C. After the reaction mixture was stirred at room tempera-
ture for 30 min. 2-chloro-3-nitropyridine (6.33 mmol, 1.0 g) 
was portion wise added and left with stirring at room 
15 
temperature. for 2 h. Water was then added to the reaction 
mixture, and the resulting mixture was extracted with ethyl 
acetate. The organic layer was washed with a saturated 
aqueous solution of sodium chloride, and dried over sodium 
sulfate, filtered and concentrated under reduced pressure to 
20 afford crude product. Because of difficulties with purifica-
tion, impure 2-(butylthio )-3-nitropyridine was directly used 
for the next step. Nitropyridine (0.47 mmol, 100 mg) was 
equiv.) was added. The reaction was refluxed for 20 min. 
The reaction was then diluted with EtOAc and water. The dissolved in a mixed solvent of acetic acid (3.3 ml) and cone. 
25 hydrochloric acid (130 µL), and zinc (5.7 mmol, 370 mg) organic phase was separated and aqueous layer was 
extracted twice with EtOAc. The combined extractions were 
washed with saturated NaCl solution, dried over magnesium 
sulfate, filtered and concentrated under reduced pressure to 
afford designed product. Ethyl 2-((3-cyano-4-phenyl-6-
(thiophen-2-yl)pyridin-2-yl)thio )acetate was then dissolved 
in DMF and treated with IM aq. NaOH at 50° C. to give 
SW206979, 3-amino-4-phenyl-6-(thiophen-2-yl)thieno[2,3-
b ]pyridine-2-carboxylic acid in 63% yield. 1H NMR (400 
MHz, DMSO-d6) Ii 8.00 (dd, J=3.7, 1.1 Hz, lH), 7.79-7.64 
(m, 2H), 7.55 (dt, J=7.6, 3.2 Hz, 5H), 7.16 (dd, J=5.0, 3.7 
Hz, lH), 5.72 (s, 2H). ESI-MS (m/z): 353 [M+Ht. 
Scheme 4 
OCN Cl NO2 NaS ~ 
0 
I 
was added in small portions while being cooled with ice. 
After the mixture was stirred for 30 minutes, the reaction 
mixture was filtered, and the filtrate was neutralized with an 
aqueous solution ofNaHCO3 , and extracted with DCM. The 
30 organic layer was washed with water and then with a 
saturated aqueous solution of sodium chloride, and dried 
over sodium sulfate. Subsequently, the solvent was evapo-
rated to obtain 2-(butylthio )pyridin-3-amine as a pale yellow 
35 oil. 
1H NMR (400 MHz, CDC13 ) Ii 7.94 (dd, J=4.1, 2.0 Hz, 
lH), 7.05-6.51 (m, 2H), 3.84 (s, 2H), 3.51-2.95 (m, 2H), 
1.72-1.60 (m, 2H), 1.56-1.36 (m, 2H), 0.91 (t, J=7.4 Hz, 
3H). ESI-MS (m/z): 183 [M+Ht. 
AcOH/HCl/Zn 
OCN S~ I NO2 
SW208068 
SW208069 
0 
I 
AcOH/H2O2 
1.5 equiv. OCN S~ I NH2 
SW208070 
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FIGS. 21 (A-B) show the shift in IC50 value with chang-
ing enzyme concentration. The result is indicative of a 
tight-binding mode of inhibition with dependency on 
enzyme: inhibitor stoichiometry, rather than on the absolute CXN s, N02 5 concentration of the inhibitor. In all cases, the IC50 values are less than the enzyme concentration, indicating that nM drug is almost fully bound by the enzyme. 
SW208069, 2-(butylsulfinyl)-3-nitropyridine. To the solu-
tion ofbutane-1-thiol (7.0mmol, 628 mg, 1.1 equiv.) in THF 
(30 mL) was added NaH (6.6 mmol, 158 mg, 1.05 equiv.) at 
FIGS. 22 (A-B) indicate that SW033291 behaves very 
much like an irreversible inhibitor of 15-PGDH, and cannot 
10 be efficiently dialyzed off the 15-PGDH protein. 
0° C. After the reaction mixture was stirred at room tem-
perature for 30 min 2-chloro-3-nitropyridine (6.33 mmol, 
1.0 g) was portion wise added and left with stirring at room 
15 
temperature, for 2 h. Water was then added to the reaction 
mixture, and the resulting mixture was extracted with ethyl 
acetate. The organic layer was washed with a saturated 
aqueous solution of sodium chloride, and dried over mag-
nesium sulfate, filtered and concentrated under reduced 20 
pressure to afford crude product. Because of difficulties with 
purification, impure 2-(butylthio)-3-nitropyridine was used 
directly for the next step. Nitropyridine (0.47 mmol, 100 
mg) was dissolved in a mixed solvent of acetic acid (1.2 ml) 
and chloroform (1.2 mL), and hydrogen peroxide (0.7 mmol, 25 
1.5 equiv., 30% solution in water) was added. After the 
mixture was stirred for 45 minutes, at 32° C., the reaction 
was diluted with EtOAc and washed with saturated NaHCO3 
solution, dried over magnesium sulfate, filtered and concen-
trated under reduced pressure to 2-(butylsulfinyl)-3-nitrop- 30 
yridine. 1H NMR (400 MHz, CDC13 ) Ii 9.14 (dd, J=4.6, 1.5 
Hz, lH), 8.54 (dd, J=8.2, 1.5 Hz, lH), 7.67 (dd, J=8.2, 4.6 
Hz, lH), 3.18 (ddd, J=12.7, 9.3, 7.2 Hz, lH), 3.00 (ddd, 
J=12.7, 9.1, 4.9 Hz, lH), 2.17-1.92 (m, lH), 1.91-1.70 (m, 
lH), 1.68-1.35 (m, 2H), 0.96 (t, J=7.3 Hz, 3H). ESI-MS 35 
(m/z): 229 [M+Ht. 
0 
The testing of whether SW033291 is a reversible inhibitor 
proceeded by: 
(i) an 8 ul aliquot taken of 15-PGDH stock (8 mg/mL 
15-PGDH in 500 µLof15-PGDH assay buffer) (4 nmol 
15-PGDH, 4 µM 15-PGDH), was incubated on ice 
with: (a) addition of 5 µL of 100 mM NAD( + )+addition 
of 3.2 µL of 2.5 mM SW033291 stock, then dialyzed 
versus 1 L buffer for 12 hours, followed by a fresh 1 L 
of buffer for 12 more hours; or (b) addition of 5 µL, 100 
mM NAD( + )+addition of 3.2 µL DMSO then dialyzed 
versus 1 L buffer for 12 hours, followed by a fresh 1 L 
of buffer for 12 more hours. 
(ii) Pre-dialysis, remove 1 µLand dilute in 200 µL assay 
Buffer (20 nM), then measure 15-PGDH activity. 
(iii) Post-Dialysis, at 24 hrs, remove 1 µL and dilute in 
200 µL assay Buffer (20 nM), then measure 15-PGDH 
activity. 
Dialysis buffer is 50 mM Tris pH7.4, 40 mM NaCl, 0.1 
mM DTT, 0.01 % Tween-20. 
Under the conditions of the assay SW033291 inhibited 
91% of 15-PGDH pre-dialysis, and 85% of 15-PGDH activ-
ity post-dialysis-that is dialysis did not reverse the inhibi-
tion of 15-PGDH. Control 15-PGDH protein that was dia-
lyzed in the absence of SW033291 remained fully active. 
FIGS. 23(A-B) show (A) at upper right the reaction rates 
for 15-PGDH in the presence of a graded set of increasing 
concentrations of SW033291. In the graph at upper right P 
is the NADH concentration as a proxy for 15-keto-PGE2. 
(P+S) is the starting PGE2 concentration of 20 µM. The I 
CXN s, NH2 Bu 
40 assay was carried out in the presence of 10 nM recombinant 
15-PGDH. In the graph at lower left (B), Vo is the initial 
velocity of the reaction in the absence ofSW033291, and Vi 
is the initial velocity of the reaction in the presence of the 
corresponding concentration of SW033291. The line shows 
SW208070, 2-(butylsulfinyl)pyridin-3-amine was pre-
pared by using synthetic procedure described for the prepa-
ration of analog SW208069 and showed in Scheme 4. 1H 
NMR (400 MHz, CDC13 ) Ii 7.90 (dd, J=4.4, 1.4 Hz, lH), 
45 the curve generated by fitting the data to the Morrison 
equation. The curve fitting yields a calculated a KiApp value 
of 0.1015 nM. The dashed line intersects the X axis at 8.5 
nM. This represents the point at which [inhibitor]=[active 
7 .09 ( dd, J=8.3, 4.4 Hz, lH), 6.93 ( dd, J=8.3, 1 .4 Hz, lH), 50 
5.30 (s, 2H), 3.24 (ddd, J=13.0, 9.5, 5.4 Hz, lH), 3.03 (ddd, 
J=13.0, 9.8, 6.3 Hz, lH), 1.95-1.61 (m, 2H), 1.55-1.35 (m, 
2H), 0.93 (t, J=7.3 Hz, 3H). ESI-MS (m/z): 199 [M+Ht. 
enzyme] showing that the enzyme preparation contains 85% 
active enzyme. In the Morrison equation, Ki is the binding 
affinity of the inhibitor; [SJ is substrate concentration; and 
Km is the concentration of substrate at which enzyme 
activity is at half maximal. Note that IC50 is the functional 
strength of the inhibitor. Whereas the IC50 value for a 
Example 4 
Analysis of the Mechanism of 15-PGDH Inhibition by 
SW033291 and Related Compounds 
55 compound may vary between experiments depending on 
experimental conditions, the Ki is an absolute value. Ki is 
the inhibition constant for a drug; the concentration of 
competing ligand in a competition assay which would 
The following Example provides data relating to the 
mechanism of action by which SW033291 inhibits 60 
15-PGDH. 
occupy 50% of the receptors if no ligand were present. 
FIGS. 24(A-B) show duplicate titrations of 15-PGDH 
Inhibitor (SW033291) that were run at 6 different concen-
trations of PGE2 (1.25 uM-40 uM). In the graph at top, 
Y-axis is % inhibition of the reaction by SW033291. The 
X-axis is the concentration of SW033291 in nM. Reactions 
Duplicate titrations of 15-PGDH Inhibitor (SW033291) 
were run at 4 different concentrations of 15-PGDH (24 nM, 
12 nM, 6 nM, 3 nM). Reactions contained the indicated 
concentration of enzyme, 250 µM NAD( + ), 25 µM PGE-2, 
and were assembled and incubated at room temperature for 
3 minutes. 
65 contain 5.0 nM added 15-PGDH, 250 µM NAD( + ), and 
indicated concentrations of PGE-2, were assembled and 
incubated at room temperature for 60 minutes. The Km for 
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103 
PGE2 is approximately 5 uM, and reactions run with PGE2 
concentrations below 5 uM go very slowly making it diffi-
cult to quantitate inhibition by SW033291. However, in 
reactions with PGE2 at concentrations of 5 uM-40 uM, the 
IC50 for SW033291 is unaffected by the increasing PGE2 5 
concentration, showing that the inhibition is noncompeti-
tive. 
10 
FIG. 25 shows the structure activity relationships of 
analogues of SW033291 versus their IC50 against recom-
binant 15-PGDH. Assigmnents of structures to the two 
isomers, A and B, of SW033291 are arbitrary, as the struc-
ture of the active isomer (isomer B) has not been deter-
mined. The optical isomers ofSW033291 were separated by 
preparative HPLC using a 10 mmx250 mm Chiralcel ODH 15 
colunm, 5% isopropanol in hexanes, 1 mL/min. The 'A' 
isomer is the faster eluting isomer. The 'B' isomer is the 
slower eluting isomer. 
The analogue family shows that SW033291, with a 4 
carbon side chain, is 2-fold more potent than SW208080 (5 20 
carbon side chain), 15-fold more potent than SW208081 (6 
carbon side chain), and 100-fold more potent than 
SW208079 (1 carbon side chain). SW033291 is also 20-fold 
more potent than SW208078, the analogue that converts the 
sulfoxide group to a sulfone. 25 
FIG. 26 shows structures of additional SW033291 ana-
logs that convert the sulfoxide group to a ketone, an amide, 
an ester, or a carboxylic acid. Also shown is structure 
SW206980 that deletes the phenyl ring from SW033291. 
FIGS. 27(A-C) show graphs that show the level of com- 30 
pound's activity in inducing the 15-PGDH-luciferase fusion 
reporter in three different test cell line backgrounds, V9m, 
LS174T, and V503. Each compound was tested at two 
concentrations, 2.5 uM, and 7.5 uM. Y-axis is luciferase 35 
activity. 
At 2.5 µM-7.5 µM, SW206980, that deletes the phenyl 
group of SW033291, shows activity comparable to 
SW033291 in all three reporter lines. 
Structures that have converted the sulfoxide group to a 40 
ketone, amide, ester, or carboxylic acid show major loss of 
activity in inducing the reporter. 
FIG. 28 shows graphs that show the percent of 15-PGDH 
enzyme activity that is inhibited at 2.5 uM and at 7.5 uM by 
each of the 5 test compounds. SW206980 that deletes the 45 
phenyl group of SW033291, shows at these concentrations 
similar potency to SW03291 in inhibiting 15-PGDH activ-
ity. 
Structures that have converted the sulfoxide group to a 
ketone, amide, ester, or carboxylic acid show major loss of 50 
activity as 15-PGDH inhibitors. 
104 
binds to and markedly stabilizes the tertiary structure of 
15-PGDH, in a manner requiring the presence of the NADH 
cofactor. 
FIGS. 31(A-C) show further analogues ofSW033291 that 
build on the previous finding that removal of the SW033291 
phenyl ring (SW206980) retained activity. The new analog 
(SW206992) adds a nitrogen to the left-hand ring. 
Table 3 provides a comparison of the properties of 
SW033291, SW206980, and SW206992. 
TABLE 3 
Summary of three SW033291 analogs 
SW033291 SW206980 SW206992 
ICso 1.59 nM 0.97 nM 1.411 nM 
Time to ~5 mins ~2 mins ~2 mins 
inhibition 
(10 nM) 
LI. Tm (NADH) 19° C. 15.5° C. 19° C. 
Concentration ~100 nM >300 nM >1 uM 
for Full Cell 
Line Reporter 
Induction 
Hepatocyte Stable > couple hrs T½ - 80 mins 
stability 
Toxicity >10 µM >7.5 µM >7.5 µM 
Time to inhibition refers to the time needed to inhibit the 
generation of NADH by 15-PGDH from the moment with 
drug is added into the reaction mix. Delta™ refers to the 
shift in melting temperature of recombinant 15-PGDH in the 
presence of drug (with cofactor NADH also present). Con-
centration of Full Cell Line Reporter Induction refers to the 
concentration of drug that needs to be added to reporter cell 
line to achieve maximal induction of the 15-PGDH-lu-
ciferase gene fusion reporter cassette, as measured by 
luciferase assays. Hepatocyte stability refers to the half-life 
of compound in the presence of hepatocytes in culture. 
Toxicity refers to the concentration of compound needed to 
decrease cell numbers in a cell culture assay. 
FIGS. 32(A-C) show titration of induction by SW033291 
of the 15-PGDH-luciferase gene fusion reporter in three 
different cell line backgrounds. In general between 80-160 
nM SW033291 exposure for 24 hours is needed to induce 
maximal reporter induction. 
FIGS. 33(A-C) show titration of induction by SW206980 
of the 15-PGDH-luciferase gene fusion reporter in three 
different cell line backgrounds. In general 2:300 nM 
SW206980 exposure for 24 hours is needed to induce 
maximal reporter induction. FIGS. 29(A-B) show a titration curve that plots percent 
inhibition of 15-PGDH enzyme activity at different concen-
trations of SW033291 and SW0206980. Under identical 
assay conditions, SW206980 shows a slightly lower IC50. 
FIGS. 30(A-B) show that SW206980 binds directly to 
15-PGDH and markedly shifts its melting curve. Shown at 
left is the melt curve of 15-PGDH as reflected by fluores-
cence of the hydrophobic dye SYPRO Orange. Shown at 
right is the negative first derivative of the melt curve. 
FIGS. 34(A-C) show titration of induction by SW206992 
of the 15-PGDH-luciferase gene fusion reporter in three 
55 different cell line backgrounds. In general 2:1000 nM 
SW206992 exposure for 24 hours is needed to induce 
maximal reporter induction. 
FIGS. 35(A-C) show the shift in the melt curve of 
recombinant 15-PGDH protein (10 uM) by 20 uM 
Three conditions are plotted, that of 10 uM 15-PGDH, 
that of 10 uM 15-PGDH plus 10 uM SW206980, and that of 
60 SW033291, SW206980, and SW206992 in the presence of 
the cofactor NAD ( + )(100 uM). Control melting temperature 
is 49 degrees centigrade. SW033291 shifts the melting 
temperature to 63 degrees. SW206980 shifts the melting 
10 uM 15-PGDH plus 125 uM NADH plus 10 µM 
SW206980. The melting temperature, as reflected by the 
inflection point of the curve at right is shifted by 20° C., 65 
from 48-degrees up to 68-degrees, in the presence of 
SW206980 and NADH, reflecting that SW206980 directly 
temperature to 61 degrees. SW206992 shifts the melting 
temperature to 59 degrees. Thus all three compounds 
directly bind to 15-PGDH and markedly increase the melt-
US 10,301,320 B2 
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ing temperature of the protein, with the order of the tem-
perature shifts being SW03329l>SW206980>SW206992. 
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Time to inhibition refers to the time needed to inhibit the 
generation of NADH by 15-PGDH from the moment with 
drug is added into the reaction mix. Delta™ refers to the 
shift in melting temperature of recombinant 15-PGDH in the 
FIGS. 36(A-B) show the shift in the melt curve of 
recombinant 15-PGDH protein (10 uM) by 20 uM 
SW033291, SW206980, and SW206992 in the presence of 
the cofactor NADH (100 uM). Control melting temperature 
5 presence of drug (with cofactor NADH also present). Con-
centration of Full Cell Line Reporter Induction refers to the 
concentration of drug that needs to be added to reporter cell 
line to achieve maximal induction of the 15-PGDH-lu-
is 55 degrees centigrade. SW033291 shifts the melting 
temperature to 74 degrees. SW206980 shifts the melting 
temperature to 70.5 degrees. SW206992 shifts the melting 10 
temperature to 68.5 degrees. Thus all three compounds 
directly bind to 15-PGDH and markedly increase the melt-
ing temperature of the protein, with the order of the tem-
perature shifts being SW03329l>SW206980>SW206992. 
FIGS. 37(A-C) show a titration curve of 15-PGDH inhibi- 15 
tor compounds in an assay measuring effect on PGE2 levels 
in the medium of A549 cells that have been stimulated with 
ILl-beta. Highest PGE2 levels, 3000 pg/ml, are achieved 
with SW033291, with maximal effect attained at 2.5 uM 
compound. Next highest PGE2 level, 2500 pg/ml are 
achieved with SW206980, with maximal effect attained at 
7.5 uM compound. Lowest induction, to 2100 pg/ml PGE2 
20 
is achieved with SW206992, with maximal effect attained at 
2.5 uM. In these reactions, A549 cells were maintained in 25 
F12K medium supplemented with 10% fetal calf serum 
(FBS) and 50 gentamicin in a humidified atmosphere con-
taining 5% CO2 at 37° C. Cells were plated in 24-well plates 
(0.5 mL per well) at about 100,000 cells per well in duplicate 30 
and grown for 24 h before stimulation with IL-1 ~ (1 ng/mL) 
overnight (16 h) to generate PGE2. SW033291 and its 
analogs were added at the indicated concentrations, and the 
incubation continued for 8 h. Medium was collected, and the 
level of PGE2 was analyzed by enzyme immunoassay. Data 35 
were analyzed from results of three independent experi-
ments. 
ciferase gene fusion reporter cassette, as measured by 
luciferase assays. Hepatocyte stability refers to the half-life 
of compound in the presence of hepatocytes in culture. 
Toxicity refers to the concentration of compound needed to 
decrease cell numbers in a cell culture assay. 
FIG. 40 provides graphical summary showing the activity 
of each of the compounds in inducing a 15-PGDH-luciferase 
fusion gene reporter introduced into three different colon 
cancer cell lines, V9m, LSI 74T, and V503. Results are 
measured by assay of luciferase activity after exposure of 
cells to compound at either 2.5 uM or 7.5 uM compounds 
concentration. 
FIG. 41 provides graphical summary showing the activity 
of each of the compounds in inhibiting the enzymatic 
activity ofrecombinant 15-PGDH enzyme when compound 
is added at 2.5 uM and at 7.5 uM. 100% inhibition corre-
sponds to complete inhibition of the enzyme. 
FIG. 42 shows measurement of IC for inhibiting 2.5 nM 
ofrecombinant 15-PGDH when incubated across a range of 
concentrations of SW208064, SW208065, SW208066, and 
SW208067. Y-axis of each graph records percent inhibition 
of the 15-PGDH enzymatic activity. 100% Inhibition corre-
sponds to complete inhibition of the enzyme. X-axis of each 
graph records the log of the inhibitor concentration 
expressed in nM. 
Example 5 
Analysis of Toxicity of SW033291 
Table 5 shows a summary of a group of 8-12 week old 
male FVB mice in control or SW033291 treatment arms 
FIGS. 38(A-C) show assays of cellular toxicity on A549 
cells at 24 hours of 15-PGDH inhibitors as assayed by 
CellTiter-Glo measurement. No effect on CellTitre-Glo lev-
els is seen by concentrations ofup to 10 uM ofSW033291, 
SW206980, and SW2206992. 
40 assessed for toxicity of SW033291, with 6 mice in each arm 
of the study. 
FIG. 39 shows structures of 7 SW033291 analogues, TABLE 5 
SW208064, SW208065, SW208066, SW208067, 45 Baseline Characteristics FVB male mice- 8-12 weeks old 
SW208068, SW208069, SW208070. 
Table 4 provides tabular s=ary of the properties of 4 
analogues, SW208064, SW208065, SW208066, 
SW208067, and in particular lists the IC50 for each of these 
4 compounds against 2.5 nM recombinant 15-PGDH. 
TABLE 4 
Summary of four SW033291 analogs from UTSW set 8 
SW033291 SW2068064 SW208065 SW208066 
ICso 1.23 nM 151.4 nM 4.865 nM 1.368 nM 
Time to ~5 mins 
inhibition 
(10 nM) 
LI. Tm (NADH) 19° C. 5° C. 13° C. 16.5° C. 
Concentration ~100 nM ~600 nM ~100 nM ~100 nM 
for Full Cell 
Line Reporter 
Induction 
Hepatocyte Stable> 
stability couple hrs 
Toxicity >10 µM 
Toxicity Study 
Number 
Sex 
SW208067 
2.395 nM 
16.5° C. 
~500 nM 
WT-Control 
6 
M 
WT-Treatment 
6 
M 
p-value 
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TABLE 5-continued 
Baseline Characteristics FVB male mice- 8-12 weeks old 
Toxicity Study 
Age (Days) 
Weight (gm) 
WT-Control 
73.7.1 ± 4.7 
27.5 ± 2.4 
WT-Treatment 
73.2 ± 5.0 
26.8 ± 3.1 
p-value 
0.465 
0.412 
FIG. 43 shows the dose response curve for induction of a 
15-PGDH-luciferase fusion gene reporter in the V9m cell 
line background of SW033291, SW208064, SW208065, 
SW208066, and SW208067. 
108 
numbers of hematopoietic colonies generated when marrow 
is plated into methylcelluose. Experimental conditions are 
noted on the figure. 
FIGS. 49(A-B) show analysis of marrow from CD45.2 
5 antigen marked C57BL/6J mice that were treated with 
SW033291 5 mg/kg IP daily for 3 doses in a vehicle of 10% 
Ethanol, 5% Cremophor EL, 85% D5W or that were treated 
with vehicle alone. On day 3 mice were sacrificed, marrow 
flushed and mixed at a 1: 1 ratio with vehicle treated CD45 .1 
10 marrow. 2 million whole BM cells were injected into the tail 
vein of lethally irradiated CD45.1 mice and percent chime-
rism measured via flow cytometry at weeks 8, 12, 16. As 
shown, at weeks 12 and 16 the percent blood chimerism of 
CD45.2 marked cells was significantly increased in recipient 
FIG. 44 Shows titration curves of 15-PGDH inhibitor 
compounds in an assay measuring effects on PGE2 levels in 
the medium of A549 cells that have been stimulated with 
ILi-beta in the same experimental design described for FIG. 
37. At 100 nM concentration of drug, the highest levels of 
PGE2 in the medium are achieved by treating cells with 
SW208066 or with SW208067, after which the next highest 
level of PGE2 in the medium is achieved by treating cells 20 
with SW033291. 
15 mice whose CD45.2 marked marrow was harvested from 
SW033291 treated donor mice, as opposed to vehicle con-
trol treated donor mice. In other words, marrow from 
SW033291 treated mice demonstrated long term increased 
fitness in competition with control marrow. In particular, at 
week 16 CD45.2 harvested from SW033291 treated mice 
show a significant increase in contribution to B and T cell 
FIG. 45 shows the daily weights of a group of 8-12 week 
old FVB mice treated with vehicle or with SW033291 IP at 
populations, suggesting marrow from SW033291 treated 
mice promotes earlier reconstitution of lymphoid popula-
tions and earlier return to immune competence. 
In an additional study, C57BL/6J mice are irradiated with 
11 Gy on day 0, followed by treatment with SW033291 5 
mg/kg IP twice daily (bid) in a vehicle of 10% Ethanol, 5% 
Cremophor EL, 85% D5W, or with vehicle only for 21 days. 
Mice treated with vehicle or with SW033291 all receive an 
5 mg/kg twice daily for 21 days. SW033291 was adminis-
tered in a vehicle of 10% Ethanol, 5% Cremophor EL, 85% 25 
D5W at a concentration of 125 ug/200 ul. As shown, both 
vehicle and drug treated mice show equal weight gain during 
the 21 day period, with no evidence for SW033291 reducing 
mouse weight. N=6 mice in both the SW033291 treated and 
the vehicle treated arms. 30 allograft of marrow from a donor C57BL/6J mouse at a dose 
of either 100,000 cells, 200,000 cells, 500,000 cells. 3 
control and 3 SW033291 mice are assessed under each 
condition. The experimental design is depicted in FIG. 50. 
Example 6 
Analysis of Effect of SW033291 on Bone Marrow Function 
This Example shows effects of SW033291 on bone mar-
row function. 
FIGS. 46(A-C) show analysis of bone marrow of wild-
type mice versus mice that are homozygous genetic knock-
outs for 15-PGDH (PGDH-/- mice). Total bone marrow 
cellularity and percent of Scal+/c-Kit+ cells in lineage 
negative (SKL) cells are the same in both sets of mice. 
However, bone marrow from 15-PGDH-/- mice shows an 
approximately 50% increase in numbers of hematopoietic 
colonies generated when marrow is plated into methylcel-
luose. Experimental conditions are noted on the figure. 
15-PGDH knockout mice are denoted by label PGDH-/-
and by label 15-PGDH. 
FIG. 47 shows assay in which bone marrow is harvested 
from a wild-type mouse, and incubated ex vivo on ice for 2 
hours with either SW033291 (0.5 uM), or 1 uM PGE2 or 1 
uM 16,16-dimethyl PGE2 (dmPGE2). Treated marrow is 
again then plated into methylcellulose for counting of 
hematopoietic colonies. SW033291 treated marrow again 
shows an approximately 50% increase in the number of bone 
marrow derived colonies generated. Under these conditions, 
a lesser increase is seen in marrow treated with PGE2, and 
a slightly greater increase is seen in marrow treated with 
dmPGE2. 
FIGS. 48(A-C) show a study of C57BL/6J mice treated 
with IP SW033291 administered in a vehicle of 10% Etha-
nol, 5% Cremophor EL, 85% D5W at a dose of 5 mg/kg or 
20 mg/kg. Panel A shows mouse bone marrow cellularity, 
white blood count (wbc), red blood count (rbc) and platelets 
counts. Panel B shows percent of Scal+/c-Kit+ cells in 
lineage negative (SKL) cells are unchanged in SW033291 
treated mice. Panel C shows that marrow from SW033291 
treated mice gives rise to approximately 30% increase in 
Table 6 shows the number of surviving mice in each 
35 cohort over the first 19 days of study. Under the conditions 
of the mouse colony during this study, control mice receiv-
ing 100,000-500,000 cells are all dead between days 4-13 of 
study. In contrast, two SW033291 treated mice receiving 
500,000 cells remain alive on day 19 of the study and are 
40 presumed to have full hematopoietic reconstitution. Thus 
treatment with the 15-PGDH inhibitor SW033291 promoted 
survival of mice receiving a bone marrow transplant, an 
observation consistent with SW033291 enabling more rapid 
and complete hematopoietic reconstitution in the trans-
45 planted mice. Other 15-PGDH inhibitors with activity simi-
lar to SW033291 would be predicted to have similar activity 
in supporting hematopoietic reconstitution. Treatment with 
SW033291 also enabled mice to be successfully trans-
planted with a smaller inoculum of donor bone marrow than 
50 the 1,000,000 cells that are standardly needed. These obser-
vations suggest SW033291, as well as other similar 
15-PGDH inhibitors, is able to support successful transplan-
tation with smaller numbers of donor stem cells. Such 
activity would be of particular utility in settings, such as 
55 transplantation with umbilical cord stem cells, in which 
donor cell numbers are limited. Improved survival of trans-
planted mice treated with SW033291 suggests efficacy of 
SW033291, and of similar 15-PGDH inhibitors, as replace-
ments for, or in enabling decreased use of, other treatments 
or growth factors commonly employed in support of patients 
60 receiving bone marrow, hematopoietic stem cell, and cord 
blood stem cell transplants. Improved survival of trans-
planted mice treated with SW033291 is consistent with 
SW033291, and by extension other similar 15-PGDH inhibi-
tors, having activity in reducing infections in the trans-
65 planted mice, and/or in promoting recovery of mice intes-
tines from damage by radiation, and/or in reducing 
pulmonary toxicity from radiation. 
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13- 14- 15-
Mar Mar Mar 
Day Day Day 
Treatment Cell number 0 1 2 
Control 1 X 10-5 3 3 3 
Control 2 X 10-5 3 3 3 
Control 5 X 10-5 3 3 3 
SW033291 1 X 10-5 3 3 3 
SW033291 2 X 10-5 3 3 3 
SW033291 5 X 10-5 3 3 3 
Example 7 
US 10,301,320 B2 
TABLE 6 
Mouse survival 
16- 17- 18- 19- 20- 21-
Mar Mar Mar Mar Mar Mar 
Day Day Day Day Day Day 
3 4 5 6 7 8 
2 0 
3 3 2 0 
3 3 3 2 
3 2 0 
3 3 3 2 2 2 
3 3 3 3 3 2 
110 
22- 23- 24-
Mar Mar Mar 
Day Day Day 
9 10 11 
2 2 2 
2 2 2 
25-
Mar 
Day 
12 
2 
26-
Mar 
Day 
13 
0 
0 
2 
1-
Apr 
Day 
19 
2 
15 10% Ethanol, 5% Cremophor EL, 85% D5W for 7 doses, or 
Analysis of Effect of SW033291 on Radiation Survival 
This Example shows studies of the effect ofSW033291 in 
mice receiving whole body irradiation. 
receiving vehicle alone. The table shows the number of mice 
surviving on sequential days of the study. Under the condi-
tions of the mouse colony during this experiment, mice 
20 receiving a lethal dose of 11 Gy lived 48 hours longer if 
treated with SW033291 than if receiving vehicle control, 
with control mice all dead on day 8; whereas SW033219 
treated mice were all dead on day 10. 
Table 7 shows the results of a study of 15 week old 
C57BL/6J female mice irradiated with 7 Gy, 9 Gy, or 11 Gy, 
and receiving daily SW033291 5 mg/kg IP in a vehicle of 
10/2 10/3 
Radiation Treatment Day Day 
Dose Arm 0 5 
7 Gy Saline 3 3 
SW033291 3 3 
9 Gy Saline 3 3 
SW033291 3 3 
11 Gy Saline 3 3 
SW033291 3 3 
11 
10/4 
Day 
6 
3 
3 
3 
3 
3 
3 
10/5 
Day 
7 
3 
3 
3 
3 
2 
3 
TABLE 7 
10/6 10/7 10/8 10/9 10/10 10/11 10/12 10/13 10/23 
Day Day Day Day Day Day Day Day Day Day 
8 9 10 11 12 13 14 15 16 25 
3 3 3 3 3 3 3 3 Looks 
Healthy 
3 3 3 3 3 3 3 3 Looks 
Healthy 
3 3 3 3 2 0 
3 3 3 3 2 2 0 
0 
3 2 0 
Table 8 shows the number of mice surviving on sequential 
days of a study of mice treated at 11 Gy treated with either 
40 vehicle control or with SW033291 IP, in a vehicle of 10% 
Ethanol, 5% Cremophor EL, 85% D5W, with SW033291 
administered either at 5 mg/kg daily for 7 days, 5 mg/kg 
daily throughout the study, or at 5 mg/kg twice daily for 7 
days. Again mice treated with SW033291 on any of these 
45 
dosing schedules live on average 1-2 days longer than mice 
receiving vehicle control. The activity of SW033291 in 
promoting resistance to toxic effects of radiation may extend 
to SW033291 and other similar 15-PGDH inhibitors in 
promoting resistance to other similar toxic insults including 
but not limited to Cytoxan, fludarabine, chemotherapy and 
immunosuppressive therapy. 
TABLE 8 
Friday Wed. Thurs. Friday Saturday Sunday Monday 
Treatment 12-Oct 17-Oct 18-Oct 19-Oct 20-Oct 21-Oct 22-Oct 
Conditions Day 0 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 
Saline (7 2 2 2 2 0 
Gy days, 1 does 
daily) 
11 SW033291 3 3 3 3 2 0 
Gy (1 does/daily) 
for 7 days 
11 SW033291 3 3 3 3 3 2 0 
Gy (1 does/daily, 
continuous 
every day) 
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TABLE 8-continued 
Friday Wed. Thurs. Friday Saturday Sunday Monday 
Treatment 12-Oct 17-Oct 18-Oct 19-Oct 20-Oct 21-Oct 22-Oct 
Conditions Day 0 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 
11 Saline (7 3 3 3 2 0 0 
Gy days, 
2 does/daily 
11 SW033291 3 3 3 3 3 2 0 
Gy (7 days, 2 
dose daily) 
Example 8 
Analysis of Effect ofSW033291 on Liver Regeneration Post 
Partial Hepatectomy 
Table 9 shows the numbers of mitosis per random high 
powered field counted in livers of control versus SW033291 
15 treated mice on post operative days 2 through 5 (2D-5D). 
This Example shows studies assessing the effect of 
SW033291 on liver regeneration in mice following partial 
hepatectomy. 
FIG. 51 shows a drawing of the anatomy of the mouse 
liver and of the partial hepatectomy procedure described in 
Mitchell et al., Nature Protocols, 3, 1167-1170 (2008), in 
which the median and left lateral lobes are resected, and then 
liver regeneration is observed via hypertrophy of the remain-
ing right and caudate lobes. The total resection is of approxi-
mately 70% of the mouse liver mass. In these studies mice 
were euthanized using carbon dioxide inhalation. The mouse 
body was weighed in its entirety. The liver was removed 
from the mouse; the necrotic renmant from the surgical 
resection was trimmed; and the regenerated liver was 30 
weighed. 
20 
25 
FIG. 52(A-D) show an anatomical view of the mouse 
liver. Pictures at left are pre-operative views, and those at 
right are post-resection views. The upper two pictures show 
anterior view of liver and at left display the median lobe and 35 
a part of the Lateral lobe. The lower two pictures show 
Inferior view of liver and at left display the Lateral lobe. In 
the partial hepatectomy procedure, the median and lateral 
lobes are resected as shown at right. 
FIG. 53(A-D) at left reiterates photographs of the imme-
diate post-hepatectomy views of the mouse liver, with 40 
anterior view at top and inferior view at bottom. Figure at 
top right shows the in situ view of the regenerated liver on 
post operative day (POD) 10, showing hypertrophy of the 
renmant right and caudate lobes. Photograph at lower right 
shows the anterior view of the regenerated liver after 45 
removal from the mouse body. Whitish region at the upper 
right liver edge is the necrotic stump from the resection, and 
is trimmed prior to weighing. 
The first study was performed in 10 week old male 
C57BL/6.1 mice, receiving daily SW033291 5 mg/kg IP in so 
a vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W, 
versus vehicle alone, and assessed daily for liver regenera-
tion with 5 control and 5 SW033291 recipient mice sacri-
ficed on each time point. In this study, ketamine anesthesia 
was employed. 55 
FIG. 54(A-B) show micrograph of the hematoxylin and 
eosin stained liver on post-operative day 3 (POD 3) in the 
SW033291 treated mouse versus the control mouse, with 
mitotic figures marked by yellow arrows in the SW033291 
treated mouse liver at left and by green arrows in the control 
mouse liver at right. 60 
FIG. 55 shows a graph of the number of mitosis per high 
powered field in livers of SW033291 treated versus control 
mice on post-operative days two through five (2D-5D). 
Mitotic figures were counted in 10 high powered fields ( 40x) 
from each of 5 livers per SW033291 or control mice per day. 65 
SW033291 treated mice demonstrated significantly 
increased hepatic mitosis versus controls on days 3 and 4. 
SW033291 treated mice show significantly increased num-
bers of mitotic liver cells on post-operative days 3 and 4. 
TABLE 9 
Mitotic index 
(40x) mean+ SD Control SW033291 p-value 
2D 0.7000 ± 0.1933 1.240 ± 0.2330 0.0915 
3D 2.000 ± 0.4364 6.160 ± 0.3250 <0.0001 
4D 2.560 ± 0.2242 4.560 ± 0.7190 0.0107 
SD 0.2000 ± 0.1069 0.2400 ± 0.08718 ns 
FIG. 56 shows the liver to body weight ratios attained 
following partial hepatectomy in control versus SW033291 
treated C57Bl/6j mice injected at 5 mg/kg SW033291 IP 
daily ( qd) starting on post operative day O and continuing 
throughout. Graph displays values from post-operative days 
2-7 (POD 2-7). The SW033291 qd injection group of mice 
attain a higher liver to body weight ratio from post-operative 
days 4-7, with the increase being statistically significant on 
postoperative day 4 and day 7. 
An additional group of mice received SW033291 5 mg/kg 
twice daily (bid) and were analyzed on post-operative day 3, 
with the data graphed as POD3b. This group of mice also 
showed a statistically significant increase in liver to body 
weight ratio compared to control mice. 
Another study was performed testing the effects of 
SW033291 given 5 mg/kg IP twice daily (bid) on liver 
regeneration in C57BL/6.1 mice. 10 mice were used in the 
control and 10 mice in the drug treated arm for analysis of 
each time point of the study. The study again employed 10 
week old male mice receiving daily SW033291 5 mg/kg IP 
in a vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W, 
versus vehicle alone, with 10 drug treated and 10 control 
mice sacrificed daily for comparison. In this study ketamine 
anesthesia was employed. 
FIG. 57 shows graph of the liver to body weight ratio 
attained following partial hepatectomy in control versus 
SW033291 treated C57BL/6.1 mice injected at 5 mg/kg 
SW033291 IP twice daily (bid) starting at 1 hour post-
surgery and continued throughout. Graph displays values 
from post-operative days 2-7 (POD 2-7). The SW033291 bid 
injected group of mice show a statistically significant higher 
liver to body weight ratio versus control mice on post-
operative days 3, 4, and 7. 
FIG. 58 reprises the graph of the liver to body weight ratio 
attained following partial hepatectomy in control mice ver-
sus in mice treated with sw033291 5 mg/kg IP twice daily. 
In data enclosed within the blue box, drug was started 1 hour 
following surgery, and significant increases in liver to body 
weight ratio are seen in drug treated mice from post-
operative day (POD) 3 onward. In data enclosed within the 
red box, the first dose of sw033291 is delivered commencing 
US 10,301,320 B2 
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hour before surgery, and significant increase in liver to 
body weight ratio is seen as early as post-operative day 1, the 
day following the surgery. 
FIGS. 59(A-B) show graphs of the serum ALT levels 
following partial hepatectomy in one control mouse versus 5 
one mouse treated with sw033291 at 5 mg/kg IP twice daily 
(bid). Post-operative day 1 values are compared at left, and 
post-operative day 2-7 values are compared at right. ALT 
values are lower in the drug treated mouse. 
FIG. 60 shows graph of serum bilirubin levels following 10 
partial hepatectomy in one control mouse versus one mouse 
treated with SW033291 at 5 mg/kg IP twice daily (bid) from 
post-operative days (POD) 1-7. 
In another study, SW033291 was tested in the partial 
hepatectomy model using the FVB strain of mice adminis- 15 
tered SW033291 5 mg/kg IP twice daily (bid), administered 
in a vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W, 
using 5 treated mice versus 5 control mice treated with 
vehicle alone for analysis at each time point from post 
operative day (POD) 1-7. In this study ketamine anesthesia 
20 
was employed. 
FIG. 61 shows a graph of the liver to body weight ratio of 
attained following partial hepatectomy in FVB mice treated 
with 5 mg/kg IP SW033291 versus control mice treated with 
vehicle alone. SW033291 treated mice show increased liver 
to body weight ratio from post-operative days 2-7, with the 25 
increase being statistically significant on POD, 2, 3, 4 and 7. 
In another study, SW033291 was tested in a partial 
hepatectomy model using the FVB strain of mice adminis-
tered SW033291 5 mg/kg IP twice daily (bid), starting 1 
hour before surgery. 10 week old male mice were employed, 30 
with 10 treated mice and 10 control mice used for analysis 
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Lower box margin denotes upper boundary of the lowest 
quartile. SW033291 treated mice show a significantly 
increased liver to body weight ratio at P=0.004. 
FIG. 67 shows "box and whisker" plot comparing liver to 
body weight ratio's on post-operative day 7 following partial 
hepatectomy of FVB mice treated twice daily with 
SWO33291 5 mg/kg or with vehicle control, with 10 mice 
in each arm. Thick bars denote population median. Upper 
box margin denotes lower boundary of the highest quartile. 
Lower box margin denotes upper boundary of the lowest 
quartile. SW033291 treated mice show a significantly 
increased liver to body weight ratio at P=0.001. 
FIG. 68 shows "box and whisker" plot comparing liver to 
body weight ratio's on post-operative day 4 following partial 
hepatectomy of FVB mice treated twice daily with 
SWO33291 5 mg/kg or with vehicle control, with 10 mice 
in each arm. Also shown is the liver to body weight ratio on 
post-operative day 4 of 15-PGDH knockout mice (PGDH-
KO) treated with vehicle only. Thick bars denote population 
median. Upper box margin denotes lower boundary of the 
highest quartile. Lower box margin denotes upper boundary 
of the lowest quartile. SW033291 treated mice show a 
significantly increased liver to body weight ratio at P=0.001. 
15-PGDH knockout mice also show greater a greater liver to 
body weight ratio than do vehicle treated 15-PGDH wild-
type mice, supporting that the liver regeneration activity of 
SW033291 is mediated through inhibition of 15-PGDH. The 
larger effect of 15-PGDH gene knockout suggests further 
increase in effect of SW033291 may be attainable with 
additional modification of dosing schedule and delivery. 
FIG. 69 shows visualization of S-phase cells following 
partial hepatectomy on post-operative day 2 in livers of 
SW033291 treated and vehicle treated control mice. Mice 
were injected with BrdU at 50 mg/kg IP 2 hours before 
sacrifice, and then S-phase cells were visualized by staining 
at each time point from post operative day (POD) 1-7. In this 
study isoflurane anesthesia was employed. Vehicle treated 
15-PGDH knockout (KO) mice were also used as an addi-
tional comparator. 
FIG. 62 shows a graph depicting the pre-operative body 
weights of the FVB mice used for analysis of liver regen-
eration on post-operative days 2, 3, 4 and 7. SW033291 and 
control treated mice used on each day are well matched. 
35 the livers with an antibody that detects BrdU that has been 
incorporated into DNA. Representative fields at !Ox mag-
nification show the clear increase in numbers of BrdU 
positive cells in the SW033291 treated liver. 
FIG. 63 shows a graph depicting the weight of the 
resected liver segment (resected LWt) from mice treated 40 
with either SW033291 or vehicle control and assayed for 
liver regeneration on post-operative days (POD) 2, 3, 4, and 
7. Weight of the resected livers is well matched between 
control and drug treated mice on each day, except on day 7, 
when the weight of the resected liver was greater in the 45 
SW033291 treated than in the control mice. 
FIG. 64 shows a graph depicting the liver weights attained 
(Regenerated_LWt) post partial hepatectomy in SW033291 
and control mice on post-operative days 2, 3, 4 and 7 (POD 
2, 3, 4, 7). SW033291 treated mice show significantly 50 
greater liver weights versus control mice at all time points, 
with SW033291 treated mice having approximately 25% 
greater liver weight on post-operative day 7 than control 
mice. 
FIG. 65 shows a graph depicting the liver to body weight 55 
ratios attained (LBWR) post partial hepatectomy in 
SW033291 and control mice on post-operative days 2, 3, 4 
and 7 (POD 2, 3, 4, 7). SW033291 treated mice show 
significantly greater liver to body weight ratios versus 
control mice at all time points, with SW033291 treated mice 
having approximately 20% greater liver to body weight ratio 60 
on post-operative day 7 than control mice. 
FIG. 66 shows "box and whisker" plot comparing liver to 
body weight ratio's on post-operative day 4 following partial 
hepatectomy of FVB mice treated twice daily with 
SWO33291 5 mg/kg or with vehicle control, with 10 mice 65 
in each arm. Thick bars denote population median. Upper 
box margin denotes lower boundary of the highest quartile. 
FIG. 70 shows high powered ( 40x) views of representa-
tive fields from the study of FIG. 69. 
FIG. 71 shows "box and whiskers" plot comparing per-
cent of BrdU positive cells in livers of SW033291 treated 
versus vehicle control treated mice on post-operative day 2 
following partial hepatectomy. Plotted in each group are the 
percent BrdU positive cells from 100 random high powered 
fields (40x magnification) counted as 10 fields from each of 
10 drug treated and each of 10 control vehicle treated mice. 
Heavy black bars show median values of each distribution. 
Upper box margin denotes lower boundary of the highest 
quartile. Lower box margin denotes upper boundary of the 
lowest quartile. SW033291 show a greater than 2-fold 
increase in median S-phase cells on post-operative day 2 
(P<0.05). 
Example 9 
Analysis of Effect of SW033291 on Survival Following 
Acetaminophen (Tylenol) Overdose 
This Example provides data showing effects of 
SW033291 in mediating resistance to lethal doses of the 
liver toxin acetaminophen (Tylenol). 
In the study, 11 week old female C57BL/6J mice are 
injected IP with a suspension of acetaminophen in phosphate 
buffered saline administered at the LD50 dose of 600 mg/kg. 
Table 10 provides a tabular summary of the number of 
mice surviving out of an initial cohort of 6 mice that are all 
treated with acetaminophen (Tylenol) in phosphate buffered 
saline administered IP at the LD50 dose of 600 mg/kg. 
us 10,301,320 B2 
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TABLE 10 
Treatment 0 hrs 16 hr 24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 96 hr 112 hr 120 hr 
1 does/daily, First dose immediately after Tylenol injection 
Saline 6 6 5 4 3 3 3 3 3 3 3 
5 mg/kg 6 6 6 4 4 4 4 4 4 4 4 
SW033291 
2 dose/daily, First dose immediately after Tylenol injection 
Saline 6 6 6 4 3 3 3 3 3 3 3 
5 mg/kg 6 6 6 4 3 3 3 3 3 3 3 
SW033291 
15 difference is noted between survival of SW033291 treated Test mice are additionally treated with SW033291 5 
mg/kg IP in a vehicle of 10% Ethanol, 5% Cremophor EL, 
85% D5W beginning immediately following acetaminophen 
and continued once daily, or twice daily. Control mice are 
additionally treated with vehicle alone once daily or twice 
daily. Survival is recorded from the 0 time point of admin- 20 
istration of acetaminophen through 120 hours following. No 
and control mice. 
Table 11 shows a summary of the number of mice 
surviving out of an initial cohort of 12 eleven week old 
C57BL/6J female mice that are all treated with acetamino-
phen (Tylenol) in phosphate buffered saline administered IP 
at the LD50 dose of 600 mg/kg, Mice are additionally 
treated with either SW033291 or vehicle control. 
Survival 0 hrs 16 hr 
5 mg/kg 12 12 
SW033291 
Saline 12 12 
Survival 0 hrs 16 hr 
5 mg/kg 6 6 
SW033291 
Saline 6 6 
TABLE 11 
24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 96 hr 112 hr 120 hr 
12 11 10 10 10 10 10 10 10 
12 6 5 5 5 5 5 5 5 
30 
SW033291 5 mg/kg was administered IP in a vehicle of 
10% Ethanol, 5% Cremophor EL, 85% D5W twice daily 
(bid) beginning 48 hours prior to acetaminophen injection 
and continuing for 48 hours following acetaminophen injec-
35 tion for 9 doses total. At 120 hours post acetaminophen injection, 10 of 12 mice have survived in the SW033291 
treated cohort versus 5 of 12 mice in the vehicle control 
treated cohort, P=0.045 in a one-tailed Fisher's exact test. 
Thus pre-administration of SW033291 protects from the 
40 
lethal hepatotoxicity of acetaminophen. 
Table 12 shows a summary of the number of mice 
surviving out of an initial cohort of 6 eleven week old 
C57BL/6J female mice that are treated with acetaminophen 
(Tylenol) in phosphate buffered saline administered IP at the 
LD50 dose of 600 mg/kg. 
TABLE 12 
24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 96 hr 112 hr 120 hr 
5 4 3 3 3 3 3 3 3 
5 3 2 2 2 2 2 2 2 
Mice are additionally treated with either SW033291 or 
55 vehicle control. SW033291 5 mg/kg was administered IP in 
a vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W 
twice daily (bid) beginning 3 hours prior to acetaminophen 
injection and continuing at time 0 through 48 hours follow-
ing acetaminophen injection for 6 total doses. At 120 hours 
post acetaminophen injection 3 of 6 mice have survived in 
60 the SW033291 treated cohort versus 2 of 6 mice in the 
vehicle control treated cohort. 
Table 13 shows a summary of the number of mice 
surviving out of an initial cohort of7 C57BL/6J 25 week old 
female 15-PGDH wild-type (WT) or 7 C57BL/6J 25 week 
65 old female 15-PGDH knockout (KO) mice treated with 
acetaminophen (Tylenol) in phosphate buffered saline 
administered IP at the LD50 dose of 600 mg/kg. 
US 10,301,320 B2 
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TABLE 13 
Survival 0 hrs 16 hr 24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 
WT 7 7 7 5 4 3 3 
KO 7 7 7 6 6 6 6 
At 120 hours post acetaminophen injection, 6 of7 knock-
out mice survive versus 3 of 7 wild-type mice. Increased 
survival of 15-PGDH knockout mice is consistent with the 
survival benefit of SW033291 being mediated through inhi-
bition of 15-PGDH. 
3 
6 
10 
118 
96 hr 112 hr 120 hr 
3 3 3 
6 6 6 
treated mice show a lower Disease Activity Index than do 
control on each day of the study, P<0.001. 
FIG. 74 shows the design of the study in which colono-
scopic examination of the left colon, up to the splenic 
flexure, was performed on live mice on days 8, 11 and 15, 
under isoflurane anesthesia. In addition, post-mortem 
Example 10 15 colonoscopy of the full colon was performed on two 
SW033291 treated and two control treated mice on day 15, 
Analysis of Effect ofSW033291 on Dextan Sodium Sulfate 
(DSS) Induced Colitis 
25 
This Example provides data from studies of the effect of 20 
SW033291 on prevention of induction of colitis in the 
dextran sodium sulfate (DSS) treated mouse. In the study, 
8-12 week old FVB male mice are fed with 2% DSS in 
drinking water for days 1-7, and then switched to normal 
drinking water beginning on day 8, and continued through 
day 22. Mice are treated with twice daily SW033291 5 
mg/kg IP in a vehicle of 10% Ethanol, 5% Cremophor EL, 
85% D5W, at 125 ug/200 ul, versus with vehicle alone. 
Clinical scoring (body weight, rectal bleeding, stool consis- 30 
tency) is recorded daily, endoscopic scoring (ulcer number, 
mucosa! thickening, and vascular pattern) is assessed on 
days 8, 11, 15. Mice are sacrificed on days 1, 8, 15 and 22 
for assessment of colon length, colon weight, ulcer number, 35 
ulcer area, and crypt damage. 
Table 14 shows summary of the baseline properties of age 
and weight of the 24 SW033291 treated mice and the 24 
control group mice used in the study. Also provided is 
baseline characteristics of 4 FVB male 15-PGDH knockout 40 
(KO) mice that are used as a comparator group. 
TABLE 14 
FVB PGDH WT/KO male mice 8-12 weeks old 45 
DSS Study WT-Control WT-Treatment KO p-value 
Number 24 24 4 
Sex M M M 
Age (Days) 74.1 ± 3.7 74.2 ± 4.0 73.9 ± 3.4 0.655 50 
Weight (gm) 26.3 ± 1.19 26.8 ± 1.78 27.4 ± 1.4 0.391 
with findings confirming that DSS induced ulcerations are 
largely confined to the descending colon distal to the splenic 
flexure. 
FIGS. 75(A-B) show at bottom left the colon as visualized 
during colonoscopy of a DSS treated control mouse that 
shows loss of the mucosa! vascular pattern and a gross 
ulceration. At bottom right is shown the colonoscopic find-
ings of a DSS treated mouse receiving SW033291, with only 
a small ulcer and with maintenance of the normal mucosa! 
vascular pattern otherwise. Graph at top shows numbers of 
ulcers present on days 8, 11, and 15 in the control versus 
SW033291 treated mice. SW033291 treatment prevents 
two-thirds of ulcer formation. Additional studies of 
15-PGDH knockout mice show that 15-PGDH gene knock-
out prevents 95% of colon ulcer formation. These findings 
support that the colitis prevention activity of SW033291 is 
mediated through its activity as a 15-PGDH inhibitor, and 
suggest further modifications of drug dosing and delivery 
may provide added colitis prevention. 
FIG. 76 shows quantitation of ulcer burden on day 15 of 
DSS treated mice as determined by embedding the full 
length of the formalin fixed colons of mice in paraffin 
blocks, and then microscopic inspection of a random 5 µm 
section along the full colon length for visualization and 
measurement of ulcerated mucosa. The graph shows that the 
average length of ulcerated mucosa is 4.48 mm per colon 
section in control mice (N=9 mice) and is reduced by 61 % 
to a length of 1.74 mm per colon section in SW033291 
(drug) treated mice (N=6 mice), P=0.045. Again, 15-PGDH 
gene knockout (KO) is highly effective in preventing colon 
ulceration, supporting that the therapeutic effect of 
SW033291 is mediated through inhibition of 15-PGDH. 
FIGS. 77(A-B) shows examples of scoring murine FIG. 72 shows a graph of the average changes from 
baseline weight of the cohort of control versus SW033291 
treated mice across the 22 days of the study. SW033291 
treated mice show greater weight at all time points, and in 
particular, show faster weight gain after washout of DSS 
then do the control mice, P=0.001. 
55 colonic mucosa according to the Murine Endoscopic Index 
of Colitis Severity (MEICS) (Becker C. et al. Gut 2005; 54: 
950-954). At top (A) is shown the colonoscopic findings and 
MEICS scoring for a DSS treated mouse receiving 
SW033291. At bottom (B) is shown the colonoscopic find-
FIG. 73 shows a graph of the daily Disease Activity Index 
(DAI) of the cohort of control versus SW033291 treated 
mice across the 22 days of the study. The Disease Activity 
Index is calculated as an equally weighted average of the 
change from baseline weight, the consistency of stool, and 
the presence of rectal bleeding, with each component nor-
malized to span an identical numerical range. SW033291 
60 ings and MEICS scoring of a DSS treated mouse receiving 
vehicle only. 
FIG. 78 shows graphs of the MEICS scores for DSS 
treated mice receiving SW033291 (treatment) versus vehicle 
65 ( control). MEI CS scores show significantly less colitis activ-
ity in SW033291 treated mice on days 8, 11 and 15 of the 
study. 
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In addition to the gross visual inspection and scoring of 
colitis activity by the MEICS index, full length colons of 
mice were formalin fixed and paraffin embedded, and micro-
scopic scoring of crypt damage was performed using the 0-4 
severity scale of Cooper H S. Et al., Lab Invest. 1993; 5 
69:238-249. For this analysis, the colons were divided into 
120 
show no loss of BrdU positive cells in the crypt on day 8, 
consistent with the protective effect of SW033291 being 
mediated by inhibition of 15-PGDH. 
Table 15 shows a summary of colon length (in cm) in DSS 
treated mice sacrificed on days 8, 15 and 22, in SW033291 
treated mice, versus vehicle treated control mice, versus 
15-PGDH knockout (KO) mice, where shortening of the 3 segments of proximal, middle, and distal colon, each 
approximately 1.6 cm in length, with each segment was 
further subdivided into 4 sections each approximately 4 mm 
in length. For each section the crypt damage severity score 
was multiplied by the length in mm of the damaged area, 
creating a 0-16 cryptitis severity index. An average cryptitis 
severity index was calculated for each segment (proximal, 
middle, and distal colon), and the summed whole colon 
cryptitis severity index was determined on a scale of 0-48 for 
each mouse colon. In parallel with the visual MEICS score, 
the microscopic cryptitis severity index on day 8 of the DSS 
protocol was significantly greater in control mice (value of 
9.49) than in the SW033291 treated mice (value of 3.16), 
P<0.05 (data described but not shown in the figure). 
colon is a measure of disease activity. 
10 
15 
Time Point 
Baseline 
Day 8 
Day 15 
20 
Day 22 
TABLE 15 
Colon length shortening may be correlated 
to severity of the colon ulceration 
Control SW033291 KO 
8.3 + 0.2 8.4 + 0.2 
6.6 + 0.4 6.6 + 0.1 
7.1 + 0.1 7.5 + 0.1 8.5 + 0.1 
7.4 + 0.2 8.6 + 0.3 
P-value 
0.71 
1.0 
0.001 
0.012 
FIG. 79 shows assessment of the effect of SW033291 on 
maintaining DNA synthesis in the colonic mucosa of DSS 
treated mice. Mice were injected with BrdU at 100 mg/kg IP 
Vehicle treated control mice show significantly greater 
colon shortening at day 22 versus SW033291 treated mice, 
25 P=0.012. This comparison is also shown graphically in FIG. 
80. 3 hours before sacrifice and then full length colons were 
formalin fixed and embedded in paraffin. S-phase cells, that 
have incorporated BrdU into DNA, were visualized by 
immuno-fluorescent staining of 5 um thick sections with an 
antibody that detects the BrdU. Colonic crypts were visu-
alized by immuno-fluorescent staining with an antibody to 
the epithelial marker E-Cadherin. Photographic insets show 
photomicrographs of high powered fields taken from the 
mid-colon on day 8 of the DSS protocol from control mice, 35 
SW033291 treated mice (treatment) and 15-PGDH knock-
out mice (KO). Red immune-fluorescence identifies BrdU 
positive nuclei, and green immune-fluorescence identifies 
E-Cadherin positive colonocytes. The number of BrdU 
40 
positive cell per crypt is determined by counting the number 
Table 16 shows a summary on day of sacrifice of mouse 
weights (gms) and colon lengths (cm) for DSS treated mice 
30 
receiving SW033291 or vehicle control. 
TABLE 16 
Vehicle SW033291 KO 
Wt@ sacrifice-gm 
Time Point 
Baseline 26.3 + 0.7 25.9 + 0.7 29.2 + 1.3 
Day 8 25.4 + 0.7 26.4 + 0.5 
Day 15 24.4 + 0.5 25.2 + 0.9 
Day 22 * 26.3 + 0.7 28.2 + 0.5 
Colon length-cm 
Time Point 
Baseline 8.3 + 0.2 8.4 + 0.2 8.5 + 0.1 
Day 8 6.6 + 0.4 6.6 + 0.1 
Day 15 7.1 + 0.1 7.5 + 0.1 
Day 22 * 7.4 + 0.2 8.6 + 0.3 
On day 22 SW033291 treated mice show greater body 
weight and greater colon lengths, indicative of therapeutic 
50 effect of SW033291 in protecting against DSS induced 
of dual labeled red and green cells per average crypt. Green 
only cells that are not in S-phase are not counted, and red 
only cells, that are likely stromal cells outside of crypts, are 
also not counted. On the photomicrograph shown crypts are 45 
displayed as vertically oriented in control and SW033291 
treated mice, and crypts are displayed as horizontally ori-
ented in the 15-PGDH knockout mice. In the photographs 
the numbers of S-phase cells are fewest in the control mice 
and are increased in the SW033291 treated mice, and 
increased further in the knockout mice. In the particular 
photographs shown, the crypts from control mice both lack 
S-phase cells and are also visually decreased in height; 
whereas, crypt height is increased in the crypts shown from 55 
SW033291 treated mice, and crypt heights is increased 
further in the crypts shown from 15-PGDH knockout mice. 
The graph depicts the sum of the average number of BrdU 
positive cells per crypt in the distal colon plus the average 
number of BrdU positive cells per crypt middle colons of 
control (Cn), SW033219 treated (Tx), and 15-PGDH knock-
out mice (KO) on day 1, day 8, and day 15 of the DSS 
treatment protocol. On day 8, SW033291 treated mice 
demonstrate 5 .7-fold greater numbers of BrdU positive cells 
than do control mice, which have lost 85% of the day 1 value 
of BrdU positive cells per crypt. 15-PGDH knockout mice 
colitis. 
Example 11: Analysis of Analogues of Lead 
Compound SW054384, a 15-PGDH Activator 
This Example provides data on a group of structural 
60 analogues of SW054384. Data on Table 17 characterize 
analogues obtained by Case Western Reserve University 
from a chemical library shared with the University of 
Cincinnati. Data on Table 18 are analogues ordered from 
65 commercial sources. Data on Table 19 are analogues held in 
chemical libraries or synthesized by members of the inven-
tors group at University of Texas Southwestern. 
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TABLE 17 
V9M V9M LS174T lS 
reporter reporter report 174T V503 V503 
activity activity . . er reporter reporter 
-........._ --------~N:am:_e ~(2~5~~~~) act1v1ty act' . reporter 0 . ,M) 0 5 (M) (OS mfy ,ctMfy ~· . 
¢ 
.µM) (7.5 µM) (2 5 iv1ty 
292301 
12
_
92 
. µM) (7.5 µM) D m, u.m 
d\(J~,O '"' 0.0> ;ec 
Structures 
396087 -8.51 10.08 4.37 10.18 17.23 30.79 
407572 -8.45 -6.12 2.22 6.94 17.22 35.88 
408961 -12.39 0.56 2.46 -4.51 11.71 17.61 
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TABLE 1 . 7-contmued 
V9M V9M~~;::;:--:-::--------
reporter reporter LS! 74T lSl 74T V503 
C ~(s(fy ~Mcy re,ortre re,_, re v,o; 
¢ 
-
-------~N;am~e__.::(2~.5~µ~M;)~(~7 ~5 :µM~)) activity activity porter reporter <>" n . (LS cMl (,.S cM)(~"fy ~(s(fy □ W.;> rn . ,M)(L5"'" 
Q(\(J~,O 05> ON LSO rn 
Structures 
414183 -9.15 -3.89 5.35 -4.77 11.49 37.17 
414195 -13.95 -16.76 -1.15 2.34 13.14 19.47 
474738 -7.27 3.48 -0.36 3.50 17.03 24.59 
474759 2.58 6.40 5.54 -0.03 -5.04 -12.72 
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TABLE 1 . 7-contmued 
Structures 
V9M V9M LS174T lS 
reporter reporter re 174T V503 
activity . . porter report V503 
-
--------;N~am:_e ~~~~ac~t1iv:1ty;) . er reporte (2.5 µM) (7 5 activity activity . . r reporter . µM) (2.5 µM) (7 5 act1v1ty activity 
50 . µM) (2 5 µM 3270 _
4
.4
7 2 
· ) (7.5 µM) 
4 -06 12 29 . 32.82 29.88 42.14 
537833 -7.54 -7.44 4.94 9.04 42.31 73.22 
539430 21.27 21.35 5.62 10.45 38.75 103.04 
543512 36.82 79.64 18.05 8.33 -4.56 -4.26 
543716 4.20 -0.14 3.26 -2.08 -8.04 -8.60 
US 10,301,320 B2 
127 128 
TABLE 1 . 7-contmued 
V9M V9M---;~::------~ 
reporter reporter LS! 74T lSl 74T V503 
, ~,,,cy , , . re,ort• re,M v,m 
"- --------~N;am::e__.::~~icii~vi:ty) acti · er reporter 
0 (2.5 µM) (
7 5 
µM vity activity . . reporter 
¢ 
. (2.5 µM) (7 5 act1v1ty activity 
74279 . µM) (2 5 µM 
D 
0 13.79 23 09 . ) (7.5 µM) 
. 1277 1732 
o ''" am 
Q(\NJij~OH 
Structures 
771064 4332 -19.19 - 2-11 -29.63 -13.75 -24.80 
771069 -22.56 -54.66 -29.88 -82.88 -62. 7l -90.88 
771074 13.50 24.69 20.67 20.60 22.96 39.52 
771081 -14.22 7.58 5.74 1538 31.87 51.68 
129 
Structures 
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TABLE 1 . 7-contmued 
V9M V9M LS174T lS 
reporter reporter re 174T V503 
activity . . porter report V503 
-
-------~N~am:_e~~~£ac~t1v~1ty~) . er reporte 
(2.5 µM) (7 5 activity activity . . r reporter 
771 
. µM) (2.5 µM) (7 5 act1v1ty activity 
. µM) (2.5 µM) (7 5 
8.~ . µ~ 
5.84 8.66 -0.48 -10.19 -3.48 
771132 -2.26 12.24 13.98 13.54 24.75 40.76 
771138 -4.36 6.75 13.64 9.23 34.44 72.58 
771146 -38.07 - 78.30 -31.58 - 68 ·78 -49.73 -86.60 
771432 -7.11 -3.13 3.86 4.24 33.72 42.82 
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TABLE 1 . 7-contmued 
Structures 
V9M V9M LS174T 
reporter lSl 74T y
503 
reporter report V503 
Name activity activity activi er reporter reporter reporter 
-
_______ _::_~(2~.5~µ~M~)~(7~ 5~µ1~) ty act1V1ty act' . · µM) (2.5 µM) (7 5 ivity activity . µM) (2.5 µM) (7 5 
-15 99 · µM) 
. 21.00 160 5.93 48.64 33.85 44.75 
785161 0.54 3.48 10.68 -41.92 56·72 -52.51 
785254 -16.05 -8.48 2.93 4.29 16.14 28.28 
918280 -16.26 -77.26 -21.21 - 72 -09 -35.68 -74.96 
919570 87.71 127.26 78.80 102.68 80.94 104.40 
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TABLE 1 . 7-contmued 
Structures 
V9M V9M LS174T lS 
reporter reporter 174T V503 
. reporter V503 
acllvity activi . . reporter reporter 
-
-------~N:am:.e ~(2~5~~~~ty) act1v1ty act' . reporter 
· µM) (7.5 µM) (
2 5 
ivity activity act' . 
. µM) (7.5 µM) (2 5 iv1ty 
919576 
49
_
89 
. µM) (7.5 µM) 
63.03 17.49 30.74 49.20 73.74 
920847 9.26 17.73 6.18 2.97 -4.47 -10.57 
924740 -0.54 6.33 7.69 16.73 20.16 52.17 
924787 -1.45 18.08 4.32 13.10 21.87 47.97 
928861 64.65 134.49 74.89 124.37 73.17 138.59 
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TABLE 1 . 7-contmued 
Structures 
V9M V9M LS174T 
reporter lSl 74T y
503 
reporter report V503 
Name activity activity activi er reporter reporter reporter 
-
_______ _::_~(2~.5~µ~M~)~(7~ 5~µ1~) ty act1V1ty act' . · µM) (2.5 µM) (7 5 ivity activity . µM) (2.5 µM) (7 5 
-11.15 · µM) 
-9.81 6.50 -1.64 12.58 16.25 93 
'-o:Yo" 
967134 -10.12 -2.64 5.11 
/o)O)✓NJ~ 
5.73 18.43 36.12 
,OD\~ D 
'-o:¢ B, 
l002065 7.38 18.64 9.90 15.22 38.12 52.53 
O(~~:J)O 
II 
0 
91 1002654 -2.58 -3.96 5.51 -1.24 B,"O(\✓NJ n 
0.78 19.23 
D \ ~ 0/ 
0/ 
o......___ l003012 -10.45 -0.90 5.54 19.77 34.43 58.54 
'-----o 
o Ou! 
d\('s/,l_ij~ 
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TABLE 1 . 7-contmued 
l003378 -4.42 -3.27 7.30 1.27 7.23 16.73 
1003429 12.60 4.17 8.82 -6.88 -7.46 -19.23 
l003669 6.30 7.58 5.98 -1.93 1.22 27.08 
l004292 0.88 -0.21 20.34 0.14 23.50 21.16 
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TABLE 1 . 7-contmued 
Structures 
V9M V9M~-=-=----------~ 
reporter LS! 
74
T lSl 74T reporter V503 V50 
activi . reporter reporter 3 
Name ty activity activi . . reporter reporter 
-
________ .:::....~(2~.5~µM~~)~(7~ 5~!) ty act1V1ty act'. 
· µM) (2.5 µM) (
7 5 
ivity activity 
. µM) (2.5 µM) (7.5 µM) 
100 - 6·09 10.99 12.35 29.28 29.09 85.80 
1004631 -3.66 12.03 4.51 45.32 52.12 87.08 
------------- TTABLElS 
V9M~--~V~9=M--~:=----------
Structure 
SC3 SC3 
Reporter Reporter 
activity activity 
(2.5 µM) % 
Ls174T-
SC! 
reporter 
activity, 
% 
(2.5µM) 
Ls174T- V503-
SC! 3H9-7 
reporter reporter 
activity, activity, 
% % 
(7.5 µM) (2.5 µM) 
V503-
3H9-7 Enzyme 
reporter inhi- Enzyme 
activity, bition inhibition 
% % (2.5 % 
(7.5 µM) µM) (7.5 µM) 
:--=:O~'-._~------~C~A~S~# -~('¾~,)~. (7.5 µM) 
333447-
'--o rn-, -o5 " 
O'\- / N w r"'yO'-. 
7.54 14.44 76.87 158.91 27.01 46.46 
()'\ ~~As/ 
o'-.. 332419-
63-3 
'---o 
0 0 00 ~ N '-._ ()'\~~¾_I 
2.5 2 12.44 9.81 1.65 46.28 36.59 47.22 
141 
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TABLE 1 . 8-contmued 
V9M- V9M-
SC3 SC3 
Reporter Reporter 
activity activity 
(2.5 µM) % 
Ls174T-
SC! 
reporter 
activity, 
% 
(%) (7.5 µM) Structure 
----=-=~------- CCAS# 
,o!lo" 311333- 53 117.25 (2.5µM) 29.97 
\_,,N " r""r 
()'\ ~ij~ 
o-........_ 
'-...a O'._,,NJ ~ 
()'\ ij~ 
86-5 
428460-
22-4 
1.5 
10 
339589- -7 o-........_ 
'-...
0 
55-8 
0'. _,,NJ rrc, 
()'\ ~~c, 
15.25 -7.63 
2.5 16.17 
-5.54 
4.25 51.18 
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Ls174T- V503- V503-
SC! 3H9-7 3H9-7 Enzyme 
reporter reporter reporter inhi- Enzyme 
activity, activity, activity, bition inhibition 
% % % % (2.5 % 
(7.5 µM) (2.5 µM) (7.5 µM) µM) (7.5 µM) 
53.41 102.18 131.25 33.99 34.01 
-1.99 1.39 47.04 15.05 19.30 
22.07 64.02 113.49 39.81 56.40 
8.81 63.97 52.49 19.14 21.99 
89.74 199.56 105.28 35.46 37.35 
143 
Structure 
o-........_ 
............ 00 0 D 
~/N ()\~~ 
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333449-
58-4 
333446-
93-8 
333450-
97-8 
311315-
V9M-
SC3 
6.5 
16.5 
V9M-
71.25 
44 
Ls174T-
SC! 
reporter 
activity, 
% 
(2.5µM) 
-5.90 
12.90 
62.59 o-........_ 
-..........0 25-0 
O',,-N~ 0 (}\ ~AAc, 
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Ls174T- V503- V503-
SC! 3H9-7 3H9-7 Enzyme 
reporter reporter reporter 
activity, activity, activity, 
% % % 
(7.5 µM) (2.5 µM) (7.5 µM) 
-3.99 50.08 20.72 9.72 -3.12 
13.53 53.78 44.10 -5.31 5.85 
75.79 18.69 34.70 
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TABLE 18-continued 
V9M- V9M- Ls174T- Ls174T- V503- V503-
SC3 SC3 SC! SC! 3H9-7 3H9-7 
Reporter Reporter reporter reporter reporter reporter 
activity activity activity, activity, activity, activity, 
(2.5 µM) % % % % % 
CAS # (%) (7.5 µM) (2.5µM) (7.5 µM) (2.5 µM) (7.5 µM) 
701217- -2.05 79.49 -6.89 -0.54 20.078 33.42 
00-7 
592469- -9.74 18.46 
85-7 
526206- 23.08 113.85 
05-3 
3.77 13.99 10.16 5.30 
68.46 145.94 110.21 197.50 
428473- -17.95 
22-7 
2.051 -15.50 10.58 19.09 19.81 
Enzyme 
inhi- Enzyme 
bition inhibition 
% (2.5 % 
µM) (7.5 µM) 
10.07 13.12 
6.23 17.24 
41.97 70.19 
3.76 8.67 
US 10,301,320 B2 
147 148 
TABLE 18-continued 
V9M- V9M- Ls174T- Ls174T- V503- V503-
SC3 SC3 SC! SC! 3H9-7 3H9-7 Enzyme 
Reporter Reporter reporter reporter reporter reporter inhi- Enzyme 
activity activity activity, activity, activity, activity, bition inhibition 
(2.5 µM) % % % % % % (2.5 % 
Structure CAS # (%) (7.5 µM) (2.5µM) (7.5 µM) (2.5 µM) (7.5 µM) µM) (7.5 µM) 
............ 0 418783- 0.51 67.18 -12.59 5.81 11.63 6.68 10.85 12.12 65-0 ¢ N 
0~ 
0\,,..-N~N ~ I u\ H 
!? 367929- -27.79 -19 18.80 -17.98 -0.87 -6.22 8.95 34.80 80-4 'so o ~ 
o~,,..-N~ ~ I US N \ H 
/0!? 335392- -12.82 7.18 -0.54 14.32 18.89 21.95 11.00 5.37 I # N 39-7 
0~ 
0\,,..-N~N ~ I u\ H 
331727- 28.21 120 -7.53 9.47 8.13 1.14 9.65 17.53 
07-2 9 N 
0~ 
0\,,..-N~N ~ I u\ H 
:Ye, 328012- -15.38 0.51 127.66 175.99 242.64 -4.89 67.39 82.06 52-8 
N 
"o o ~ 
o~,,..-N~ ~ I US N \ H 
149 
Structure 
'---o 
'---oo o ~N 
~/N u\ ~~¾_I 
Cl 
Clo O ~N 
~/N u\ ~~¾_I 
US 10,301,320 B2 
TABLE 1 . 8-contmued 
CAS # 
310875-
38-8 
833428-
03-8 
528580-
69-0 
V9M- V9M-
SC3 SC3 
Reporter Reporter 
activity activity 
(2.5 µM) % 
(%) (7.5 µM) 
-8.72 -16.41 
-4.10 17.44 
4.71 -0.5 
461439-84-9 - 30·29 -41.75 
Ls174T-
SC! 
reporter 
activity, 
% 
(2.5µM) 
27.66 
25.08 
11.49 
4.83 
Ls174T-
SC! 
reporter 
activity, 
% 
(7.5 µM) 
101.94 
47.36 
-4.81 
-34.97 
680599-
58-0 
-5.29 -22.5 11.489 -13.81 
150 
V503- V503-
3H9-7 3H9-7 Enzyme 
reporter reporter inhi- Enzyme 
activity, activity, bition inhibition 
% % % (2.5 % 
(2.5 µM) (7.5 µM) µM) (7.5 µM) 
64.11 147.62 23.51 33.40 
96.38 149.97 16.39 49.25 
66.03 110.41 -8.22 10.23 
1.57 5.41 9.28 3.35 
16.66 28.86 31.81 50.71 
US 10,301,320 B2 
151 152 
TABLE 18-continued 
V9M- V9M- Ls174T- Ls174T- V503- V503-
SC3 SC3 SC! SC! 3H9-7 3H9-7 Enzyme 
Reporter Reporter reporter reporter reporter reporter inhi- Enzyme 
activity activity activity, activity, activity, activity, bition inhibition 
(2.5 µM) % % % % % % (2.5 % 
Structure CAS # (%) (7.5 µM) (2.5µM) (7.5 µM) (2.5 µM) (7.5 µM) µM) (7.5 µM) !lo' 505072- 94.71 71.5 100.91 109.26 242.42 238.88 67.44 84.57 23-1 N 
'o o ,,() 
o~,.....-N~ ~ I frS N \ H 
!lo' 527699- -31.03 -37.25 7.31 -29.61 38.78 70.92 -20.58 27.93 66-7 
,0 0 D 
0\,.....-N~N I ✓,::,N 
/~ H 
0 
TABLE 19 
V9M- V9M- Lsl 74T- Lsl 74T-
SC3 SC3 SC! SC! 
Reporter Reporter reporter reporter 
activity activity activity, activity, 
(2.5 µM) (7.5 % % 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) 
SW054384 116.34 147.89 129.91 155.75 
:Yo '-o '-0 ° D 
~/N I 
a\~N #N 0 H ~ 
(Yo" 
D
"\YJ ("1 
\ ~~ 
~ 
SW202939 75.34 127.84 75.46 166.46 
(Yo" 
N
"\)J ("1 
\ ii~ 
Cl 
SW202942 52.69 104.86 53.59 122.86 
V503- V503-
3H9-7 3H9-7 
reporter reporter Enzyme 
activity, activity, inhibition 
% (2.5 % % 
µM) (7.5 µM) (2.5 µM) 
148.89 157.49 20.17 
26.60 27.30 53.54 
37.26 86.87 48.39 
Enzyme 
inhibition 
% (7.5 µM) 
58.20 
78.32 
64.86 
Enzyme 
inhibition 
(IC50) 
Decrease 
PGE-2 
(IL-
lbeta-
A549 
%) 
41.96 
Decrease Decrease 
Cell of 
viability coloning 
in A549 formation 
cell(%) % 
.... 
Ul 
~ 
.... 
Ul 
.i;... 
C (/J 
....... 
0 
(.;_) 
0 
....... 
vJ 
N 
0 
to 
N 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % 
!7"" SW202945 28.49 89.98 45.67 134.54 33.99 127.43 8.83 11.07 N ,0 0 D .... 
o~,.,.-N~ I.,,:::::; 
Ul 
Ul 
~N 
0 H 
~N !lo' SW202949 5.76 -5.69 -1.58 -5.87 -12.46 5.32 12.52 34.37 C (/J ....... N 0 
,0 0 D (.;_) 
o~,.,.-N~ I.,,:::::; 
0 
....... 
vJ C( N N \ H 0 to 
N 
Cl 
0 SW202950 12.59 23.87 -2.70 10.69 -6.56 12.95 46.26 56.39 
~§° " .... /'NITND Ul O'I 
/o~o b I N 
# 0/ 
Structure 
I ~o.....___ 
y IT ("~ 
,:::::,-y~~ NA~ I O H 
~ F F'tF 
0 
eel ~~u 
// 'N II I 
~
o u 0 ~ N / 
I ✓,;::; o/ 
!70......__ '---o O DN o~,.,...N I ~ 
CQ ~~ # F 
F 
F 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202953 12.97 
SW202954 2.70 
SW202944 -0.95 
TABLE 19-continued 
V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC! SC! 3H9-7 3H9-7 PGE-2 
Reporter reporter reporter reporter reporter Enzyme (IL-
activity activity, activity, activity, activity, inhibition Enzyme Enzyme 1 beta-
(7.5 % % % (2.5 % % inhibition inhibition A549, 
µM). 01c (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) 
34.79 20.69 30.69 31.98 50.93 8.81 15.06 
4.80 -4.59 -6.99 -8.94 2.39 6.02 9.88 
-3.73 32.47 15.76 130.94 94.57 28.28 57.78 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
Ul 
-....J 
.... 
Ul 
QO 
C (/J 
....... 
0 
(.;_) 
0 
....... 
vJ 
N 
0 
to 
N 
TABLE 19 -continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter 
activity 
reporter 
activity activity, 
reporter reporter 
activity, 
reporter 
activity, 
_Enzyme 
activity, mhibition Enzyme Enzyme 
(IL- Cell 
!beta-
of 
viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, mA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % 
/o'C(ijJf) SW202948 -21.99 -23.05 -6.73 I N ,# 8.36 16.44 
,# H 
7.54 
0/ 
28.27 56.73 
.... 
Ul 
1,0 
:Yo' SW202947 
'
0 0 f) 
21.89 2.57 52.05 21.22 142.96 
o~,......N I ~
97.85 
cc\,~~ ,,,, 
28.80 59.19 
F 
C (/J 
....... 
~o 
vJ 
0 
....... 
vJ 
N 
0 SW202952 -20.74 -19.53 -10.30 10.58 26.18 7.16 29.01 57.03 0 
)lNi ij /o'Qo tr 
,# / 0 
to 
N 
:Yo' SW202940 
'-....a 
146.58 181.17 147.86 
o O ,0 
210.71 180.73 
~ ........ N I 
182.58 24.30 
N\~N"'-N 
63.29 -5 80.46 
0 H 
µM 
45.18 
'-....a 
.... 
O'I 
0 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
Structure UTSW ID (%) 
SW202942 1.00 
!lo'-.... '-....o \ _,,N " (N"l 
D \ ~N',, 0 Cl ii ~ !lo' SW202943 7.12 
'
0 0 f) o~/N I ~cc>~~ ,,, 
!lo' SW202946 
'-....o 
64.59 
o O ,Cl 
~/N N CY\ ~N ~ I 0 H Cl 
~ 
TABLE 19-continued 
V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC! SC! 3H9-7 3H9-7 PGE-2 
Reporter reporter reporter reporter reporter Enzyme (IL-
activity activity, activity, activity, activity, inhibition Enzyme Enzyme 1 beta-
(7.5 % % % (2.5 % % inhibition inhibition A549, 
µM). 01c (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) 
32.05 46.96 86.98 95.39 129.34 -3.72 28.87 
17.84 33.07 55.73 72.27 146.87 -7.42 21.84 
-41.52 105.33 -23.62 136.73 34.27 81.60 89.84 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
O'I 
.... 
.... 
O'I 
N 
C (/J 
....... 
~o 
vJ 
0 
....... 
vJ 
N 
0 
to 
N 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % !lo' SW202951 4.56 17.661 34.26 47.64 97.53 131.49 -15.43 -8.59 -1.01 
'----o o 
.... 
O'I 
0\ / N ~0/"--._ 
~ 
u\ qo, SW122063 1.67 4.80 22.56 19.86 42.51 44.12 -12.23 -10.49 C (/J 
'----o o 
....... 
0 
\/N~OH 
(.;_) 
0 
....... u\ vJ N 0 
to 
N !lo' SW202938 154.92 230.12 216.99 240.95 309.09 300.99 52.66 75.64 2.67 -47.55 µM 
,0 0 D 
o~,,,,,N~ I # (YS N .... \ H O'I 
.i;... 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
Structure UTSW ID (%) 
SW202941 -10.89 !70'-... '---o 0 ~o D~ ~ ......... N I 
CY\ N # 0 H ~ 
!71 SW202965 -30.92 
'---o l 
o OX) 
~/N CY\ ~N ¾_ I 
0 H 
~ !70' SW202966 
'---o 
-0.84 
\,,N_J__ ,Cl CY\ N # 0 H 
~ 
TABLE 19-continued 
V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC! SC! 3H9-7 3H9-7 PGE-2 
Reporter reporter reporter reporter reporter Enzyme (IL-
activity activity, activity, activity, activity, inhibition Enzyme Enzyme 1 beta-
(7.5 % % % (2.5 % % inhibition inhibition A549, 
µM). 01c (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) 
2.57 -23.79 -43.20 75.94 83.54 10.86 35.61 
-25.80 -23.51 3.52 23.76 98.06 11.26 33.13 
67.67 1.82 78.15 115.05 248.97 44.66 61.39 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
O'I 
Ul 
.... 
O'I 
O'I 
C (/J 
....... 
~o 
vJ 
0 
....... 
vJ 
N 
0 
to 
N 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
Structure UTSW ID (%) 
SW202967 -15.98 
!lo-........._ '-----o O'._,NJ li'i 
CY\. N/ 0 ~ 
'I 
ii 
~N 
!lo' SW202968 
'
0
0 o X) 
-21.10 
~/N CY\ ~N ¾,_ I 
0 H 
~ !lo' SW202969 
'-----o 
-20.96 
\_,NJ,Q CY\ N # 0 H 
~ 
TABLE 19-continued 
V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC! SC! 3H9-7 3H9-7 PGE-2 
Reporter reporter reporter reporter reporter Enzyme (IL-
activity activity, activity, activity, activity, inhibition Enzyme Enzyme 1 beta-
(7.5 % % % (2.5 % % inhibition inhibition A549, 
µM). 01c (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) 
0 -11.69 9.37 34.05 69.62 -11.56 0.94 
-7.36 -17.50 6.08 35.18 53.87 -7.09 0.78 
-14.30 -15.87 17.90 62.42 126.16 0.91 9.43 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
O'I 
-....J 
.... 
O'I 
QO 
C (/J 
....... 
~o 
vJ 
0 
....... 
vJ 
N 
0 
to 
N 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
Structure UTSW ID (%) 
SW202970 32.74 
:Yo...._____ '----o o O ,VCl 
~/N I 
CY\ ~N ,9N 0 H ~ 
:Yo" SW202971 -14.51 
'----o 
0 0 ~/N~~ CY\ 0 0 
~ 
:Yo" SW202972 "oo oc,~ -15.42 
~/N CY\ ~N ¾_ I 
0 H 
~ 
TABLE 19-continued 
V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC! SC! 3H9-7 3H9-7 PGE-2 
Reporter reporter reporter reporter reporter Enzyme (IL-
activity activity, activity, activity, activity, inhibition Enzyme Enzyme 1 beta-
(7.5 % % % (2.5 % % inhibition inhibition A549, 
µM). 01c (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) 
17.81 47.94 55.89 179.12 121.93 17.46 48.04 
9.67 -7.91 34.55 85.50 169.04 -0.72 -13.18 
0.14 -17.45 16.64 39.42 100.21 -6.29 -2.94 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
O'I 
1,0 
.... 
-....J 
0 
C (/J 
....... 
~o 
vJ 
0 
....... 
vJ 
N 
0 
to 
N 
V9M- V9M-
SC3 SC3 
Reporter Reporter 
activity activity 
(2.5 µM) (7.5 
Structure UTSW ID (%) µM),% 
!lo'-... '-..._O O O ClX)N 
~/N 
a\~N ""--- I 0 H ~ 
SW202973 -15.63 5.61 
!lo'-... '----o \_,,N " (N') 
CY\ ~N~ 0 H ~ 
SW202974 -9.04 35.90 
!lo'-... '-..._O O O Cl)O 
~/N I 
a\ ~N #N 0 H ~ 
SW202977 -8.69 26.22 
TABLE 19-continued 
Lsl 74T- Lsl 74T- V503-
SC! SC! 3H9-7 
reporter reporter reporter 
activity, activity, activity, 
% % % (2.5 
(2.5 µM) (7.5 µM) µM) 
-16.38 19.29 41.53 
-8.77 34.79 59.88 
-16.61 15.09 16.92 
V503-
3H9-7 
reporter 
activity, 
% 
(7.5 µM) 
106.91 
179.28 
85.24 
Enzyme 
inhibition 
% 
(2.5 µM) 
3.3 
-4.42 
-14.95 
Enzyme 
inhibition 
% (7.5 µM) 
13.55 
24.85 
-8.63 
Enzyme 
inhibition 
(IC50) 
Decrease 
PGE-2 
(IL-
lbeta-
A549 
%) 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
-....J 
.... 
.... 
-....J 
N 
C (/J 
....... 
0 
(.;_) 
0 
....... 
vJ 
N 
0 
to 
N 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % 
:Yo' SW202978 -13.81 -0.07 -10.05 20.43 46.77 116.46 4.14 3.12 
,0 0 D .... -....J ~ 
~/N~ (Y' 0 \
:Yo' SW202979 -14.44 10.79 -8.92 17.83 41.64 133.05 3.92 6.24 C (/J 
'---o o 
....... 
0 
o\/N~ok (.;_) 0 ....... CY\ vJ N 0 
to 
N 
:Yo' SW202980 -27.55 -13.39 -7.34 5.17 11.41 50.62 -4.19 1.44 
'---o o 
O~/N~/ (Y' 0 .... \ -....J .i;... 
Structure 
!lo'---'---o \,,NJ 0 CY" ,A~ H ~Cl 
:Yo' 
'---o 
0 0 
~/N~ CY"' 0~ 0 
~ !lo' 
'
0
0 
° c,:x) 
~/N I CY"' ~N ¾-0 H 
~ 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202985 -27.34 
SW202986 -22.86 
SW202987 -22.01 
TABLE 19-continued 
V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC! SC! 3H9-7 3H9-7 PGE-2 
Reporter reporter reporter reporter reporter Enzyme (IL-
activity activity, activity, activity, activity, inhibition Enzyme Enzyme 1 beta-
(7.5 % % % (2.5 % % inhibition inhibition A549, 
µM). 01c (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) 
-21.87 -4.89 26.32 79.56 149.89 13.79 30.87 
-9.60 0.21 33.80 60.17 175.41 -2.22 2.58 
-21.03 -8.30 20.65 70.129 145.13 4.61 6.13 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
-....J 
Ul 
.... 
-....J 
O'I 
C (/J 
....... 
~o 
vJ 
0 
....... 
vJ 
N 
0 
to 
N 
Structure 
(Yo" 
~'\YJ r-r ~N u\ ~~· 
!70' 
'
0
0 ° ,0 ~ /N r 0\ -JlN ¾-0 H 
"a 
'!70' 0 #Ou 
~/N I u\ -JlN ¾-0 H Cl 
~ 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202988 7.36 
SW202989 187.65 
SW202990 3.57 
V9M-
SC3 
Reporter 
activity 
(7.5 
µM),% 
54.41 
183.80 
23.49 
TABLE 19-continued 
Lsl 74T- Lsl 74T-
SC1 SC! 
reporter 
activity, 
% 
(2.5 µM) 
40.50 
158.81 
32.01 
reporter 
activity, 
% 
(7.5 µM) 
125.44 
171.45 
106.56 
V503-
3H9-7 
reporter 
activity, 
% (2.5 
µM) 
125.39 
207.62 
172.00 
V503-
3H9-7 
reporter Enzyme 
activity, inhibition Enzyme Enzyme 
% % inhibition inhibition 
(7.5 µM) (2.5 µM) % (7.5 µM) (IC50) 
258.27 10.27 33.70 -10 
µM 
213.94 81.32 89.86 427 
nM 
214.22 22.88 47.16 
Decrease 
PGE-2 Decrease 
(IL- Cell 
!beta- viability 
A549, inA549 
%) cell(%) 
-16.79 
69.40 30.59 
Decrease 
of 
coloning 
formation 
% 
.... 
-....J 
-....J 
.... 
-....J 
QO 
C (/J 
....... 
~o 
vJ 
0 
....... 
vJ 
N 
0 
to 
N 
Structure 
!1 0.........._ ........... 0 0 0 X) 
~/N 
CY
\ ~N ¾-_ I 
0 H 
~ 
!1 0.........._ ~ '-o \_,,NJ~Mo✓ CY\ 
!1 0.........._ ........... 0 O',_,,N, J_ 0 CY\ T ~N• 
V9M-
SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202975 -26.64 
SW202976 -18.51 
SW202991 -25.03 
TABLE 19-continued 
V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC! SC! 3H9-7 3H9-7 PGE-2 
Reporter reporter reporter reporter reporter Enzyme (IL-
activity activity, activity, activity, activity, inhibition Enzyme Enzyme 1 beta-
(7.5 % % % (2.5 % % inhibition inhibition A549, 
µM). 01c (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) 
-8.97 -7.32 17.21 47.35 116.21 -14.82 4.53 
9.60 -9.97 30.14 36.75 138.31 7.87 29.78 
-7.50 -15.58 2.09 -6.08 8.90 -14.71 -6 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
-....J 
1,0 
.... 
QO 
0 
C (/J 
....... 
0 
(.;_) 
0 
....... 
vJ 
N 
0 
to 
N 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % !70' SW203680 13.98 25.21 11.73 45.97 10.43 32.98 34.82 62.10 
"a O D .... QO 
o~,.....-N~ I -vN .... (YS N N ~ H 
0 
~ !70' SW203681 17.99 121.71 120.56 151.88 90.42 72.37 36.77 64.87 C (/J 
'o o ,,() 
....... 
0 
~/N~ IQ (.;_) 0 
....... (YS N N ~ H vJ N 0 0 
~ to 
N !70' SW131633 77.21 140.98 8.42 149.84 103.52 -40.56 23.13 35.21 
"a o \,-N~o .... u\ QO N 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % !lo' SW203682 15.31 22.45 187.26 13.76 -32.19 79.19 15.73 36.23 
"----o o .... QO 
O~/N~ / 
~ (YS N \ H 
!lo' SW203683 137.32 190.83 3.76 209.77 103.81 -41.03 23.41 57.09 -7 -3.41 µM C (/J 'o o f) ....... 0 (.;_) 
~/N~ _✓,::;N 0 (YS N ....... \ H vJ N 
0 
to 
N 
:Yo' SW131635 11.39 15.05 110.93 14.07 -37.66 14.39 11.80 35.44 
"----o o 
\/N~NH 
.... er\ , QO .i;... 
Structure 
!lo-......__ -......__o 
O~/NJ 0 v\ ~/,,,·" 
!lo-......__ ......___0 o O ,C 
~/N I I 
CY\ ~N #N 0 H ~ 
!lo-......__ -......__o 
O~/N " 0 ("'Y \ ~NN' 
VO I 
UTSW ID 
SW203684 
SW203685 
SW203686 
V9M- V9M-
SC3 SC3 
Reporter Reporter 
activity activity 
(2.5 µM) (7.5 
(%) µM),% 
50.72 74.89 
99.95 204.48 
15.05 30.30 
TABLE 19-continued 
Lsl 74T- Lsl 74T- V503-
SC! SC! 3H9-7 
reporter reporter reporter 
activity, activity, activity, 
% % % (2.5 
(2.5 µM) (7.5 µM) µM) 
170.37 119.07 81.19 
22.34 253.97 121.53 
116.07 28.49 -11.03 
V503-
3H9-7 
reporter 
activity, 
% 
(7.5 µM) 
52.46 
-33.18 
65.60 
Enzyme 
inhibition 
% 
(2.5 µM) 
36.35 
44.34 
14.86 
Enzyme 
inhibition 
% (7.5 µM) 
64.72 
73.30 
34.24 
Enzyme 
inhibition 
(IC50) 
5 µM 
Decrease 
PGE-2 
(IL-
lbeta-
A549 
%) 
17.84 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
QO 
Ul 
.... 
QO 
O'I 
C (/J 
....... 
0 
(.;_) 
0 
....... 
vJ 
N 
0 
to 
N 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % !lo' SW202942 85.24 132.15 30.25 143.05 69.32 3.29 36.78 53.24 N 
,0 0 D .... 
o~,....,.N~ I# 
QO 
-....J Ds N \ H 
Cl !lo' SW203687 28.25 47.51 1.75 56.00 45.74 -41.65 15.07 33.55 C (/J 
,0 0 D ....... 0 
o~,....,.N~ I# (.;_) 0 ....... (YS N vJ \ H N 
0 
to 
N 
«' 
SW203688 12.10 6.04 12.59 14.75 -28.10 -99.52 13.13 39.96 
,0 0 D 
o\,....,.N~N I _✓,;;N 
.... CY'° H QO QO 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % 
:Yo' SW203691 7.78 19.82 5.47 22.03 47.07 90.04 2.62 3.12 36.76 0.00 
.......... 0 0 N~ 
.... 
QO 
1,0 
\/N~N)LS er\ H 
!lo' SW203703 108.15 105.91 85.80 80.20 142.81 77.97 26.50 58.88 31.90 -1.97 C (/J 
......__o O ):)s ....... 0 (.;_) 
~/N~ :::::,._ 0 (YS N ....... \ H vJ N 
0 
to 
N !lo' SW203704 8.71 8.04 8.64 12.47 52.84 37.84 4.19 7.26 22.33 -2.70 
.......... 0 0 J:)-
~/N~ :::::,._ (YS N .... \ H 1,0 
0 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % qo, SW125991 77.40 74.63 67.28 83.33 160.61 148.71 11.61 31.62 31.33 -2.13 
........... 0 0 .... 1,0 
\,,N~ l .... ()'\ L 0 
!lo' SW203736 132.36 145.08 126.75 155.67 244.43 203.63 1.70 24.86 31.86 -3.06 2.5 µM (3.12%), C 7.5 µM (/J N (5.18%) ....... 
,0 0 D 0 
o~,,....N~ I# (.;_) 0 
D'S N ....... \ H vJ N 
0 
F to N !lo' SW203737 93.37 103.47 76.65 85.09 175.94 153.58 23.81 42.45 47.78 -2.56 2.5 µM (10.25%), 7.5 µM N (82.15%) 
,0 0 D 
o~,,....N~ I# D' N .... \ H 1,0 N 
Br 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % 
:Yo" SW208001 19.59 23.31 -0.61 1.87 -4.07 6.68 21.79 27.74 
-.......__o o .... 1,0 \,,N~o ~ u\ 
:Yo" SW208002 -12.39 -21.84 -14.51 -14.57 -15.65 -16.54 34.73 59.23 C (/J 
-.......__o o 
....... 
0 
\/N~)) (.;_) 0 ....... u\ vJ N 0 0 to 
N 
-QI SW208003 13.32 -11.46 37.00 45.62 117.02 75.883 15.19 20.91 
"o j~ oy % .... 
1,0 
.i;... (X> # 
Structure 
!lo'-... '-.._O F 0
'\, / N " ~f 
CY\ ~NA/ 0 H ~ 
'-...a !lo'-... o O ,Cl ~ __,...N N 
CY\ ~N ""- I 0 H F ~ 
I 
~o ~ 
'-o~ \)_,J oy1_,,\ 
co 
V9M- V9M-
SC3 SC3 
Reporter Reporter 
activity activity 
(2.5 µM) (7.5 
UTSW ID (%) µM),% 
SW208004 43.68 76.14 
SW208005 42.44 19.75 
SW208006 34.85 0.15 
TABLE 19-continued 
Lsl 74T- Lsl 74T- V503-
SC! SC! 3H9-7 
reporter reporter reporter 
activity, activity, activity, 
% % % (2.5 
(2.5 µM) (7.5 µM) µM) 
62.19 118.21 146.61 
63.86 53.93 102.72 
38.20 42.18 89.69 
V503-
3H9-7 
reporter 
activity, 
% 
(7.5 µM) 
176.82 
61.24 
43.90 
Enzyme 
inhibition 
% 
(2.5 µM) 
52.33 
44.10 
15.71 
Enzyme 
inhibition 
% (7.5 µM) 
57.00 
52.02 
24.78 
Enzyme 
inhibition 
(IC50) 
Decrease 
PGE-2 
(IL-
lbeta-
A549 
%) 
Decrease 
Cell 
viability 
inA549 
cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
1,0 
Ul 
.... 
1,0 
O'I 
C (/J 
....... 
0 
(.;_) 
0 
....... 
vJ 
N 
0 
to 
N 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503- V503- Decrease 
SC3 SC3 SC! SC! 3H9-7 3H9-7 PGE-2 Decrease Decrease 
Reporter Reporter reporter reporter reporter reporter Enzyme (IL- Cell of 
activity activity activity, activity, activity, activity, inhibition Enzyme Enzyme !beta- viability coloning 
(2.5 µM) (7.5 % % % (2.5 % % inhibition inhibition A549, inA549 formation 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) (7.5 µM) (2.5 µM) % (7.5 µM) (IC50) %) cell(%) % 
F F SW208007 -25.48 -26.41 -9.01 -5.15 -3.17 -2.10 48.27 38.41 
F F 
F F 
.... ~ I N 1,0 -....J OD \,✓N~N I# er\ H 
C !70' SW208000 33.54 36.63 41.98 70.53 121.50 138.25 5.82 12.47 (/J ....... 0 
'---o o 
(.;_) 
0 \/N~o ....... vJ N u\ 0 to N 
F SW208008 -5.96 -0.92 -2.16 10.01 31.93 39.63 58.70 70.90 
F 
F 
c, 1( 0 ,D .... 1,0 
F' IO I QO 
F\,,,-N~N ~ N 0\ H 
'---o 
TABLE 19-continued 
V9M- V9M- Lsl 74T- Lsl 74T- V503-
SC3 SC3 SC! SC! 3H9-7 
Reporter Reporter reporter reporter reporter 
activity activity activity, activity, activity, 
(2.5 µM) (7.5 % % % (2.5 
Structure UTSW ID (%) µM),% (2.5 µM) (7.5 µM) µM) !lo' SW207997 59.48 71.03 87.60 94.08 148.77 
.....,__o o 
o',_,,N~ I 
,0\ L 0 
.....,__o 
!lo' SW207998 53.36 58.94 65.15 76.99 143.67 
.....,__o o \_,,N~o 
,0\ 
.....,__o 
!lo.....,__ .....,__o o ~o 
N\\N 0 
.....,__OA,) 
SW207999 128.11 124.32 98.00 122.98 123.99 
V503-
3H9-7 
reporter Enzyme 
activity, inhibition Enzyme Enzyme 
% % inhibition inhibition 
(7.5 µM) (2.5 µM) % (7.5 µM) (IC50) 
156.90 -7.08 -0.86 
147.18 8.09 14.38 
110.28 -0.86 3.34 
Decrease 
PGE-2 Decrease 
(IL- Cell 
!beta- viability 
A549, inA549 
%) cell(%) 
Decrease 
of 
coloning 
formation 
% 
.... 
1,0 
1,0 
N 
0 
0 
C (/J 
....... 
0 
(.;_) 
0 
....... 
vJ 
N 
0 
to 
N 
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Data provided include level of induction of a 15-PGDH-
luciferase fusion gene reporter, recorded as % induction of 
luciferase activity over basal level, in three colon cancer cell 
lines, V9m, V503, and LSI 74T, engineered to contain the 
5 
reporter, and treated with either 2.5 uM or 7.5 uM com-
pound. Also recorded for some compounds is the inhibition 
of enzyme activity of recombinant 15-PGDH protein treated 
with 2.5 µMor 7.5 µM compound. Also recorded for some 
compounds is the IC50 of each compound for inhibiting lO 
enzymatic activity of recombinant 15-PGDH in an in vitro 
assay. Additionally, for selected compounds is recorded the 
decrease in PGE2 levels in the media of compound treated 
A549 cells that have been stimulated with IL-1 beta. Addi- 15 
tionally recorded for selected compounds is the effect on 
A549 cell viability as measured by a CellTiter-Glo assay, 
and the effect of compounds onA549 cell colony formation. 
We first note that the amino group participating in the 
peptide bond in SW054384 can be modified as shown in 
compound MCD-03-025, and that the derived compound 
retains the ability to activate expression of the 15-PGDH-
luciferase reporter in reporter cell lines, and indeed shows 
lesser inhibition of recombinant 15-PGDH at 2 µM in the 25 
test tube than does parent compound SW054384. 
We also note that addition to the phenyl ring of 
SW054384 of fluorine (SW203736) or bromine 
(SW203737), is well tolerated, and yields a compound that 30 
is active in inducing 15-PGDH-luciferase reporter activity in 
cell lines, is similar or improved compared to parental 
SW054383 in minimally inhibiting recombinant 15-PGDH 
at 2.5 uM, and is similar or improved versus parental 
SW054384 in decreasing PGE2 levels in the media of 35 
compound treatedA549 cells that have been stimulated with 
IL-1 beta. The phenyl ring of SW054384 also tolerates 
addition of a methoxy group (SW202940), which yields a 
compound that is that is active in inducing 15-PGDH-
40 
luciferase reporter activity in cell lines, and is similar to 
parental SW054384 in not inhibiting recombinant 15-PGDH 
at 2.5 uM. 
We also note the favorable properties of compound 
SW125591, also denoted SW125991, which converts the 45 
nitrogen in the SW054384 peptide bond from an (Ary!)-
202 
reporter construct, and all show much less inhibition of 
enzymatic activity of 15-PGDH at 2.5 µMand 7.5 µM than 
does SW054384. 
Example 12 
The following Example describes the synthesis of 
SW054384 and analogues thereof as well as provides mass 
spectrometry NMR confirmation of the structures. 
General Procedure 1 : 
NH2 
I 
(Het)Ar 
Procedure 
0° C. --> RT 
Dioxane/DMF 
120° C. 
(Hetero )aryl amine was dissolved in 1: 1 mixture ofDMF/ 
dioxane (1.215 M based on amine) and cooled to 0° C. 
NH- group into a cyclic amine. This compound retains 
activity in induction of the 15-PGDH-luciferase reporter 
assay. It shows less inhibition of 15-PGDH at high com-
pound concentration than does the lead enzyme activator 
SW054384. SW125991 shows similar activity to SW054384 
50 Bromoacetyl bromide (1.26 equiv) added drop-wise and 
allowed to warm to room temperature overnight. Dioxane 
and excess acid bromide were removed under reduced 
pressure, and 2,5-dimethoxy aniline (3.5 equiv) was added. in reducing PGE2 levels in ILi-beta stimulated A549 cells. 
SW125991 shows no toxicity as assessed by effect on 
CellTiter-Glo assays done at 24 hours. Moreover, 55 
SW125991 shows marked improvement in metabolic sta-
bility. 
We also note the favorable properties of compounds 
SW207997, SW207998, and SW207998. These three com-
pounds, like SW125991, have all converted the nitrogen in 
the SW054384 peptide bond from an (Aryl)-NH- group 
into a cyclic amine. In addition, SW207997, SW207998, and 
SW207998, have all added a methoxy group to the phenyl 
ring in SW054384. SW207997, SW207998, and SW207998 
all show activity equal to, or in some assays greater than, 
SW054384 in inducing the 15-PGDH-luciferase gene fusion 
The crude material was heated to 120° C. for three hours. 
The reaction was cooled to room temperature, diluted with 
EtOAc, and filtered through celite. The filtrate was washed 
with water (3x), sodium bicarbonate, and brine. The organic 
phase was dried with MgSO4 and concentrated to give crude 
amide (1 ). The product was further purified by flash chro-
60 matography to afford pure N-aryl glycinamide 1. 
N-Aryl glycinamide (1) was dissolved in CH2 Cl2 (IM). 
Pyridine (4.9 equiv) and sulfonyl chloride (2) were added 
(1.3 equiv) and the reaction was stirred overnight. The 
solution was diluted with EtOAc, washed with water (3x) 
65 and brine, dried over MgSO4 and concentrated under 
reduced pressure to give crude sulfonamide 3. The product 
was purified by flash chromatography. 
US 10,301,320 B2 
General Procedure 2: 
4 
Procedure 
203 
Pyridine 
NaH,DMF 
or 
or 
C: EDCl, DMAP, R30H 
SA:X~NRi 
SB: X~NH 
SC:X~O 
Aniline 4 (1 equiv) was dissolved in CH2Cl2 (1 M based 
5 
204 
Without purification, secondary sulfonamide 5 (1 equiv) 
was dissolved in a solution ofDMF (0.1 M) and ethyl bromo 
acetate (4 equiv). This solution was added drop-wise to 
sodium hydride at 0° C. After bubbling ceased, the reaction 
was warmed to room temperature and left stirring overnight. 
After 12-18 hours, water was added and the aqueous phase 
was extracted 3 times with CH2 Cl2 . The combined organic 
extracts were washed again with water followed by brine, 
10 dried with MgSO4, and concentrated under reduced pressure 
to provide an oil. Addition of hexanes resulted in precipi-
tation of the crude product, which was isolated by filtration 
and used without purification. 
15 
20 
Ester 6 was dissolved in 3:3: 1 ratio ofMeOH:THF:Water. 
Lithium hydroxide was added and the reaction was stirred 
until complete (1-3 hrs). The reaction was concentrated 
under reduced pressure and then diluted with CH2Cl2 . The 
acid (7) was extracted into saturated sodium bicarbonate. 
The aqueous layer was neutralized with IM HCl (pH-5) and 
extracted with CH2Cl2 to afford 7, which was used without 
purification. 
General Procedure 2A 
25 Acid 7 (1 equiv) was dissolved in EtOAc (2 vol). Pyridine 
(1 vol) and secondary amine (1.1 equiv) were added fol-
lowed by T3P (2 equiv, 50% in EtOAc) and reaction was 
stirred overnight. The reaction was quenched with HCl (0.5 
30 M, 3 vol), and the mixture was diluted with EtOAc, washed 
with water, bicarbonate, and brine, dried with sodium sulfate 
and concentrated. Compound SA was purified by flash 
chromatography. 
35 
General Procedure 2B 
Primary amine (1 equiv), DMAP (0.3 equiv) and EDCI 
(1.3 equiv) were added to a solution of acid 7 (1 equiv) in 
CH2Cl2 (0.5 M). The reaction vial was purged with nitrogen 
stirred for 12-24 h. The reaction mixture was diluted with 
40 CH2Cl2 and washed with brine, water, HCl (1 M), sodium 
bicarbonate and brine again. The organic layer was dried 
with sodium sulfate and concentrated to afford 8B. If 
needed, the compound was purified by flash chromatogra-
phy. 
45 General Procedure 2C: 
Alcohol (4 equiv), DMAP (0.3 equiv) and EDCI (1.1 
on 4). DMAP (0.3 equiv) and pyridine (4.9 equiv) were 50 
added followed by sulfonyl chloride 2 (1 equiv). The reac-
tion was stirred for 36 hours, diluted with CH2Cl2 and 
washed with water, HCl (1 M), sodium bicarbonate, and 
brine. The organic layer was dried over MgSO4 and solvent 
was removed under reduced pressure to afford 5. 
equiv) were added to a solution of acid 7 (1 equiv) in CH2Cl2 
(0.5 M) at 0° C. After five minutes the reaction was allowed 
to warm to room temperature and was stirred until complete. 
The reaction mixture was diluted with CH2 Cl2 and washed 
with brine, HCl (1 M), and water. The organic phase was 
dried with MgSO4 and concentrated to afford the pure ester 
SC. 
General Procedure 3 
0 
Br 
~Br 
9 
Pyridine 
THF 
10 
12 
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-continued 
0 
R' ~ 
DCM,DMAP j 0 K2C03 '-N I R' HN'O 
H2N-o 
_I RI R
2S02Cl 
_';ZR! ~I 
Procedure: Pyridine (1.1 equiv) was added to a solution of 
secondary amine 9 in THF (0.5M), and reaction mixture was 
cooled to 0° C. Bromoacetyl bromide (1 equiv) was then 
added drop-wise and reaction was warmed to room tem-
perature. The reaction was stirred for two hours at this 
temperature and then diluted with EtOAc and washed with 
water. The organic layer was dried with sodium sulfate and 
concentrated to afford bromo acetamide 10, which was 
purified by flash chromatography on silica gel. 
General Procedure 3A: A solution of amide 10 in DMF 
(0.0.075 M) was added to a solution of sulfonamide 12 (1.5 
equiv; synthesis identical to sulfonamide 5 in Procedure 2), 
potassium carbonate (2 equiv), and DMF (0.075 M). The 
reaction was stirred overnight and then diluted with EtOAc 
and washed with water and brine. EtOAc was removed 
under reduced pressure to afford crude 12, which was 
purified by flash chromatography on silica gel. 
General Procedure 3B: A solution of amide 10 in DMF 
(0.075 M) was added to a solution of aniline, potassium 
carbonate (2 equiv), and DMF (0.075 M). The reaction was 
stirred overnight and was then diluted with EtOAc and 
washed with water and brine to afford amide 11 crude, which 
was used without purification. 
DMAP (0.3 equiv), pyridine (4.9 equiv) and then sulfonyl 
chloride (1 equiv) were added to a solution of amide 11 in 
CH2 Cl2 (1 M). The reaction was stirred for 12-24 hours, 
diluted with CH2 Cl2 and washed with water, HCl (1 M), 
sodium bicarbonate, and brine. The organic layer was dried 
over MgSO4 and compound concentrated under reduced 
pressure to afford sulfonamide 12, which was purified by 
flash chromatography. 
Example 13: Properties of Selected Analogues of 
Lead Compound SW054384, a 15-PGDH Activator 
This Example provides data on properties of selected 
analogues of SW054384. 
FIG. 81 shows structures of selected analogues of 
SW054384. 
FIGS. 82(A-C) show graphs that show the level of activity 
11 
FIGS. 84(A-C) show at left (84A) activity in lowering 
15 PGE2 levels in media of A549 cells that are stimulated to 
produce PGE2 by treatment with ILl-beta. All of the com-
pounds tested, including SW054384, SW203703, 
SW125991, SW203736, and SW203737, show activity in 
lowering PGE2, consistent with their acting in vivo as 
20 inducers of 15-PGDH activity. FIG. 84B shows at right that 
none of the tested compounds demonstrate any toxicity 
againstA549 cells as assessed by CellTitre-Glo assay levels 
at 24 hours of treatment. FIG. 84C shows at bottom photo-
graphs of A549 cells tested in the CellTitre-Glo assay 
25 ordered left to right in the same order as in the graphical 
display of CellTitre-Glo data at upper right. 
30 
FIG. 85 shows measurement of metabolic stability of 
SW054384 by incubation with murine liver S9 microsomes. 
Measured half-life is 21.72 minutes. SW054384 (2 mM in 
DMSO) was incubated with Murine S9 (Lot KWB) fraction 
and Phase I (NADPH Regenerating System) cofactors for 
0-240 minutes. Reactions were quenched with a 1 mL (1:1) 
ofMeOH/( + )IS/0.2% Formic Acid, vortexed for 15 seconds, 
35 incubated at RT for 10 minutes and spun for 5 minutes at 
2400 rpms. Supernatant (1 mL) was then transferred to an 
eppendorftube and spun in a table top, chilled centrifuge for 
5 minutes at 13.2K rpms. Supernatant (800 µL) was trans-
ferred to an HPLC vial (w/out insert) and analyzed by 
40 HPLC/MS. A: dH2O+0.1% FA B: MeOH+0.1% FA 
FIG. 86 shows measurement of metabolic stability of 
SW125991 by incubation with murine liver S9 microsomes. 
Measured half-life is 204 minutes. SW125991 (2 mM in 
DMSO) was incubated with Murine S9 (Lot KWB) fraction 
45 and Phase I (NADPH Regenerating System) cofactors for 
0-240 minutes. Reactions were quenched with 1 mL (1: 1) of 
methanol containing 0.2% formic acid and 100 ng/ml IS (IS 
final conc.=50 ng/ml). Samples were vortexed for 15 sec-
onds, incubated at RT for 10 minutes and spun for 5 minutes 
50 at 2400 rpm. Supernatant (1 mL) was then transferred to an 
eppendorftube and spun in a table top, chilled centrifuge for 
5 minutes at 13.2K rpm. Supernatant (800 µL) was trans-
ferred to an HPLC vial (w/out insert). Analyzed by Qtrap 
3200 mass spectrometer. 
FIG. 87 shows the structures of additional analogues of 
SW054384. 
FIGS. 88-90 show graphs that show the level of activity 
in inducing the 15-PGDH-luciferase fusion reporter in three 
different test cell line backgrounds, V9m, LSI 74T, and 
in inducing the 15-PGDH-luciferase fusion reporter in three 
different test cell line backgrounds, V9m, LSI 74T, and 55 
V503. Each compound was tested at two concentrations, 2.5 
uM, and 7 .5 uM. Y-axis is luciferase activity. Compounds 
active in inducing the 15-PGDH-luciferase reporter include 
SW20370, SW203704, SW125991, SW203736, 
SW203737. 60 V503. Each compound was tested at two concentrations, 2.5 
uM, and 7 .5 uM. Y-axis is luciferase activity. Compounds 
active in inducing the 15-PGDH-luciferase reporter include 
(but are not limited to): SW207997, SW207998, and 
SW207999. 
FIG. 83 shows activity of tested compounds in inhibiting 
enzymatic activity ofrecombinant 15-PGDH when tested at 
high concentrations of 2.5 uM and 7.5 uM. SW125991 and 
SW203736 show lesser inhibitory activity at high concen-
tration than the lead 15-PGDH activator, SW054384. 65 
SW203737 at these concentrations shows inhibitory activity 
against recombinant 15-PGDH that is similar to SW054384. 
FIG. 91 shows activity of tested compounds in inhibiting 
enzymatic activity of 15-PGDH when tested at high con-
centrations of 2.5 uM and 7.5 uM. SW207997, SW207998, 
US 10,301,320 B2 
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and SW207999 show lesser inhibitory activity at high con-
centration than the lead 15-PGDH activator, SW054384. 
FIG. 92 reprises structures of 15-PGDH activators 
SW054383, SW125991, SW207997, SW207998, 
SW207999. 5 
FIG. 93 shows graphical display of the activities of 
SW054383, SW125991, SW207997, SW207998, 
SW207999 in lowering PGE2 levels in medium of A549 
cells that have been treated with 2.5 µM of each compound 
for 24 hours, along with addition of 2.5 ng/ml ILi-beta for 10 
the last 16 hours of the incubation, and with then collection 
and assay of PGE2 concentration in the medium at the 24 
hour time point. Activity of compounds in lowering 
15-PGDH in the ILi-beta stimulatedA549 cells is consistent 
with these compounds activating intracellular 15-PGDH. 
FIG. 94 shows titration curves of 15-PGDH activator 15 
compounds in an assay measuring effects on PGE2 levels in 
the medium of A549 cells that have been stimulated with 
ILi-beta in the same experimental design described for FIG. 
93. At 100 nM concentration of drug, the greatest reduction 
in levels of PGE2 in the medium are achieved by treating 20 
cells with SW207997 or with SW207998, followed by 
SW125991. SW054384 and SW207999 attain comparable 
levels of reduction of PGE2 in the medium at doses of 
between 0.5 µM-1.0 µM. 
FIG. 95 shows assessment of toxicity of SW125991 by 25 
testing effect of increasing doses on colony formation of 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 
activity is seen at doses up to 7.5 µM compound. 
FIG. 96 shows assessment of toxicity of SW207997 by 30 testing effect of increasing doses on colony formation of 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 
activity is seen at doses up to 7.5 µM compound. 
FIG. 97 shows assessment of toxicity of SW207998 by 
testing effect of increasing doses on colony formation of 35 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 
activity is seen at doses up to 7.5 µM compound. 
FIG. 98 shows assessment of toxicity of SW207999 by 
testing effect of increasing doses on colony formation of 40 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 
activity is seen at doses up to 7.5 µM compound. 
While this invention has been particularly shown and 
described with references to preferred embodiments thereof, 45 
it will be understood by those skilled in the art that various 
changes in form and details may be made therein without 
departing from the scope of the invention encompassed by 
the appended claims. All patents, publications and refer-
ences cited in the foregoing specification are herein incor-
50 porated by reference in their entirety. 
The following is claimed: 
1. A method of inhibiting the activity of 15-PGDH 
enzyme, the method comprising: 
administering to the enzyme a compound having the 
following formula (III): 
(III) 
55 
60 
65 
208 
wherein n is 1 or 2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted; 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF3 , CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R')2, O(CO)R', COOR' (wherein R' is H or a lower alkyl group); 
Z1 is S; 
X2 is Nor C; 
R6 and R7 are optional and if present are the same or 
different and are each selected from the group consist-
ing ofa H, F, Cl, Br, I, a lower alkyl group, (CH2)niOR' (whereinnl=l, 2, or 3), CF3 , CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X (wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' (wherein R' is H or a lower alkyl group); substituted or 
unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, and a substituted or unsubstituted hetero-
cyclyl; or a pharmaceutically acceptable salt thereof. 
2. The method of claim 1, wherein the compound has a 
formula selected from the group consisting of: 
s 
0 
// 
s~ 
I 
S=O· ~ , 
0 
srD 
~ 
0 
( s 
( s 
US 10,301,320 B2 
209 
-continued 
O· // , 
s 
\ 
0 
// 
s~ 
0 
// 
s~ 
0 
// 
s~• 
0 
// 
s~• 
210 
-continued OyN 0 
5 ~ // 
s 
N 
,::9 ~ 
10 
0 
15 // 
s 
~ 
20 
25 0 // 
s~ 
30 
and pharmaceutically acceptable salts thereof. 
35 3. The method of claim 1, wherein the compound has the 
formula: 
40 
45 
50 
55 
60 
65 
0 
// 
s~ 
and pharmaceutically acceptable salts thereof. 
4. The method of claim 1, wherein the compound has the 
formula: 
and pharmaceutically acceptable salts thereof. 
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5. The method of claim 1, wherein the compound has the 
formula: 
212 
10. The method of claim 7, where the compound or 
pharmaceutically acceptable salt thereof is administered to 
the subject after receipt of the bone marrow graft. 
s 
11. The method of claim 7, wherein the administration 
5 occurs following treatment of the subject or the bone mar-
row of the subject with radiation therapy, chemotherapy, or 
immunosuppressive therapy. 
12. A method for treating colitis in a subject, comprising 
administering to the subject a compound having the follow-
IO ing formula (III): 
and pharmaceutically acceptable salts thereof. 
6. The method of claim 1, wherein the 15-PGDH enzyme 
is in a tissue of a subject and the compound is administered 
15 
to the tissue of the subject at an amount effective to increase 20 
prostaglandin levels in the tissue. 
7. A method for mitigating rejection or enhancing engraft-
ment of a bone marrow graft in a subject recipient of the 
bone marrow graft, comprising administering to the subject 
a compound having the following formula (III): 25 
(III) 
30 
35 
wherein n is 1 or 2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 40 
which is unsubstituted or substituted; 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)ni0R' (wherein nl=l, 2, or 3), CF3 , CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 45 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is Hor a lower alkyl group); 
(III) 
(~\ 
z s, 
N R1 R,;t N_,.,.R2 
X -\ I 2 R3 
R1 
wherein n is 1 or 2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted; 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF3 , CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is H or a lower alkyl group); 
Z 1 is S; 
X2 is Nor C; 
R6 and R7 are optional and if present are the same or 
different and are each selected from the group consist-
ing ofa H, F, Cl, Br, I, a lower alkyl group, (CH2)niOR' 
(whereinnl=l, 2, or 3), CF3 , CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is H or a lower alkyl group); substituted or 
unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, and a substituted or unsubstituted hetero-
cyclyl; or a pharmaceutically acceptable salt thereof. 
13. The method of claim 12, wherein the colitis is 
ulcerative colitis. 
zl is S; 
X2 is Nor C; 
R6 and R7 are optional and if present are the same or 
different and are each selected from the group consist-
ing of a H, F, Cl, Br, I, a lower alkyl group, (CH2)n 1 OR' 
(whereinnl=l, 2, or3), CF3 , CH2----CH2X, O----CH2-
14. A method for promoting liver regeneration following 
50 liver surgery or injury in a subject, comprising administering 
to the subject a compound having the following formula 
(III): 
CH2X, CH2-CH2-CH2X, O-CH2-CH2X 55 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is H or a lower alkyl group); substituted or 
unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, and a substituted or unsubstituted hetero- 60 
cyclyl; or a pharmaceutically acceptable salt thereof. 
8. The method of claim 7, where the compound or 
pharmaceutically acceptable salt thereof is administered to 
the subject before receipt of the bone marrow graft. 
9. The method of claim 7, where the compound or 65 
pharmaceutically acceptable salt thereof is administered to 
the subject during receipt of the bone marrow graft. 
(III) 
(O)n 
z ~, 
N R1 R,;t N_,.,.R2 
X -\ I 2 R3 
R1 
wherein n is 1 or 2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted; 
US 10,301,320 B2 
213 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF3 , CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, s 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is Hor a lower alkyl group); 
Z1 is S; 
X2 is Nor C; 
R6 and R7 are optional and if present are the same or 10 
different and are each selected from the group consist-
ing of a H, F, Cl, Br, I, a lower alkyl group, (CH2)n 1 OR' 
(whereinnl=l, 2, or3), CF3 , CH2----CH2X, O----CH2-
CH2X, CH2-CH2-CH2X, O-CH2-CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 15 
NO2, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is H or a lower alkyl group); substituted or 
unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, and a substituted or unsubstituted hetero-
cyclyl; or a pharmaceutically acceptable salt thereof. 20 
15. The method of claim 14, wherein the surgery is liver 
resection. 
* * * * * 
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